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Abstract 
 Supramolecular synthesis relies upon the creative and rational use of the common 
intermolecular forces and a proper understanding of these forces is critical for design and 
assembly of molecular building blocks into extended networks. The strength of seven 
substituted pyridines as hydrogen-bond acceptors was probed using a series of fifteen 
mono/dicarboxylic acids to demonstrate the interrelationship between the charge on the 
substrate and its ability to form co-crystals/salts. The higher charge in the acceptor led to 
proton transfer (100% yield) from the hydrogen bond donor to give a salt, whereas the 
lower charge led to co-crystals. This specificity observed for small molecules was 
extended to an investigation of selectivity in ditopic molecules. A series of nineteen 
hydrogen-bond donors, including fifteen carboxylic acids and four cyanoximes, were 
tested for binding preferences against ten ditopic ligands with variable charges. The 
overall supramolecular yield of 82% (9/11) proved a high degree of reliability in terms of 
best acceptor/donor approach, hence establishing the efficiency of the calculated charges 
as a guideline for molecular recognition processes.  
Solubility and thermal properties of pharmaceutical drug mimics were altered via 
formation of co-crystals/salts. The ligands and their co-crystals/salts with five even-chain 
dicarboxylic acids were synthesized and their comparative solubility in pure water and in 
pH 6.8 buffer solution measured. Solubility enhancement to a degree of 9x is observed 
for pharmaceutical drug haloperidol, whereas decrease in solubility down to 81% is 
achieved for 2-amino-5-(3-pyridyl)pyrimidine (which has agrochemical significance). 
Also the thermal and solubility behavior of these co-crystals were shown to reflect the 
properties of their parent co-crystallizing agents, allowing for a modulation of physical 
properties. 
Finally, the specificity and selectivity of the intermolecular interactions observed 
for small molecules were applied in the synthesis of hydrogen and halogen-bonded 
capsules. Several resorcinarene-based cavitands were synthesized and their upper rim 
decorated with acetamidopyridyl, aminopyrazinyl, 3-pyridyl, and 4-pyridyl moieties with 
hydrogen and halogen-bonding potentials. A homomeric hydrogen-bonded capsule was 
  
formed with self-assembly of acetamidoethynylcavitand via N-H···O=C interactions, 
whereas a heteromeric halogen-bonded capsule, the very first of its kind, was formed 
with N···I halogen-bonded interaction between 3-pyridylcavitand and tetrafluoroiodo-
substituted calixarene. 
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assembly of molecular building blocks into extended networks. The strength of seven 
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mono/dicarboxylic acids to demonstrate the interrelationship between the charge on the 
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proton transfer (100% yield) from the hydrogen bond donor to give a salt, whereas the 
lower charge led to co-crystals. This specificity observed for small molecules was 
extended to an investigation of selectivity in ditopic molecules. A series of nineteen 
hydrogen-bond donors, including fifteen carboxylic acids and four cyanoximes, were 
tested for binding preferences against ten ditopic ligands with variable charges. The 
overall supramolecular yield of 82% (9/11) proved a high degree of reliability in terms of 
best acceptor/donor approach, hence establishing the efficiency of the calculated charges 
as a guideline for molecular recognition processes.  
Solubility and thermal properties of pharmaceutical drug mimics were altered via 
formation of co-crystals/salts. The ligands and their co-crystals/salts with five even-chain 
dicarboxylic acids were synthesized and their comparative solubility in pure water and in 
pH 6.8 buffer solution measured. Solubility enhancement to a degree of 9x is observed 
for pharmaceutical drug haloperidol, whereas decrease in solubility down to 81% is 
achieved for 2-amino-5-(3-pyridyl)pyrimidine (which has agrochemical significance). 
Also the thermal and solubility behavior of these co-crystals were shown to reflect the 
properties of their parent co-crystallizing agents, allowing for a modulation of physical 
properties. 
Finally, the specificity and selectivity of the intermolecular interactions observed 
for small molecules were applied in the synthesis of hydrogen and halogen-bonded 
capsules. Several resorcinarene-based cavitands were synthesized and their upper rim 
decorated with acetamidopyridyl, aminopyrazinyl, 3-pyridyl, and 4-pyridyl moieties with 
  
hydrogen and halogen-bonding potentials. A homomeric hydrogen-bonded capsule was 
formed with self-assembly of acetamidoethynylcavitand via N-H···O=C interactions, 
whereas a heteromeric halogen-bonded capsule, the very first of its kind, was formed 
with N···I halogen-bonded interaction between 3-pyridylcavitand and tetrafluoroiodo-
substituted calixarene. 
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CHAPTER 1 - Supramolecular assembly and molecular 
recognition  
1.1 Supramolecular Chemistry  
 
“Molecular chemistry, thus, has established its power over the covalent bond. The time 
has come to do the same for non-covalent intermolecular forces.”
 1
 
              -  Jean-Marie Lehn 
 
The rich structural diversity and complexity found in nature may be unraveled if 
we look into the simplicity present within. Nature uses molecules as building blocks to 
build a variety of complex architectures. Much of traditional chemistry focuses on 
covalent bonds whereas supramolecular chemistry deals with the weaker and reversible 
non-covalent interactions between molecules.1 The study of these non-covalent 
interactions is of importance for many biological processes, which may even be an 
inspiration for supramolecular research. 
 
    
  (a)      (b) 
Figure 1.1 Assembly of larger structures from smaller building blocks. 
 
Ever since the works on host-guest chemistry and self-assembling systems, which 
led to a Nobel Prize in 1987 for Cram, Lehn, and Pedersen, the field of supramolecular 
chemistry has gained much attention and interest.2 Also termed “chemistry beyond the 
molecules” supramolecular chemistry focuses on assembly of discrete molecular subunits 
into a larger target. The intermolecular forces responsible for the organization of these 
subunits include hydrogen bonding, halogen bonding, metal coordination, pi-pi stacking, 
and van der Waals interaction. Molecular recognition is a key aspect of supramolecular 
chemistry with a focus on molecular associations and determines how host molecules 
recognize guests in host-guest systems. Molecular recognition in the solid-state is 
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exemplified by the structure of a simple organic crystal which behaves as a 
supermolecule with the molecules in the crystal held together by non-covalent 
interactions.3  
 
1.1.1 Crystal Engineering 
 
“The knowledge and control of intermolecular interactions is as vital to crystal synthesis 
as is control of the covalent bond is to molecular synthesis.” 4 
           -  Jack David Dunitz 
 
 Crystal engineering is the design and synthesis of functional molecular solid-state 
structures from neutral or ionic building blocks using intermolecular interactions.5 It 
focuses on the understanding of intermolecular interactions and connectivities which can 
later be utilized to control the solid state assembly of small molecular building blocks 
into extended architectures or supermolecules.6 Valuable information related to molecular 
recognition, self-assembly, and the packing of the building blocks7 help to identify 
bonding preferences and reliable synthons in crystals packing. Various intermolecular 
forces from strong, directional hydrogen bonds and halogen bonds, to the weak non-
directional van der Waals’ forces are employed as the engineering tools to investigate the 
self-assembly of molecules in a crystal lattice.8 
 
 
 
Figure 1.2 Schematic of molecular recognition in smaller molecules to build larger 
structures. 
  
 
 
 
 3  
1.1.2 What is a hydrogen bond? 
 
“A hydrogen bond is an interaction that directs the association of a covalently bound 
hydrogen atom with one or more other atoms, groups of atoms, or molecules into an 
aggregate structure that is sufficiently stable to make it convenient for the chemist to 
consider it as an independent chemical species.”
9
 
 
Etter10 put forth general guidelines for the formation of hydrogen bonds in organic 
molecules based on systematic structural studies of hydrogen-bonded crystals.  
1. All good proton donors and acceptors are used in hydrogen bonding.11 
2. Six-membered-ring intramolecular hydrogen bonds are preferentially formed to 
intermolecular hydrogen bonds. 
3. The best proton donors and acceptors left after the formation of intramolecular 
hydrogen bonds, take part in intermolecular hydrogen bonding. 
 
Etter suggested that the best hydrogen-bond donor and the best hydrogen-bond acceptor 
will preferentially form hydrogen bonds to one another. The most common hydrogen 
bond donors include carboxylic acids, amides, ureas, imides, anilines, phenols; whereas 
the hydrogen bond acceptors are typically acid and amide carbonyl groups, sulfoxides, 
nitroxides, phosphoryls, and amine nitrogens.10 
 
1.1.3 What is a halogen bond? 
 
 
 
Y = C, N, halogen etc. 
X = I, Br, Cl. 
D = N, O, S, Se, Cl, Br, I, I-, Br-, Cl-, F-... 
 
Figure 1.3 General scheme for the formation of halogen bonds.12 
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Halogen bonding is a non-covalent intermolecular interaction between halogen 
atoms (electrophilic) acting as halogen bond donors (D) and electron rich moieties like 
the nitrogen atom in pyridine acting as a halogen bond acceptor (X), (Figure 1.3).12 
Similar to hydrogen bonding (HB), halogen bonding (XB) also plays a major role in 
intermolecular recognition and self-assembly process.  
 
     
 
Figure 1.4   Halogen bonding via N…I interactions.13 
 
1.1.4 Synthons 
 
Supramolecular synthons are the “structural units within supermolecules which 
can be formed and/or assembled by known or conceivable intermolecular interaction.” 
The synthons, despite being smaller and less complex than its target molecule, contains 
most of the vital information inherent in the mutual recognition required to synthesize the 
supermolecules.14,15 The use of synthons simplifies the understanding of the crystal 
structures by breaking down the complexity present in the supramolecules. The structures 
of benzoic acid, terephthalic acid, isophthalic acid, trimesic acid and adamantine-1,3,5,7-
tetracarboxylic acid in zero-, one-, two- and three-dimensional arrangement contain the 
same carboxy dimer motif.16  
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Figure 1.5 Examples of supramolecular synthons. 
 
 
1.2 Guidelines for hydrogen-bond driven synthesis 
 
1.2.1 Co-crystals as a way of probing molecular interactions 
 
The ability to convince two or more different molecules to co-exist within one 
crystalline lattice has become an important part of the synthesis of supramolecular solid-
state architectures.17 Co-crystallizations proceed without making or breaking covalent 
bonds, and rely on self-assembly processes that must overcome the innate structural 
‘selfishness’ of molecules that makes re-crystallization such a powerful and versatile 
method of chemical purification.  The fundamental aspects of co-crystal synthesis18 offer 
unique opportunities for examining the balance and competition between intermolecular 
forces.19   
 
      
 
 
 
 
Figure 1.6 Schematic of re-crystallization (homomeric interaction) vs co-crystallization 
(heteromeric interaction). 
Re-crystallization 
Co-crystallization 
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Co-crystals consist of a single crystalline phase with multiple components present 
in a given stoichiometric ratio. These different molecular components in the co-crystals 
interact via intermolecular interactions. The strength and directionality of the hydrogen 
bond make it the most important interaction in co-crystal formation. The commonly 
encountered hydrogen-bond interactions in co-crystals are O-H…O, O-H…N, N-H…O, 
N-H…N, C-H…N, C-H…O etc. with carboxylic acids, amines, amides, oximes, and 
alcohols. Halogen-bond interactions involve N-heterocycles (pyridine, pyrimidine, 
pyrazine, imidazole) with N…Br, N…I synthons. Co-crystals are prepared using 
solution-based evaporation,20 cooling of heteromeric solution,21 thermal microscopy 
(Kofler technique),22 reaction crystallization method (RCM),23 neat grinding,24 liquid-
assisted grinding, sublimation and growth from the melt25 or slurry.26 The 
mechanochemical methods of grinding have been demonstrated to provide better 
results;27 however solution crystallization is commonly used especially to obtain single 
crystals for X-ray analysis.28  
1.2.2 Binary and ternary co-crystals 
 
By changing/modifying the hydrogen bonding sites in a molecule, we can change 
the way it binds to give various types of co-crystals. When molecules with single donor 
and single acceptor are mixed, usually 1:1 binary co-crystals are obtained with two 
different types of molecules in the same crystalline lattice, (Figure 1.7).  
 
   
 
 7  
  
 
Figure 1.7 Hydrogen-bonded binary co-crystals 
 
However when a molecule has two donor/acceptor sites with variable hydrogen 
bonding potential, then it is possible to make ternary co-crystals, (Figure 1.8).   
 
 
 
 
 
Figure 1.8 Ternary hydrogen-bonded co-crystal between isonicotinamide, 3,5-
dinitrobenzoic acid, and 3,4-dimethoxycinnamic acid.29 
 
 
Hence a ternary co-crystal can be constructed by using an asymmetric hydrogen-
bond acceptor and two different donors and vice-versa. The choice between the two 
asymmetric sites in the donor molecule depends on the comparative binding strength in 
these sites, as explained by Etter10 “the best hydrogen-bond donor preferentially forms 
hydrogen bond with the best hydrogen-bond acceptor”, (Figure 1.9). 
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Figure 1.9 Schematic of the best hydrogen bond donor (D1) binding with best hydrogen 
bond acceptor (A1) and the second best hydrogen bond donor (D2) with second best 
hydrogen bond acceptor (A2).
29 
 
1.2.3 Establishing the hydrogen-bonding hierarchy  
 
In order to establish a hydrogen-bonding hierarchy of donors and acceptors in a 
system, the molecular behavior encountered and the underlying reasons need to be 
understood. Two approaches based on pKa differences and molecular electrostatic 
potential are used to detail the general hierarchy in the hydrogen-bonded systems.   
 
∆pKa rule 
 
It was proposed that the formation of salts and co-crystals can be explained based 
on the pKa difference between the donor and acceptor molecules.
30 The complete proton 
transfer from donors to acceptors leading to the charged species, and hence the salt 
formation is prompted by the difference in pKa [∆pKa = pKa (base) – pKa (acid)] values 
greater than 3, whereas if the difference is negative it exclusively forms co-crystals.31 The 
predictability of formation of salt or co-crystal is low for the values in the range 0 to 3, 
where proton-sharing or mixed ionizations states were encountered and hence cannot be 
assigned to either category and termed salt-co-crystal continuum. The co-crystallization 
of theophylline with various carboxylic acids in the ∆pKa ranges 0< ∆pKa<2.5 resulted in 
16 salts, two co-crystals, and two mixed ionization states.30   
 
Electrostatic potential 
 
The ∆pKa approach is based on the transfer of proton and acts as a guideline for 
the prediction of salt and co-crystal formation, and is less of a measure of the hydrogen 
bonding strength of the acceptors and donors. Within a class of functional groups like 
pyridines and phenols, the pKa approach correlates well with the trends in hydrogen bond 
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donor/acceptor strength; however the marked contradictions were seen for other 
functional groups.32 e.g. thiols are more acidic than alcohols but are worse hydrogen-
bond donors.  Similarly, pyridine is more basic than DMSO, but is a worse hydrogen-
bond acceptor. Hunter33 came up with a new approach based on molecular electrostatic 
potentials (MEPs) to calculate the strength of hydrogen bond donors and acceptors in a 
wide range of functional groups.  His approach was based on a purely electrostatic view 
of the hydrogen bond. The molecular electrostatic surface potential charges are 
determined by the effective charge on the nucleus, the location of the lone pair, and the 
van der Waals radius.  
Considering the electrostatic nature of the hydrogen bond, the association 
constant (K) for pairwise hydrogen-bonding interaction between two functional groups is 
given by the relationship.34 
 
log K = c1α2β2 + c2     Equation 1.1 
 
where c1 and c2 are constants that depend on the solvent and, α2 and β2 are the functional 
group constants that relate to the hydrogen bonds donor and hydrogen-bond acceptor 
properties of the molecules. 
 
The constant c1 is solvent-dependent and increases with a decrease in the polarity of the 
medium, whereas the constant c2 is relatively insensitive to solvent hence making it the 
fundamental property of interaction between two molecules. Hunter demonstrated that 
even at relatively low level of theory (semi empirical AM1), the calculated maxima and 
minima in the molecular electrostatic potential surface is well-correlated with the 
experimentally determined values of α2 and β2.
33  
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Figure 1.10 Molecular electrostatic potential surface of 2-amino-5-bromopyridine, 
calculated by using AM1 and a positive charge in vacuum as probe; blue (positive 
regions, Emax), red (negative regions, Emin), and green (neutral regions). 
 
The approach is extendable to include the hydrogen-bond strengths of donors and 
acceptors in solutions as well by using the normalization constant of 52 kJ mol-1 obtained 
from the theoretical-experimental correlations and the gas phase value of c1, with some 
classes of functional groups like amides showing poor consistency (±20%).33 
α = Emax/52 kJmol
-1  β = Emax/52 kJmol
-1  
1.3 Changing properties of specialty chemicals via co-crystallization 
 
Co-crystals represent new solid forms that can enable the modification of 
physicochemical properties such as solubility, stability, hygroscopicity, shelf-life, 
dissolution rate and biocompatibility of active pharmaceutical ingredients (APIs),35- 36 
without tampering with their inherent pharmacological properties.37, 38, 39, 40  
Pharmaceutical co-crystals with their neutral components held together via non-covalent 
interactions have an advantage over their more common counterparts, the pharmaceutical 
salts, in being able to generate solid forms of APIs even when they do not contain any 
ionizable functional groups. Examples of pharmaceutical co-crystals are found in 
literature, with co-crystals of theophylline and phenobarbital41, caffeine and barbital42, 
caffeine and gentisic acid43, co-crystal of itraconazole with different carboxylic acids.44 
Childs and Rodriguez-Hornedo et. al. mentioned 50 co-crystals of piroxicam with 23 
different carboxylic acids45  and 35 co-crystals of carbamazepine with carboxylic acids, 
amides and amines. 46 
-275 kJmol-1 
+165 kJmol-1 
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1.3.1 Dissolution advantage 
 
The works of Childs47 et. al. with antidepressant fluoxetine hydrochloride co-
crystallized with carboxylic acids like benzoic acid, succinic acid and fumaric acid 
resulted in salt. The intrinsic dissolution studies showed approximately 3 times higher 
dissolution for 2:1 succinic acid complex, whereas for 1:1 benzoic acid complex the 
dissolution is reduced to half, and no change observed for 2:1 fumaric acid complex. 
Studies with norfloxacin (solubility 0.21 mg/mL) revealed 3 times increase in solubility 
with isonicotinamide co-crystal (0.59 mg/mL), whereas 20-45 times solubility increase is 
noted for salts with succinic, malonic, and maleic acids.48  Similarly, 1:1 glutaric acid co-
crystal of an extremely insoluble (<0.1 mg/mL) neuropathic drug, 2-[4-(4-chloro-2-
fluorophenoxy)phenyl]pyrimidine-4-carboxamide showed 18 times greater intrinsic 
dissolution rate.49 Furthermore, co-crystals of water-insoluble anti-fungal drug, 
itraconazole with succinic acid, L-malic acid, and L-tartaric acid showed 4- to 20-fold 
higher dissolution than that of the drug itself.44 
 
 
Figure 1.11 Trimer unit of the itraconazole-succinic acid co-crystal.44 
 
1.3.2 Hygroscopicity improvement 
 
The co-crystal of caffeine with oxalic acid was found to be non-hygroscopic 
whereas the crystalline caffeine by itself absorbs moisture and forms a hydrate.50 Similar 
stabilities to moisture were reported for co-crystals of carbamazepine with nicotinamide 
and saccharin.51 Co-crystals of theophylline with oxalic acid, malonic acid, maleic acid, 
and glutaric acid failed to form any hydrates; the 2:1 co-crystal with oxalic acid was 
found to be stable even at 98% RH for 7 weeks.39d 
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1.4 Hydrogen and halogen bonded cavitands 
 
 The ability to trap or include guest molecules in a defined cavity of a larger host is 
an excellent example of host-guest chemistry. The potential for subsequent structural 
modification that will change the environment inside the cavity is very intriguing with the 
possibility of changing the properties of the trapped guests. The application of non-
covalent reversible self-assembly processes dictated by ‘weak’ intermolecular 
interactions like hydrogen and halogen bonds to bind these two hosts together into a 
capsular framework opens a new world of molecular capsules. Newer dimensionless 
possibilities including selective delivery of guests, changing conditions for guests with 
reaction acceleration, as well as initiation of completely new reactions.52  
1.4.1 Molecular capsules 
 
Molecules that result in capsules should possess two important characteristics: they must 
be able to self-assemble and encapsulate the guest molecules. The self-assembly is 
pertinent to the self-complementary components based on the capsule components 
capable of reversible non-covalent interactions primarily hydrogen bonds. The 
subsequent encapsulation of the guest molecules depends on the complementarity of the 
guest size, shape and chemical surface with the host cavity. 53 Various types of molecular 
capsules that can self-assemble from smaller components using non-covalent interactions 
have been developed.54 
    
          a           b 
Figure 1.12 Self-assembling glycoluril-based dimeric capsules;53 (a) “tennis ball” and (b) 
“softball” 
 
The first reversibly formed molecular capsule was named “tennis ball” with the 
monomer consisting of two self-complementary glycoluril subunits holding the tennis 
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ball (methane, ethane, ethylene, noble gases) via eight hydrogen bonds (C=O…H-N) in 
its tiny cavity (50 Å3), (Figure 1.12a).55 Variation in the spacer led to a range of smaller 
and larger capsules (internal cavity 240-320 Å3), termed “softballs”, (Figure 1.12b).56 
1.4.2 Calixarene capsules 
 
Calix[4]arenes and resorcin[4]arenes are commonly used for due to their 
architecture, straightforward synthesis, and the potential for derivatization at the rim with 
complementary functionalities suitable for non-covalent interactions for capsular 
assembly.  The decoration of the calix[4]arene rim with hydrogen bond donor/acceptor 
groups has led to various capsular structures; self-complementary carboxylic acid groups 
produced a homomeric capsule held via four hydrogen bonds (Figure 1.13a),57 whereas 
with pyridyl and carboxylic acid groups on opposing calixarene rims led to formation of 
heteromeric capsule (Figure 1.13b).58 The more common urea-derivatized calixarene 
monomers self-assemble to give a dimeric capsule with a cavity of approx 180 Å3 held 
via sixteen hydrogen bonds (Figure 1.13c).59 The combination of different urea 
monomers resulted in mixtures of homo- and heterodimers.60 
. 
   
          (a)              (b)             (c) 
Figure 1.13 (a) Homodimeric hydrogen-bonded capsule with carboxylic acid rim 
substituents (R = propyl); (b) Heterodimeric capsule with hydrogen bonding between a 
pyridyl functionalized monomer and a complementary carboxylic acid functionalized 
monomer, (R = octyl); (c) Urea-functionalized homodimeric capsule. 
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The limitation in guest size due to the smaller cavity of resorcinarenes capsule can 
be removed by (a) expanding the size of the macrocycle (calix[5]arene61 and 
calyx[6]arene62)  or (b) adding spacing units between the monomeric units (either 
covalently63 or  non-covalently64). McGillivray and Atwood65 provided an alternative 
approach to create larger capsules by using multiple bowl fragments to create a giant 
capsular assembly. Their hexameric capsule consisted of a chiral arrangement of six 
resorcinarene subunits and eight water molecules with huge cavity 1375 Å3 with 60 
hydrogen bonds, (Figure 1.14). 
 
   
 
Figure 1.14 Giant hydrogen bonded capsule formed by self-assembly of six monomeric 
resorcinarenes units with eight water molecules. 
 
 Specific examples of molecular capsules formed via self-assembly of 
calix[4]arenes equipped with oppositely charged functional groups in their upper rims are 
found in literature. 1:1 complexes of highly charged complementary building blocks 
based on ammonium (or amidinium) and phosphonate ions (tetracationic and 
tetraanionic) have high thermodynamic stability, and association constants Ka up to 
7x105M-1 in methanol and >103 M-1 in water.66 
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Figure 1.15 Charged capsule obtained via complementary interactions between two 
oppositely charged ammonium and carboxylate ions at the rim. 
 
 
1.4.3 Cavitand capsules  
 
The structural rigidification by covalent modification of the hydroxyl arms of 
resorcinarenes result in cavitands. The transformation into cavitands exclude the 
conformational switching of resorcinarenes and allow them to hold their guests more 
tightly. Cram67 synthesized a series of eighteen cavitands with deeper cavity and rigid 
surfaces, (Figure 1.16).  
 
      
 
Figure 1.16 Vase and kite conformation in Cram’s cavitand due to folding of the 
quinoxaline arms. 
 
Rebek68 synthesized a vase-shaped cavitand with four imide functionalities on the 
rim which dimerizes though bifurcated hydrogen bonds to give a capsule. He showed that 
the size of this capsule can be increased by insertion of glycolurils units, which are a 
perfect fit, between the cavitand units, hence generating higher order capsules that can 
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hold larger-sized or larger number of guests, (Figure 1.17).69 The glycoluril-based self-
assembled molecular capsules were shown to stabilize reactive species or molecules in 
uncommon conformations via encapsulation as well as function as molecular reaction 
chamber for acceleration and catalysis of Diels-Alder reactions. 70 
 
 
Figure 1.17 Dimension and inner space in a series of capsules obtained by incorporating 
0, 4, 8, and 12 glycoluril spacers in the imide-functionalized cavitands. 
 
 
Chapman and Sherman71 utilized ionic hydrogen bonds to prepare capsules from 
hydroxyl-substituted resorcinarenes, (Figure 1.18 a). Kobayashi72 et al. synthesized 
resorcinarenes based cavitand functionalized with four carboxylic acid, held together by 
2-aminopyrimidine acting as linker (Figure 1.18 b). They also integrated guest/ solvent-
induced assembly of tetracarboxylcavitand and tetra(3-pyridyl)cavitand into a 
heterodimeric capsule held together via four intermolecular acid-pyridyl hydrogen bonds 
(Figure 1.18 c).73 
 17  
                 
 
    (a)          (b)      (c) 
 
Figure 1.18 Dimeric molecular capsules based on resorcin[4]arene building blocks: (a) 
capsule held via charged hydrogen bonds, (b) a capsule with 2-aminopyrimidine as a 
linker to hold the cavitand sub-units, (c) a heterodimeric capsule formed via assembly of 
tetra(3-pyridyl)cavitand and tetracarboxyl cavitand. 
 
 
1.5 Goals 
 
A proper understanding of intermolecular non-covalent interactions in self-assembly 
and molecular recognition processes will allow us to select proper components for the 
design of supramolecular networks as well as to modulate their physical properties. We 
will examine molecular recognition in small molecules at first and extend it into larger 
molecules to establish robust and versatile supramolecular synthetic methods. The 
understanding will be translated into the physical properties alteration of multi-
component crystals as well as generation of capsular frameworks held via interplay of 
weak intermolecular interactions. 
 
The goals pursued in this thesis are: 
1. To establish a boundary defined by the molecular electrostatic surface potential 
charges to uncover the hierarchy of hydrogen-bonding strength in small-molecule 
pyridine family in terms of their capability to form salts and co-crystals with a series 
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of mono/di-carboxylic acids. Molecular recognition in solution was alos studied using 
isothermal titration calorimetry. (Chapter 2 and 3) 
 
2. To investigate whether binding specificity in small molecules can be translated into 
binding selectivity in case of larger molecules. This will also test the Etter’s approach 
that the best hydrogen-bond donor would bind with best hydrogen-bond acceptor in 
competitive conditions. We examined the competition between the acceptor sites in a 
family of ditopic coupled N-heterocycles comprising pyridine, pyrimidine, and 
pyrazine moieties with a series of mono/di-carboxylic acids and cyanoximes. 
(Chapter 4) 
 
3. To address the key questions concerning pharmaceutical co-crystals/salts: 1) Do co-
crystals/salts offer any solubility alterations over its parent forms? ii) Is there any 
change in thermal behavior? iii) Can their crystal structure be related to the displayed 
molecular behavior? We synthesized co-crystals/salts of three drug mimics and a 
pharmaceutical drug and tested their thermal stability and solubility in water and 
buffer solutions. (Chapter 5) 
  
4. To assemble hydrogen and halogen-bond functionalized cavitands into molecular 
capsules. Various hydrogen and halogen-bond functionalized resorcinarenes-based 
cavitands were synthesized and their ability to co-crystallize as well as to self-
assemble to give homodimeric and heterodimeric hydrogen and halogen-bonded 
capsules were studied. (Chapter 6) 
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CHAPTER 2 - Mapping out the synthetic landscape of 
recrystallization, co-crystallization and salt formation 
2.1 Introduction 
The synthetic method of choice for co-crystal synthesis typically employs a 
combination of complementary hydrogen-bond functionalities that reside on different 
molecular entities, and a key aspect of this approach is that heteromeric interactions 
(resulting in co-crystallization) need to be more favorable than homomeric interactions 
(which simply lead to recrystallization).1  Our operating strategy for supramolecular 
synthesis of binary co-crystals will be that if we can control the binding affinity between 
different molecules bearing complementary hydrogen-bond moieties, then we can 
manipulate the balance between homomeric and heteromeric interactions.  
Most hydrogen bonds are primarily electrostatic in nature and centers on the 
Coulombic attraction between an acidic hydrogen atom and a suitable acceptor atom with 
surplus negative charge.2  Therefore, it makes sense to foconcetrate on controlling the 
balance between electrostatic charges when developing versatile and modular synthetic 
strategies for hydrogen-bond driven assembly of co-crystals.3  By simply adding (through 
covalent synthesis) suitable electron-donating/withdrawing groups to a molecule, we can 
dial-in the electrostatic charge on the acidic proton of the hydrogen-bond donor site.  An 
increase in charge difference will increase the strength of the hydrogen bond which, in 
turn, will increase the chances of co-crystal formation (as long as the primary hydrogen-
bond donor and acceptor sites are located on different molecules).4   Hunter has 
demonstrated how molecular electrostatic potential (MEP) surface calculations can be 
used to assign relative hydrogen-bond donor/acceptor strengths of various chemical 
functionalities,2 and we will employ this approach for quantifying the electrostatic charge 
on individual atoms within molecules.  Prevailing definitions of the term ‘co-crystal’ 
state that such a compound only contain electrically neutral components5 and therefore in 
addition to controlling the efficiency of the assembly process, the supramolecular yield, 
we must also ensure that we actually produce the targeted co-crystal, and not a salt, Table 
2.1.     
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Table 2.1 Summary of possible outcomes in a series of attempted co-crystallization 
reactions. 
Reactants Driving force Products 
Homomeric interactions dominate A(s) + D(s)      Recrystallization 
Heteromeric interactions dominate [A⋅⋅⋅D](s)         Co-crystallization Asoln + Dsoln 
Proton transfer [A]n+[D]n-(s)     Salt formation 
 
The goal of this study is to map out the synthetic landscape that determines the 
solid-state outcome of the reactions between a series of Brönsted-Lowry acids and bases.  
The reactivity of each component will be examined using co-crystallization reactions, and 
rationalized in the context of electrostatic charges on individual hydrogen-bond 
donor/acceptor sites.   
Our model system comprises a library of aliphatic and aromatic carboxylic acids 
as the hydrogen-bond donor, and a series of substituted aminopyridine-based molecules 
as the hydrogen-bond acceptor.  The rationale behind the choice of base was based upon 
existing crystallographic data from the Cambridge Structural Database.6   
 
Table 2.2 CSD search on the ligands of interest in a series of pyridines. 
 Ligands Hits Salts Co-crystals 
1 2-aminopyridine 35 33 2 
2 2-amino-5-bromopyridine 1 1 0 
3 2-acetamidopyridine 8 0 8 
4 2-propiamido-5-bromopyridine 0 0 0 
5 2-amino-3,5-dibromopyridine 0 0 0 
6 2-acetamido-5-bromopyridine 0 0 0 
7 2-acetamido-3,5-dibromopyridine 0 0 0 
 
A CSD search for crystal structures containing 2-aminopyridine and a carboxylic 
acid resulted in 35 hits, 33 of which were salts.  A similar search for 2-acetamidopyridine 
and carboxylic acids yielded eight hits, all of which were co-crystals.  The latter base has 
the same chemical and geometric complementarity towards a carboxylic acid as does 2-
aminopyridine, but it is significantly less basic, and the pyridyl nitrogen atom has a 
substantially lower electrostatic charge.  The fact that the difference in electrostatic 
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charge on the two pyridyl-compounds lead to dramatically different products (33/35 salts 
vs 8/8 co-crystals), Table 2.2, indicates that this type of molecule can offer a test-bed for 
examining the parameters that govern hydrogen-bond driven co-crystal synthesis.  
           
                               (a)            (b) 
Figure 2.1 Formation of (a) 2-aminopyridinium carboxylate salt,  
    (b) 2-acetamidopyridine carboxylic acid co-crystal. 
 
Through covalent synthesis we can produce a specific charge on the pyridyl 
nitrogen atom and subsequently establish if there are defined boundaries between 
recrystallization/co-crystallization/salt-formation that can be understood and predicted a 
priori using MEPS derived charges and a simple electrostatic view of hydrogen-bonds.   
2.2 Experimental  
We employed seven pyridine-based molecules as hydrogen-bond acceptors, Figure 2.2.  
All of them have the same primary binding moiety comprising an N/N-H hydrogen-bond 
donor/acceptor site and the electrostatic charge on the pyridyl nitrogen atom is modulated 
through covalent substitutions that do not create any steric impediments to binding. 
          N NH2        N NH2
Br
         
N N
H
O
CH3       
N N
H
O
C
H2
Br
CH3
 
  1                               2                          3                                      4  
 
N NH2
Br Br
           
N N
H
O
CH3
Br
         
N N
H
O
CH3
Br Br
 
                        5                                    6                                          7 
Figure 2.2 Library of pyridine-based hydrogen-bond acceptors. 
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2.2.1 Synthesis of pyridyl compounds 
All carboxylic acids and the ligands 2-aminopyridine 1, 2-amino-5-bromopyridine 
2, and 2-amino-3,5-dibromopyridine 5 were purchased from Aldrich and used without 
further purification. Acetamido-substituted pyridines were synthesized following 
previously reported methods.7 The determinations of melting points were carried out on 
Fisher-Johns melting point apparatus and are uncorrected. Compounds were prepared for 
infrared spectroscopic (IR) analysis as a mixture in KBr. 1H NMR and 13C NMR spectra 
were recorded on a Varian Unity plus 200 MHz spectrometer in CDCl3. 
 
2.2.1.1 Synthesis of 2-acetamidopyridine, 3 
 
 
                           1                         3 
The synthesis of 2-acetamidopyridine 3 was carried out by a previously reported 
method.7 2-Aminopyridine 1 (1.0 g, 10.6 mmol) was dissolved in a mixture of pyridine (4 
mL) and acetic anhydride (5 mL). The resulting solution was stirred at room temperature 
for 24 hours. Water (20 mL) was added to the mixture and the solution evaporated to 
dryness. Upon recrystallization with ethyl acetate, large colorless crystals were obtained. 
Yield 80%, M. P. 73-75 °C; IR (KBr pellet) υ 1695 cm-1 (C=O, s), 1533 cm-1 (Amide II, 
s); 1H NMR (δH; 200 MHz, CDCl3): 9.05 (NH, br), 8.26 (2H, overlap), 7.72 (1H, dt), 
7.05 (1H, dt), 2.21 (3H, s). 
 
2.2.1.2 Synthesis of 2-propioamido-5-bromopyridine, 4  
 
     2       4 
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2-Amino-5-bromopyridine 2 (5.0 g, 28.9 mmol) was dissolved in propionic 
anhydride (5 mL). The mixture was refluxed at 65°C for 1 hr. The excess of propionic 
anhydride and propionic acid produced was removed via vacuum distillation to obtain a 
white powder. Upon recrystallization from ethyl acetate, white needle shaped crystals 
were obtained. Yield 95%,  M. P. 140-143 °C; IR (KBr pellet) υ 3241 cm-1 (N—H, br),  
1667 cm-1 (C=O, s), 1566 cm-1 (Amide II, s) ; 1H NMR (δH; 200 MHz, CDCl3): 8.31 
(1H, d), 8.17 (1H, d), 7.95 (NH, br), 7.8 (1H, dd), 2.44(2H, q), 1.25 (3H, t); 13C NMR 
(δC; 200 MHz, CDCl3): 172.71, 150.49, 148.54, 141.03, 115.63, 114.53, 30.82, 9.45.  
 
2.2.1.3 Synthesis of 2-acetamido-5-bromopyridine, 6   
 
     2            6 
2-Amino-5-bromopyridine 2 (3.47g, 20.00 mmol) was dissolved in acetic 
anhydride (5 mL) added dropwise. The mixture was heated under reflux at 60°C for 30 
mins. Excess acetic anhydride and acetic acid produced were removed via vacuum 
distillation to obtain a white powder. Upon recrystallization from methanol, white needle 
shaped crystals were obtained. Yield 85%, M. P. 176-178 °C; IR (KBr pellet) υ 3242 cm-
1 (N—H, br),  1670 cm-1 (C=O, s), 1538 cm-1 (Amide II, s); 1H NMR (δH; 200 MHz, 
CDCl3): 8.32 (1H, d), 8.2 (1H, s), 8.13 (NH, br), 7.8 (1H, dd), 2.21 (3H, s); 
13C NMR 
(δC; 200 MHz, CDCl3): 168.99, 150.44, 148.57, 141.1, 115.67, 114.69, 24.87. 
 
2.2.1.4 Synthesis of 2-acetamido-3,5-dibromopyridine,  7 
 
       5          7 
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2-Amino-3,5-dibromopyridine 5 (2.00 g, 7.94 mmol) was dissolved in acetic 
anhydride (3 mL). The mixture was refluxed at 50°C for 30 mins. The acetic acid was 
removed via vacuum distillation to obtain a mixture of 2-acetamido-3,5-dibromopyridine 
7, 2-bisacetamido-3,5-dibromopyridine, and the starting material.  Purification was 
carried out via column chromatography with hexane: ethyl acetate (7:3) as eluant. Upon 
recrystallization in acetonitrile, white needle shaped crystals were obtained. Yield 40%, 
M. P. 165-168 °C; IR (KBr pellet) υ 1678 cm-1 (C=O, s), 1510 cm-1 (Amide II, s); 1H 
NMR (δH; 200 MHz, CDCl3): 8.39(1H, d), 8.02(1H, d), 7.86(NH, br), 2.43(3H, s); 
13C 
NMR (δC; 200 MHz, CDCl3). 
 
2.2.2 Synthesis of co-crystals and salts 
Each of the seven pyridyl compounds was subjected to co-crystallization reactions 
with fifteen different carboxylic acids. There were ten monocarboxylic acids:  4-
cyanobenzoic acid (a), 3-hydroxybenzoic acid (b), 4-chlorobenzoic acid (c), 4-
fluorobenzoic acid (d), 4-nitrobenzoic acid (e), 3,4-dichlorobenzoic acid (f), 2,6-
difluorobenzoic acid (g), 3,5-dimethylbenzoic acid (h), 3,5-dinitrobenzoic acid (i), 
pentafluorobenzoic acid (j) and five dicarboxylic acids: suberic acid (k), phthalic acid (l), 
fumaric acid (m), succinic acid (n), and sebacic acid (o). A mixture of aliphatic and 
aromatic carboxylic acids, weak and strong, were included in the set in order to remove 
any inadvertent bias arising from the nature of the carboxylic acids. 
Stoichiometric amounts of base and acid, either 1:1 (monoacids) or 2:1 (diacids) 
were dissolved separately in suitable solvents and mixed together. The resulting solution 
was warmed and allowed to stand for slow evaporation at room temperature. The 
resulting precipitates were initially examined using IR spectroscopy.  Reactions that 
produced suitable crystals were characterized using single-crystal X-ray diffraction 
(eighteen such samples were obtained). 
2.2.2.1 Synthesis of 2-aminopyridinium 4-cyanobenzoate, 1a   
2-Aminopyridine (0.015 g, 0.160 mmol) was dissolved in 5mL of ethyl acetate. 
To this solution was added 4-cyanobenzoic acid (0.023 g, 0.160 mmol) in 5 mL of ethyl 
acetate. The resulting solution was warmed and allowed to stand for slow evaporation at 
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room temperature. Colorless, rod-shaped crystals were obtained after 4 days. M. P. 
191─194°C; IR (KBr pellet) υ 2433 cm-1, 1976 cm-1 (O-…H-N+, br), 1655 cm-1 (COO-, s) 
2.2.2.2 Synthesis of 2-aminopyridinium 4-chlorobenzoate, 1c   
2-Aminopyridine (0.015 g, 0.160 mmol) was dissolved in 5mL of ethyl acetate. 
To this solution was added 4-chlorobenzoic acid (0.025 g, 0.160 mmol) in 5 mL of ethyl 
acetate. The resulting solution was warmed and allowed to stand for slow evaporation at 
room temperature. Colorless, block-shaped crystals were obtained after 4 days. M. P. 
148─150°C; IR (KBr pellet) υ 2518 cm-1, 1947 cm-1 (O-…H-N+, br), 1670 cm-1 (COO-, s) 
2.2.2.3 Synthesis of 2-aminopyridinium 2,6-difluorobenzoate, 1g   
2-Aminopyridine (0.015 g, 0.160 mmol) was dissolved in 5mL of ethyl acetate. 
To this solution was added 2,6-difluorobenzoic acid (0.025 g, 0.160 mmol) in 5 mL of 
ethyl acetate. The resulting solution was warmed and allowed to stand for slow 
evaporation at room temperature. Colorless, hexagon-shaped crystals were obtained after 
3 days. M. P. 158─160°C; IR (KBr pellet) υ 2564 cm-1, 2022 cm-1 (O-…H-N+, br), 1617 
cm-1 (COO-, s) 
2.2.2.4 Synthesis of 2-aminopyridinium pentafluorobenzoate, 1j   
2-Aminopyridine (0.015 g, 0.160 mmol) was dissolved in 5mL of ethyl acetate. 
To this solution was added pentafluorobenzoic acid (0.034 g, 0.160 mmol) in 5 mL of 
ethyl acetate. The resulting solution was warmed and allowed to stand for slow 
evaporation at room temperature. Colorless, block-shaped crystals were obtained after 3 
days. M. P. 168─170°C; IR (KBr pellet) υ 2598 cm-1, 2022 cm-1 (O-…H-N+, br), 1593 
cm-1 (COO-, s) 
2.2.2.5 Synthesis of bis(2-aminopyridinium) suberate, 1k   
2-Aminopyridine (0.015 g, 0.160 mmol) was dissolved in 5mL of ethyl acetate. 
To this solution was added suberic acid (0.014 g, 0.080 mmol) in 5 mL of ethyl acetate. 
The resulting solution was warmed and allowed to stand for slow evaporation at room 
temperature. Colorless, needle-shaped crystals were obtained after 4 days. M. P. 
112─115°C; IR (KBr pellet) υ 2741 cm-1, 2016 cm-1 (O-…H-N+, br), 1502 cm-1 (COO-, s) 
 30  
2.2.2.6 Synthesis of bis(2-aminopyridinium) succinate, 1n   
2-Aminopyridine (0.015 g, 0.160 mmol) was dissolved in 5mL of ethyl acetate. 
To this solution was added succinic acid (0.01 g, 0.08 mmol) in 5 mL of ethyl acetate. 
The resulting solution was warmed and allowed to stand for slow evaporation at room 
temperature. Colorless, needle-like crystals were obtained after 4 days. M. P. 162─165 
°C; IR (KBr pellet) υ 2495 cm-1, 1964 cm-1 (O-…H-N+, br), 1656 cm-1 (COO-, s). 
2.2.2.7 Synthesis of bis(2-aminopyridinium) sebacate, 1o   
2-Aminopyridine (0.015 g, 0.160 mmol) was dissolved in 5mL of ethyl acetate. 
To this solution was added sebacic acid (0.016 g, 0.080 mmol) in 5 mL of ethyl acetate. 
The resulting solution was warmed and allowed to stand for slow evaporation at room 
temperature. Colorless, plate-like crystals were obtained after 4 days. M. P. 98─100 °C; 
IR (KBr pellet) υ 2370 cm-1, 1936 cm-1 (O-…H-N+, br), 1661 cm-1 (COO-, s). 
2.2.2.8 Synthesis of 2-amino-5-bromopyridinium 4-cyanobenzoate, 2a  
A solution of 2-amino-5-bromopyridine (0.030 g, 0.173 mmol) in 5 mL of 
acetonitrile was mixed with 4-cyanobenzoic acid (0.026 g, 0.173 mmol) in 5mL of 
acetonitrile and allowed to stand at room temperature for slow evaporation. Colorless, 
block-shaped crystals were obtained after 4 days. M. P. 143—145°C; IR (KBr pellet) υ 
2363 cm-1, 1983 cm-1 (O-…H-N+, br), 1671 cm-1 (COO-, s). 
2.2.2.9 Synthesis of 2-amino-5-bromopyridinium 4-nitrobenzoate, 2e   
A solution of 2-amino-5-bromopyridine (0.030 g, 0.173 mmol) in 5 mL of 
acetonitrile was mixed with 4-nitrobenzoic acid (0.029 g, 0.173 mmol) in 5mL of 
acetonitrile and allowed to stand at room temperature for slow evaporation. Yellow 
colored, flat crystals were obtained after 5 days. M. P. 172—174°C; IR (KBr pellet) υ 
2712 cm-1, 1945 cm-1 (O-…H-N+, br), 1649 cm-1 (COO-, s). 
2.2.2.10 Synthesis of 2-acetamidopyridine/succinic acid (2:1), 3n 
A solution of 2-acetamidopyridine (0.027 g, 0.200 mmol) and succinic acid 
(0.012g, 0.100 mmol) in 10 mL of ethanol was boiled and allowed to stand at room 
temperature for slow evaporation. Colorless prisms were afforded after one week. M. P. 
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165—167°C; IR (KBr pellet) υ 2450 cm-1, 1870 cm-1 (O—H…N, br), 1706 cm-1 (C=O, s), 
1550 cm-1 (Amide II, s). 
2.2.2.11 Synthesis of 2-propiamido-5-bromopyridine/3,4-dichlorobenzoic acid (1:1), 4f 
A solution of 2-propiamido-5-bromopyridine (0.030 g, 0.131 mmol) in 5 mL of 
acetonitrile was mixed with 3,4-dichlorobenzoic acid (0.025 g, 0.131 mmol) in 5mL of  
acetonitrile and allowed to stand at room temperature for slow evaporation. Colorless, 
thin, needle-shaped crystals were obtained after 4 days. M. P. 170—172°C; IR (KBr 
pellet) υ 2474 cm-1, 1923 cm-1 (O—H…N, br), 1705 cm-1 (C=O, s), 3259 cm-1 (N—H 
amide, s),  1570 cm-1 (Amide II, s). 
2.2.2.12 Synthesis of 2-propiamido-5-bromopyridine/suberic acid (2:1), 4k 
A solution of 2-propiamido-5-bromopyridine (0.030 g, 0.131 mmol) in 5 mL of 
acetonitrile was mixed with suberic acid (0.012 g, 0.066 mmol) in 5mL of acetonitrile 
and allowed to stand at room temperature for slow evaporation. Colorless, block-shaped 
crystals were obtained after 6 days. M. P. 118—120°C; IR (KBr pellet) υ 2597 cm-1, 
1816 cm-1 (O—H…N, br), 1700 cm-1 (C=O, s), 3255 cm-1 (N—H amide, s),  1565 cm-1 
(Amide II, s). 
2.2.2.13 Synthesis of 2-propiamido-5-bromopyridine/fumaric acid (2:1), 4m   
A solution of 2-propiamido-5-bromopyridine (0.030 g, 0.131 mmol) in 5 mL of 
acetonitrile was mixed with fumaric acid (0.008 g, 0.066 mmol) in 5mL of acetonitrile 
and allowed to stand at room temperature for slow evaporation. Colorless, thin, needle-
shaped crystals were obtained after 5 days. M. P. 176—180°C; IR (KBr pellet) υ 2456 
cm-1, 1867 cm-1 (O—H…N, br), 1705 cm-1 (C=O, s), 3254 cm-1 (N—H amide, s),  1550 
cm-1 (Amide II, s). 
2.2.2.14 Synthesis of 2-propiamido-5-bromopyridine/succinic acid (2:1), 4n  
A solution of 2-propiamido-5-bromopyridine (0.030 g, 0.131 mmol) in 5 mL of 
acetonitrile was mixed with succinic acid (0.008 g, 0.066 mmol) in 5mL of acetonitrile 
and allowed to stand at room temperature for slow evaporation. Colorless, rod-shaped 
crystals were obtained after 7 days. M. P. 150—151°C; IR (KBr pellet) υ 2529 cm-1, 
 32  
1863 cm-1 (O—H…N, br), 1702 cm-1 (C=O, s), 3259 cm-1 (N—H amide, s),  1580 cm-1 
(Amide II, s). 
2.2.2.15 Synthesis of 2-propiamido-5-bromopyridine/sebacic acid (2:1), 4o  
A solution of 2-propiamido-5-bromopyridine (0.030 g, 0.131 mmol) in 5 mL of 
acetonitrile was mixed with sebacic acid (0.013 g, 0.066 mmol) in 5mL of acetonitrile 
and allowed to stand at room temperature for slow evaporation. Colorless, block-shaped 
crystals were obtained after 5 days. M. P. 115—117°C; IR (KBr pellet) υ 2609 cm-1, 
1901 cm-1 (O—H…N, br), 1697 cm-1 (C=O, s), 3250 cm-1 (N—H amide, s),  1560 cm-1 
(Amide II, s). 
2.2.2.16 Synthesis of 2-amino-3,5-dibromopyridine/3,5-dinitrobenzoic acid (1:1),  5i   
A solution of 2-amino-3,5-dibromopyridine (0.015 g, 0.060 mmol) in 5 mL of 
ethanol was mixed with 3,5-dinitrobenzoic acid (0.013 g, 0.060 mmol) in 5mL of  
ethanol. The mixture was allowed to stand at room temperature for slow evaporation. 
Light brown colored, rod-shaped crystals were obtained after 4 days. M. P. 150—152°C; 
IR (KBr pellet) υ 2550 cm-1, 1890 cm-1 (O—H…N, br), 1697 cm-1 (C=O, s), 3477 cm-1 
(N—H amine, s). 
2.2.2.17 Synthesis of 2-amino-3,5-dibromopyridine/fumaric acid (2:1),  5m   
A solution of 2-amino-3,5-dibromopyridine (0.015 g, 0.060 mmol) in 5 mL of 
ethanol was mixed with 2,4-dinitrobenzoic acid (0.004 g, 0.030 mmol) in 5mL of  
ethanol. The mixture was allowed to stand at room temperature for slow evaporation. 
Light brown colored, needle-shaped crystals were obtained after 5 days. M. P. 198—
200°C; IR (KBr pellet) υ 2398 cm-1, 1930 cm-1 (O—H…N, br), 1696 cm-1 (C=O, s), 3437 
cm-1 (N—H amine, s). 
2.2.2.18 Synthesis of 2-acetamido-5-bromopyridine/succinic acid (2:1), 6n 
A solution of 2-acetamido-5-bromopyridine (0.03 g, 0.14 mmol) in 5 mL of ethyl 
acetate was mixed with fumaric acid (0.008 g, 0.070 mmol) in 5mL of ethyl acetate. The 
mixture was allowed to stand at room temperature for slow evaporation. Colorless, thin, 
rod-shaped crystals were obtained after 4 days. M. P. 158—160°C; IR (KBr pellet) υ 
2452 cm-1, 1870 cm-1 (O—H…N, br), 1707 cm-1 (C=O, s), 1560 cm-1 (Amide II, s). 
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2.2.3 Electrostatic charges calculations 
The magnitude of electrostatic charge on hydrogen-bond donors and acceptors in 
these molecules were obtained using semi-empirical AM1 calculations.8 Values for 
individual atoms are obtained by probing the MEPS (0.002 e/au isosurface, from AM1 
calculations) with a point charge.  For example, the 2-aminopyridine with its strongly 
electron donating amino group has higher charge (-288 kJ/mol) on the pyridyl-N than the 
pyridyl nitrogen atom in 2-acetamidopyridine (-260 kJ/mol). 
 
 
 
 
 
        
      
       2-aminopyridine, 1           2-amino-5-bromopyridine, 2       2-acetamidopyridine, 3 
          (-288 kcal/mol)                        (-275 kcal/mol)             (-260 kcal/mol) 
 
 
 
 
 
 
 
              2-propiamido-5-bromopyridine, 4           2-amino-3,5-dibromopyridine, 5 
                             (-244 kcal/mol)                         (-237 kcal/mol) 
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     2-acetamido-5-bromopyridine, 6      2-acetamido-3,5-bromopyridine, 7 
                                 (-230 kcal/mol)            (-220 kcal/mol) 
 
Figure 2.3 AM1 calculations of charges on pyridyl-N on all the ligands under study. 
 
2.2.4 Single Crystal X-ray Crystallography 
X-ray data were collected on a Bruker SMART APEX or a SMART 1000 
diffractometer using Mo Kα radiation and, where noted, were corrected for absorption 
using the multiscan procedure implemented by SADABS.  Data were collected using 
SMART.  The relevant X-ray data are summarized in Table 2.5 and labeling schemes and 
thermal ellipsoids for all structures are shown in Figures 2.4, 2.7, 2.15, and 2.18.   
 
2.3 Results  
Each pyridyl compound was allowed to react with the same set of 15 carboxylic 
acids. The solids from all 105 (7 x 15) reactions were screened by IR spectroscopy in 
order to establish if the result was a co-crystallization, salt formation or a 
recrystallization.9  The outcome of this analysis is displayed in Table 2.3. The IR 
stretching frequencies of interest of all the salts and co-crystals under study is listed in 
Table 2.4.   
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Table 2.3 Results in attempted co-crystallization reactions in pyridine series. 
 Ligands Salts Co-crystals No Reaction 
Supramol. 
yield % 
1 2-aminopyridine 15 0 0 100 
2 2-amino-5-bromopyridine 15 0 0 100 
3 2-acetamidopyridine 0 13 2 87 
4 2-propiamido-5-bromopyridine 0 14 1 93 
5 2-amino-3,5-dibromopyridine 0 12 3 80 
6 2-acetamido-5-bromopyridine 0 11 4 73 
7 2-acetamido-3,5-dibromopyridine 0 1 14 7 
 
 
A total of 20 crystal structures are obtained, out of which two are of the ligands 
by themselves, nine are co-crystals, and nine are salts. The co-crystals and salts are either 
in 1:1 or 2:1 stoichiometry 
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Table 2.4 IR stretching frequencies (cm-1) of salts and co-crystals under study. 
 
 Acids        
  1 2 3 4 5 6 7 
  
2-amino 
pyridine 
2-amino-5-
bromopyridin
e 
2-
acetamido 
pyridine 
2-
propiomido
-5-
bromopyrid
ine 
2-amino-
3,5-
dibromo 
pyridine 
2-
acetamido-
5-bromo 
pyridine 
2-acetamido-
3,5-dibromo 
pyridine 
         
a 
4-Cyano 
benzoic acid 
1376, 1531, 
1655, 1976,  
2433 
1364, 1475, 
1671, 1983, 
2363 
1702, 
1942, 2444 
1698, 
1893, 2546 
1707, 
1867, 2433 
1701, 
1902, 2553 
no reaction 
b 
3-Hydroxy 
benzoic acid 
1365, 
15551668, 
1970, 2524 
1398, 1525, 
1915, 2478 
1691, 
1873, 2478 
1674, 
1830, 2584 
1724, 
1890, 2627 
1688, 
1866, 2584 
no reaction 
c 
4-Chloro 
benzoic acid 
1382, 1540, 
1670, 1947, 
2518 
1394, 1500, 
1670, 1983, 
2550 
1713, 
1930, 2450 
1705, 
1889, 2460 
1685, 
1873, 2484 
no reaction no reaction 
d 
4-Fluoro 
benzoic acid 
1376, 1548, 
1595, 1966, 
2461 
1402, 1515, 
1650, 1863, 
2426 
1702, 
1862, 2415 
1710, 
1879, 2553 
1698, 
1868, 2461 
1711, 
1870, 2549 
no reaction 
e 
4-
Nitrobenzoic 
acid 
1348, 1554, 
1990, 2524 
1337, 1512, 
1649,  1945, 
2712 
1702, 
1919, 2455 
1698, 
1859, 2542 
1696, 
1890, 2444 
no reaction no reaction 
f 
3,4-Dichloro 
benzoic acid 
1371, 1542, 
1982, 2478 
1330, 1500, 
1633, 1880, 
2354 
1708, 
1936, 2455 
1705, 
1923, 2474 
1697, 
1879, 2495 
1714, 
1926, 2409 
no reaction 
g 
2,6-Difluoro 
benzoic acid 
1376, 1601, 
1617, 2022, 
2564 
1335, 1510, 
1652, 1929, 
2357 
1740, 
1944, 2433 
1710, 
1885, 2409 
1702, 
1839, 2490 
1713, 
1862, 2524 
no reaction 
h 
3,5-
Dimethylben
zoic acid 
1375, 1505, 
2008, 2386 
1325, 1486, 
1641, 1874, 
2443 
1696, 
1868, 2480 
1698, 
1857, 2518 
1690, 
1845, 2587 
1708, 
1873, 2598 
no reaction 
i 
3,5-Dinitro 
benzoic acid 
1350, 1548, 
1670, 1982, 
2735 
1350, 1539, 
1671, 2011, 
2470 
1725, 
1959, 2550 
1716, 
1821, 2527 
1698, 
1890, 2553 
1716, 
1896, 2774 
1691, 1919, 
2455 
j 
Pentafluoro 
benzoic acid 
1359, 1593, 
2022, 2598 
1371, 1601, 
1670,  1997, 
2410 
1724, 
1873, 2513 
1720, 
1866, 2439 
no reaction 
1711, 
1926, 2518 
no reaction 
k Duberic acid 
1338, 1502, 
2016, 2741 
1330, 1490, 
1650, 1927, 
2422 
1711, 
1869, 2500 
1700, 
1816, 2597 
1702, 
1890, 2655 
no reaction no reaction 
l Phthalic acid 
1390, 1561, 
1671, 1979, 
2480 
1355, 1535, 
1671, 1961, 
2520 
1730, 
1945, 2478 
no reaction 
1695, 
1953, 2541 
no reaction no reaction 
m Fumaric acid 
1379, 1483, 
1992, 2490 
1325, 1495, 
1645, 1874, 
2364 
1710, 
1845, 2440 
1705, 
1867, 2456 
1697, 
1930, 2398 
1707, 
1870, 2452 
no reaction 
n 
Succinic 
acid 
1376, 1542, 
1656, 1964, 
2495 
1340, 1475, 
1670, 1991, 
2525 
1706, 
1870, 2450 
1702, 
1863, 2529 
1702, 
1873, 2421 
1703, 
1870, 2540 
no reaction 
o Sebacic acid 
1312, 1500, 
1661, 1936, 
2370 
1312, 1505, 
1628, 1932, 
2456 
1709, 
1895, 2454 
1697, 
1901, 2609 
no reaction 
1711, 
1861, 2539 
no reaction 
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A summary of the crystallographic information for the salts and co-crystals are 
presented in the Appendix A and all the hydrogen-bond geometries are listed in Table 
2.5. 
 
Table 2.5 Hydrogen-bond geometries for the ligands, salts, and co-crystals under study. 
____________________________________________________________________________________ 
Structure D-H...A d(D-H)/Å           d(H...A)/Å d(D...A)/Å <(DHA)/º 
______________________________________________________________________________________ 
  
4i N(17)-H(17)...O(17)#1 0.84(4)  2.05(4)  2.858(3)  161(3) 
 
6ii N172-H172...O171#1  0.86(3)  2.10(2)  2.946(2)  167(2) 
  N171-H171...O172  0.80(3)  2.13(3)  2.925(2)  174(2) 
 
1aiii N(11)-H(11)...O(21)        0.96(2)  1.73(2)       2.6835(16)         175.6(19) 
         N(12)-H(12A)...O(22)   0.90(2)                  1.87(3)  2.7743(18) 174(2) 
         N(12)-H(12B)...O(22)#1         0.85(2)  2.01(2)               2.8329(18)           163(2) 
 
1civ  N(11)-H(11)...O(21)  0.94(2)  1.78(2)  2.7253(15) 174.9(18) 
  N(12)-H(12A)...O(22)  0.92(2)  1.85(2)  2.7631(16)          179(2) 
  N(12)-H(12B)...O(21)#1  0.89(2)  1.95(2)  2.8381(15) 176.0(18) 
 
1gv  N(11)-H(11)...O(21)  0.926(15)  1.730(15)  2.6531(11) 174.2(13) 
  N(12)-H(12A)...O(22)  0.874(16)  2.026(16)  2.8790(12) 165.0(14) 
  N(12)-H(12B)...O(21)#1  0.885(16)  1.937(16)  2.8139(12) 170.5(14) 
 
1jvi  N(11)-H(11)...O(21)  0.926(15)  1.783(15)  2.7037(11) 172.4(14) 
  N(12)-H(12A)...O(22)  0.871(16)  1.973(16)  2.8256(12) 165.7(14) 
  N(12)-H(12B)...O(21)#1  0.866(15)  1.977(15)  2.8388(12) 173.3(14) 
 
1kvii  N(11)-H(11)...O(21)  0.945(12) 1.675(12)  2.6166(9)  174.1(11) 
  N(12)-H(12A)...O(22)  0.893(14)  1.875(14)  2.7639(10) 173.5(12) 
  N(12)-H(12B)...O(22)#2  0.890(13)  1.941(13)  2.7876(9)  158.5(12) 
 
1nviii   N(11)-H(11)...O(21)  0.958(13)  1.742(13)  2.6981(9)  174.9(12) 
  N(12)-H(12A)...O(22)  0.885(14)  1.985(14)  2.8526(10) 166.2(14) 
  N(12)-H(12B)...O(22)#3  0.858(15)  2.078(15)  2.9222(10) 168.0(13) 
  O(31)-H(31)...O(21)  0.886(15)  1.699(15)  2.5806(9)  172.6(14) 
 
1oix   N(11)-H(11)...O(21)  1.007(12)  1.574(12)  2.5786(9)  174.3(10) 
  N(12)-H(12A)...O(22)  0.915(13)  1.912(14)  2.8224(10) 172.7(12) 
  N(12)-H(12B)...O(22)#2  0.901(13)  2.009(13)  2.8641(10) 158.0(11) 
 
2ax   N(11)-H(11)...O(21) 0.85(3) 1.79(3) 2.627(3) 171(2) 
  N(12)-H(12A)...O(22)  0.71(3)  2.11(3)  2.817(2)  172(3) 
  N(12)-H(12B)...O(21)#1  0.91(2)  2.10(3)  2.954(2)  154(2) 
 
2exi  N(11)-H(11)...O(21)  1.03(3)  1.60(4)  2.614(3)  170(3) 
  N(12)-H(12A)...O(22)  0.84(4)  2.03(4)  2.829(3)  161(4) 
  N(12)-H(12B)...O(21)#1  0.94(4)  2.21(4)  3.061(3)  151(3) 
 
3nxii  O(31)-H(31)...N(11)  0.930(16)  1.716(16)  2.6421(10) 173.7(14) 
  N(12)-H(12)...O(32)  0.861(14)  2.016(14)  2.8743(10) 174.7(11) 
 
4fxiii  N(12)-H(12)...O(22)  0.83(2)  2.09(2)  2.9242(16) 174.0(18) 
  O(21)-H(21)...N(11)  0.90(2)  1.74(2)  2.6274(16) 170(2) 
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_____________________________________________________________________________________ 
Structure D-H...A d(D-H)/Å           d(H...A)/Å d(D...A)/Å <(DHA)/º 
______________________________________________________________________________________  
 
4kxiv  O(21)-H(21)...N(11) 0.77(2) 1.98(2) 2.7538(19) 174(2) 
  N(12)-H(12)...O(22)  0.75(2)  2.12(2)  2.8686(19) 177(2) 
 
4mxv  N(16)-H(16)...O(22)  0.76(2)  2.12(2)  2.8818(18) 174(2) 
  O(21)-H(21)...N(11) 0.73(2) 1.93(2) 2.6537(18) 168(2) 
 
 
4nxvi  O311-H311...N111  0.84   1.87   2.705(12)  171.6 
  O312-H312...N112  0.84   1.87  2.705(12)  174.1 
 O313-H313...N113  0.84  1.85 2.689(14)  172.9 
  O314-H314...N114  0.84  1.84  2.677(13)  177.8 
  N171-H171...O321  0.88   2.02   2.874(17)  162.3 
  N172-H172...O322  0.88   2.06   2.887(15)  156.7 
  N173-H173...O323  0.88   2.06   2.917(18)  163.0 
  N174-H174...O324  0.88   2.06   2.921(18)  166.2 
  O341-H341...N211  0.84   1.84   2.672(12)  169.5 
  O342-H342...N212  0.84   1.88   2.711(11)  171.2 
  O343-H343...N213  0.84   1.88   2.714(12)  173.1 
  O344-H344...N214  0.84   1.86   2.699(13)  176.2 
  N271-H271...O331  0.88   2.02   2.878(16)  164.8 
  N272-H272...O332  0.88   2.00   2.867(16)  169.3 
  N273-H273...O333  0.88   2.03   2.900(18)  170.1 
  N274-H274...O334   0.88   2.07  2.926(18) 163.1 
 
4oxvii  O(31)-H(31)...N(11) 0.77(2) 1.99(2) 2.7522(17) 174(2) 
  N(12)-H(12)...O(32)  0.82(2)  2.01(2)  2.8209(17) 169(2) 
 
5ixviii  O211-H211...N111 0.83(3) 1.76(4) 2.580(3) 170(3) 
  O212-H212...N112  1.19(3)  1.35(3)  2.538(3)  173(3) 
  N121-H12A1...O221  0.85(4)  2.21(4)  3.030(3)  161(3) 
  N122-H12A2...O222  0.93(4)  2.03(4)  2.946(3)  170(3) 
  N121-H12B1...O232  0.89(4)  2.20(4)  3.034(3)  157(3) 
  N122-H12B2...O231#1  0.94(3)  2.22(3)  2.958(3)  135(3) 
 
5mxix  O(21)-H(21)...N(11) 0.839(16) 1.758(17) 2.5855(12) 168.3(15) 
  N(12)-H(12A)...O(22)  0.814(16)  2.145(16)  2.9510(13) 170.7(14) 
  N(12)-H(12B)...O(22)#2  0.812(15)  2.272(14)  2.9839(11) 146.5(14) 
 
6nxx  O(21)-H(21)...N(11) 0.73(4) 1.99(4) 2.716(4) 174(5) 
  N(12)-H(12)...O(22)  0.77(4)  2.13(4)  2.900(4)  171(4) 
 
 
 
i) #1 x-1/2,y,-z+3/2   ii) #1 x+1,y+1,z   iii) #1 -x+1,y-1/2,-z+1   iv) #1 x-1/2,-y+1,z-1/2   v) #1 -x+3/2,y+1/2,z   vi) #1 
x,-y+1/2,z-1/2   vii) #1 -x,-y+2,-z    #2 -x+1/2,y-1/2,-z+1/2   viii) #1 -x+1,-y,-z+1    #2 -x,-y+2,-z+1    #3 -x+1,y-1/2,-
z+3/2   ix) #1 -x,-y+2,-z    #2 -x+1/2,y-1/2,-z+1/2   x)  #1 x-1/2,-y+1,z   xi) #1 x,y-1,z   xii) #1 -x+1,-y,-z; xiii) n/a   xiv) 
#1 -x-1,-y+1,-z   xv)  #1 -x-1,-y+1,-z+1   xvi) n/a   xvii) #1 -x,-y+1,-z+1   xviii) #1 x+1,y,z+1   xix) #1 -x+1,-y,-z+1    
#2 -x+1,y+1/2,-z+3/2   xx) #1 -x-1,-y,-z      
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4     6 
Figure 2.4 Thermal ellipsoid plots (50 % probabilities) and labeling schemes for 2-
propiamido-5-bromopyridine 4, and 2-acetamido-5-bromopyridine 6.  
 
2.3.1 Crystal structure of 2-propiamido-5-bromopyridine, 4 
The crystal structure of 2 shows one molecule within the asymmetric unit, with the 
extension of the molecular architecture showing the ligands forming zigzag 1-D strands 
via self-complementary N-H···O hydrogen bonds (N17…O17, 2.858(3) Å), Figure 2.5. 
 
 
Figure 2.5 Formation of 1-D strands of 2-propiamido-5-bromopyridine, 4 via N-H···O 
hydrogen bonding. 
 
2.3.2 Crystal structure of 2-acetamido-5-bromopyridine, 6 
The crystal structure of 1 shows one molecule within the asymmetric unit, with 
the extension of the molecular architecture showing the ligands forming zigzag 1-D 
strands via self-complementary N-H···O hydrogen bonds (N17…O17, 2.946(2) Å), Figure 
2.6. 
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Figure 2.6 Formation of 1-D strands of 2-acetamido-5-bromopyridine, 6 via N-H···O 
hydrogen bonding. 
 
 
 
   
    
            1a       1c 
    
            1g          1j 
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                     1k              1o 
 
                    1n 
Figure 2.7 Thermal ellipsoid plots (50 % probabilities) and labeling schemes for 1a-1o. 
 
2.3.3 Crystal structures of 1a, 1c, 1g, 1j, 1k, and 1o 
The crystal structures of 1a, 1c, 1g, and 1j show an 1:1 ionic salt comprising a 
protonated ligand 2-aminopyridinium ion and a 4-cyanobenzoate ion, 4-chlorobenzoate 
ion, 2,6-diflurobenzoate ion, and pentaflurobenzoate ion respectively; whereas the crystal 
structures of 1k and 1o reveal 2:1 ionic salts consisting of two 2-aminopyridium ions and 
a suberate or sebacate ion respectively connected via hydrogen-bonding interactions 
between aminopyridinium and carboxylate moieties. The primary synthons in these 
structures are charge-assisted N–H+···O- and N–H···O- hydrogen bonds. These individual 
1:1 or 2:1 ion pairs are further connected to the neighboring ion pairs via N–H···O 
hydrogen bonds between the anti-amino proton and the carboxylate oxygen atom to give 
a cross-linked network, Figure 2.8 – 2.13. 
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Figure 2.8 1-D strand formed through secondary N–H···O- hydrogen bonds in 2-
aminopyrimidinium 4-cyanobenzoate, 1a. 
 
 
Figure 2.9 1-D strand formed through secondary N–H···O- hydrogen bonds in 2-
aminopyrimidinium 4-chlorobenzoate, 1c. 
 
 
Figure 2.10 1-D strands of 2-aminopyridinium 2,6-difluorobenzoate, 1g. 
 
 
Figure 2.11 1-D strands of 2-aminopyridinium pentafluorobenzoate, 1j. 
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Figure 2.12 1-D strands of bis(2-aminopyridinium) suberate, 1k. 
 
 
Figure 2.13 1-D strands of bis(2-aminopyridinium) sebacate, 1o. 
  
2.3.4 Crystal structure of bis(2-aminopyridinium) succinate succinic acid, 1n 
The crystal structure of 1n is an interesting exception to the complexes obtained 
from 2-aminopyridine. The main motif consists of 2:1 protonated 2-aminopyridine linked 
with a succinate ion via charge-assisted N–H+···O- and N–H···O hydrogen bonds with 
N(11)–H(11)...O(21) and N(12)–H(12A)...O(22) distances of 2.6981(9)Å and 2.8526(10) 
Å respectively, which are further connected to the next ion pair via N–H···O hydrogen 
bonds between the anti-amino proton and the carboxylate oxygen atom, N(12)–
H(12B)...O(21) with 2.9222(10), similar to the previous complexes. In addition, there is a 
free carboxylic acid which is connected to the carboxylate ion moiety via complementary 
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O–H···O- hydrogen-bond interactions to extend into 2-D network, O(31)-H(31)...O(21)  
with bond distance 2.5806(9), Figure 2.14. 
 
 
Figure 2.14 1-D strands of bis(2-aminopyridinium) succinate succinic acid, 1n. 
 
 
 
         
   2a                 2e 
Figure 2.15 Thermal ellipsoid plots (50 % probabilities) and labeling schemes for 2a and 2e. 
 
2.3.5 Crystal structure of 2-amino-5-bromopyridinium 4-cyanobenzoate, 2a 
 The crystal structure of 2a displays 1:1 architecture with similar connectivities as 
seen for the salts of 2-aminopyridine. The asymmetric unit consists of one protonated 2-
amino-5-bromopyridinium ion and 4-cyanobenzoate ion as the primary synthon 
connected via charge-assisted N–H+···O- and N–H···O- hydrogen bonds with N(11)–
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H(11)...O(21) and N(12)–H(12A)...O(22) distances of 2.627(3) Å and 2.817(2) Å 
respectively.   Secondary N–H···O- hydrogen bonds, N(12)–H(12B)...O(21) with 2.954(2) 
Å exists between the anti-amino proton and the carboxylate oxygen atom, resulting in the 
extension of the network, Figure 2.16. 
 
 
Figure 2.16 1-D strands of 2-amino-5-bromopyridinium 4-cyanobenzoate, 2a. 
 
2.3.6 Crystal structure of 2-amino-5-bromopyridinium 4-nitrobenzoate, 2e 
The crystal structure of 2e displays 1:1 architecture similar to 2a with one 
protonated 2-amino-5-bromopyridinium ion and a 4-nitrobenzoate ion connected via 
charge-assisted N–H+···O- and N–H···O- hydrogen bonds with N(11)–H(11)...O(21) and 
N(12)–H(12A)...O(22) distances of 2.614(3) Å and 2.829(3) Å respectively and 
secondary N–H···O- hydrogen bonds, N(12)–H(12B)...O(21) with 3.061(3) Å between the 
anti-amino proton and the neighboring carboxylate oxygen atom to form a 2-D network. 
The bromine atom in this case, in contrast to 2a, is actively involved in formation of 
halogen bond between the nitro-oxygen atom of the nitrobenzoic acid via N–O···Br 
interaction, hence binding the hetero-dimers together into chain-like sheets which in turn 
were held together via N-H---O- secondary interactions, Figure 2.17. 
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Figure 2.17 2-D network of 2-amino-5-bromopyridinium 4-nitrobenzoate, 2e.  
 
 
   
   3n      4f 
 
 
   
4k      4m 
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4n      4o 
 
     
                       5i     5m 
 
          6n 
Figure 2.18 Thermal ellipsoid plots (50 % probabilities) and labeling schemes for 3n, 4f, 4k, 
4m, 4n, 4o, 5i, 5m, and 6n. 
 
2.3.7 Crystal structures of 3n, 4f, 4k, 4o, and 6n 
The crystal structures of 3n,  4k, 4o and 6n show 2:1 co-crystal (1:1 co-crystal for 
4f) comprising of the neutral ligand and one acid molecule connected via hydrogen 
bonding interactions in the asymmetric unit. The primary synthons in these structures are 
N–H···O and N···H–O hydrogen bonds. The bromine atom present in the ligand does not 
contribute in the interaction, Figure 2.19 – 2.23.  
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Figure 2.19 2:1 Co-crystal of 2-acetamidopyridine/succinic acid, 3n. 
 
 
Figure 2.20 1:1 Co-crystal of 2-propiamido-5-bromopyridine/3,4-dichlorobenzoic acid, 
4f 
 
 
Figure 2.21 2:1 Co-crystal of 2-propiamido-5-bromopyridine/suberic acid, 4k. 
 
 
Figure 2.22 2:1 Co-crystal of 2-propiamido-5-bromopyridine/sebacic acid, 4o. 
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Figure 2.23 2:1 Co-crystal of 2-acetamido-5-bromopyridine/succinic acid, 6n. 
 
2.3.8 Crystal structures of 4m and 4n 
The crystal structure of 4m and 4n displays a primary motif composed of the 
ligand 2-propiamido-5-bromopyridine and the fumaric acid or succinic acid in a 2:1 ratio. 
The primary synthons in these structures are N–H···O and N···H–O hydrogen bonds 
between the propiamidopyridine moieties and the carboxylic acid. The secondary Br···O–
H interaction between the carboxylic O-H and the bromine atom from the ligand extend 
the architecture into a four-component square, Figure 2.24 – 2.25. 
  
 
Figure 2.24 2:1 Co-crystal of 2-propiamido-5-bromopyridine/fumaric acid, 4m. 
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Figure 2.25 2:1 Co-crystal of 2-propiamido-5-bromopyridine/succinic acid, 4n exhibiting 
the four-component square-like system. 
 
2.3.9 Crystal structure of 2-amino-3,5-dibromopyridine/3,5-dinitrobenzoic acid, 
5i 
The crystal structure of 5i displays a 1:1 co-crystal with 2-amino-3,5-
dibromopyridine and 3,5-dinitrobenzoic acid connected via N–H···O and N···H–O 
hydrogen bonds. The anti-amino proton in the ligand interacts with the nitro group of the 
carboxylic acid via N–H···O=N interaction to extend the architecture. This secondary 
interaction is further augmented by a halogen bond Br···O=C interaction between one of 
the bromine atoms in the ligand and the carbonyl oxygen atom in the acid, whereas the 
second Br atom remains inactive. An interesting feature in this crystal structure is the 
intermolecular N=O···O=N interaction between two dinitrobenzoic acids, Figure 2.26. 
 
 
Figure 2.26 1:1 Co-crystal of 2-amino-3,5-dibromopyridine/3,5-dinitrobenzoic acid,  5i. 
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2.3.10 Crystal structure of 2-amino-3,5-dibromopyridine/fumaric acid, 5m 
The crystal structure of 5m displays 2:1 co-crystal with 2-amino-3,5-
dibromopyridine and fumaric acid as the primary synthon connected via N–H···O and 
N···H–O hydrogen bonds. The anti-amino proton in the ligand interacts with the carbonyl 
oxygen atom from the neighbouring carboxylic acid via N–H···O=C interaction. Halogen 
bonding Br···O–H is seen between one of the bromine atoms in the ligand and the 
hydroxyl oxygen atom in the acid, whereas the second Br atom remains inactive, Figure 
2.27. 
 
Figure 2.27 2:1 Co-crystal of 2-amino-3,5-dibromopyridine/fumaric acid, 5m. 
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2.4 Discussion 
2.4.1 Analysis of pyridine-carboxylic acid salts and co-crystals through FT-IR 
spectroscopy 
 
The distinction between salt and co-crystal was based on the specific stretches and 
shifting of carbonyl stretches between free and ligand-bonded carboxylic acids. In 
general, a free monomeric C=O stretch for aromatic carboxylic acids is seen around 1760 
cm-1 whereas a dimeric C=O stretch is seen around 1720-1706 cm-1. The 
presence/absence of broad stretches near 1950 and 2450 cm-1 are indicative of 
intermolecular O—H---N(heterocycle) hydrogen bonds and will only appear in salts and 
co-crystals, and not in physical mixtures of the two reagents.10 The characteristic 
difference in the IR spectrum between the salt and co-crystal lies in the position of the 
C=O stretch, which in case of a co-crystal (containing a neutral carboxylic acid) is seen 
as a strong band near 1700 cm-1 in view of the intact COOH moiety and a weak C—O 
stretch near 1275 cm-1. The salts containing the carboxylate anion however, show a 
strong asymmetrical COO- stretch around 1650-1550 cm-1 and a weaker symmetrical 
stretch around 1400 cm-1(absent in co-crystals).10 In the case where no reaction has taken 
place between the two reactants, the IR spectrum of the resulting solid is simply a 
superimposition of the IR spectra of the two components with no new bands.  
 
An analysis of the infrared spectra obtained for the combination of different 
carboxylic acids, a-o, with each of the seven ligands, 1-7,  showed that out of 105, 30 
resulted in salts (28%), 51 gave co-crystals (49%), and 24 produced no reaction (23%).  
All attempted reactions between a carboxylic acid and any of the two ligands 1 and 2 
resulted exclusively in salts.  These results correlate well with the charge calculation on 
these molecules since the presence of a strongly electron-donating amino group in the 
ring raises the charge on the pyridyl-N and hence boosts its capability to remove a proton 
from the acid resulting in two charged species.  Even though the presence of a weakly 
electron withdrawing bromine in the ligand 2 decreases the charge on the pyridyl 
nitrogen atom (to –275 kJ/mol), it is still sufficiently basic to produce salts in every case. 
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Table 2.6 Summary of results in a series of attempted co-crystallization reactions. 
  
charge 
(kJ mol-1) 
salt co-crystal no reaction %  
1 
N NH2  
-288 15 0 0 100 
2 
N NH2
Br
 
-275 15 0 0 100 
salt 
3 
N N
H
C
O
CH3  
-260 0 13 2 87 
4 
N N
H
C
O
Br
CH3
 
-244 0 14 1 93 
5 
N NH2
Br Br
 
-237 
 
0 12 3 80 
6 
N N
H
C
O
CH3
Br
 
-230 0 11 4 73 
co-crystal 
7 
N N
H
C
O
CH3
Br Br
 
-220 0 1 14 7 none 
 
None of the less basic ligands (3 - 6) produced salts but instead were capable of 
producing co-crystals with varying degree of success.   These results are also in complete 
agreement with the trend suggested by AM1 charge calculations for these ligands. The 
ligand 3 and 4 with third and fourth priority in the charge order gave 13 and 14 co-
crystals (87% and 93% supramolecular yield). These results can be explained in terms of 
reduced electron donating capability of acetamido and propiamido moieties compared to 
the amino group. The ligand 5 with two bromines in the ring further decreases the 
electron density; hence the low charge on the pyridyl-N. This is implicated in the 
decreased ability to form intermolecular interactions (80% supramolecular yield). The 
ligand 7 with lowest charge has the least ability to form intermolecular interactions (7% 
supramolecular yield). 
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2.4.2 Single crystal X-ray analysis of pyridine-carboxylic acid salts and co-
crystals  
 
 
Figure 2.28 Crystal structure of 3-acetamidopyridine showing the 1D chain held by N-
H…N interaction.11 
     
The single crystal X-ray structures of the ligands under study, 2-propiamido-5-
bromopyridine 4 and 2-acetamido-5-bromopyridine 6 show one dimensional chain 
structure with the two entities held together via N-H…O hydrogen bond interactions, 
Figure 2.5 – 2.6. However, the structurally closely-related ligand 3-acetamidopyridine 
exhibit similar 1D chain structure but are held by N-H…N hydrogen bonds, figure 2.28 
One explanation may be the steric hindrance due to the bromine atom, which require the 
molecules to be as possible hence shifting the hydrogen bonding pattern from N-H…N to 
N-H..O. There is no reported crystal structures available for 2-acetamido or 4-
acetamidopyridine and bromosubstitued 3-acetamido or 4-acetamidopyridines to make a 
comparison of binding preferences with the change in the position of the acetamido group 
relative to the pyridyl nitrogen. 
  Out of 18 crystal structures studied from the co-crystallization experiment, 9 were 
co-crystals (50%), 8 were salts (44%) and 1 (6%) came out to be complex with ionic/co-
crystal pair. The stoichiometries for the salts and co-crystals were as expected; with one 
ligand and one carboxylic acid (1:1) for monocarboxylic acids and with two ligands and 
one carboxylic acid (2:1) in the asymmetric unit for dicarboxylic acids. A summary of all 
the crystallographic information for the salts and co-crystals was given in Table 2.5. 
All crystal structures revealed the primary hydrogen bonding motif as O—H---
N(Py) and C=O---H—N in co-crystals and C—O----H—N+(Py) and   C—O----H—N in 
salts.  In the ligands containing the amino group, 1a, 1c, 1g, 1j, 1k, 1n, 1o, 2a, and 2e, the 
second proton from the amino group (not involved in the primary interaction) interacts 
with C—O- from acid. In addition, Br---O—N interaction is seen for 2e. A surprising 
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case is 1n which is a complex between 2-aminopyridine and succinic acid. In addition to 
the ionic interaction (C—O----H—N+(Py) and   C—O----H—N) between the 2-
aminopyridinium moiety and the carboxylate moiety, there exists C—O----H—O (free 
acid) interaction. So this particular case can be treated as a complex with ionic/co-crystal 
pair. No secondary interactions were seen for the crystal structures 3n, 4f, 4k, 4n, 4o, 6n. 
For crystals 4m and 5m, Br---O—H interaction is seen. For 5m, the second NH proton 
interacts with carbonyl oxygen where as the second Br atom is inactive. For 5i, Br---O=C 
interaction is seen, whereas the second Br is inactive. An interesting feature in this crystal 
structure is the intermolecular N=O---O=N interaction between two dinitrobenzoic acids 
along with N=O---H—N interaction with the remaining NH proton from the amino 
group. 
Comparison of crystal data for salts and co-crystals shows that the average ratio 
of carbonyl C=O bond distance to C-OH bond distance in co-crystals is 1.08 Å, where as 
the ration of C-O- bond distance for the carboxylate anion is 1.02 Å. Similarly, the 
average C—OH---N(py) bond length in co-crystals is 2.665Å, whereas  the average C—
O----H—N+(py) bond length in salts is 2.656 Å.  The average C=O---HNR bond length in 
co-crystals is 2.908 Å and C—O----HNR is 2.814 Å. The average C—N—C pyridyl bond 
angle in carboxylic acid is 119.482° and that in C—NH+—C is 122.40°, Table 2.7. These 
are the excepted results, since the stronger binding of the carboxylate anion to the 
protonated pyridine compound would lead to stronger and hence shorter bond compared 
to the weaker, neutral hydrogen bonding found in co-crystals.  
As seen in the Table 2.2, a charge of -275 or higher resulted in salts whereas 
charges in between -260 to -230 resulted in a decreasing trend in an ability to form co-
crystals, and a charge of -220 resulted in a physical mixture only. Based upon these 
results, a cut-off point in terms of electrostatic charge on the molecule may be drawn for 
the formation of salts and co-crystals, or any interaction at all. 
Studies also revealed that in our case, the co-crystal formation is driven entirely 
by the charge in the py-N (ligand) and not by the carboxylic acid. The choice of the same 
15 carboxylic acid used aid to create homogeneity in the experiment with the trend 
showing no link with the type of acid used. The stronger acid, 4-nitrobenzoic acid (e) 
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gave a physical mixture with 2-acetamido-5-bromopyridine (6), whereas a weaker acid, 
3-hydroxybenzoic acid (c) gave co-crystal.  
 
Table 2.7 Comparison of bond distances and bond angles in salts and co-crystals 
  C─OH C=O ratio 
C─O¯ ---
H─N+(py) 
C─O¯ 
---
H─NR] ratio 
COH 
---
N(py) 
C=O-
--
HNR 
C─O¯---
H─N+(py) 
C─O¯-
--
H─NR C─N─C 
C─NH+─C 
 
             
1a  x  x  x 1.257  1.261 0.997   x  x  2.684  2.774  x 122.53  
1c  x  x  x 1.27 1.255 1.012  x  x 2.725 2.763  x 122.25 
1g  x  x  x 1.262 1.233 1.024   x  x 2.653   2.879  x 122.75 
1j  x  x  x 1.258  1.234  1.019  x  x 2.704   2.826  x 122.59  
1k  x  x  x 1.264   1.25 1.011  x  x 2.617   2.764  x 122.06 
1n  x  x  x 1.278  1.245 1.027  x  x 2.698   2.853  x 122.71 
1o  x  x  x 1.27 1.247 1.018  x  x 2.579 2.822  x 121.71 
2a  x  x  x 1.277 1.233 1.036  x  x 2.627 2.817  x 122.3 
2e  x  x  x 1.267 1.252 1.012  x  x 2.614 2.829  x 122.7 
3n 1.314 1.226 1.072 x x x 2.642 2.874 x x 118.8 x 
4f 1.319 1.226 1.076 x x x 2.628 2.924 x x 119.2 x 
4k 1.32 1.216 1.086 x x x 2.754 2.868 x x 118.7 x 
4m 1.306 1.215 1.075 x x x 2.654 2.882 x x 119.1 x 
4n 1.311 1.205 1.088 x x x 2.677 2.92 x x 120 x 
4o 1.316  1.21  1.088  x x x 2.752   2.821 x x 118.54 x 
5i 1.311 1.212 1.082 x x x 2.58 3.03 x x 121.1 x 
5m 1.305 1.224 1.066 x x x 2.585 2.951 x x 120.8 x 
6n 1.313 1.214 1.082 x x x 2.716 2.9 x x 119.1 x 
             
Avg     1.079     1.017 2.665 2.908 2.656 2.814 119.482 122.4 
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2.4.3 Secondary hydrogen bonding and halogen bonding motifs 
In addition to the primary hydrogen bonding motifs found in the crystal structures 
of the salts and co-crystals of the pyridine series under study, there exists another set of 
interactions which comprises both hydrogen and halogen bonding interactions that assists 
in extension of the architecture of these molecules. The secondary hydrogen bonding 
interaction here involves N-H---O-, N-H---O, and O-H---O- synthons. The halogen 
bonding secondary interaction involves a halogen atom (bromine atom in this case) as the 
halogen bond donor, and highly electronegative oxygen atom as the halogen bond 
acceptor. We identified seven different types of motifs, Figure 2.28, and the frequency of 
occurrence of each motif is summarized in Table 2.8. 
           
  I            II           III 
 
          
   IV             V 
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          VI               VII 
Figure 2.29 Secondary motifs observed in the salts and co-crystals in the pyridine series. 
 
 
Table 2.8 Secondary structural motifs found in the pyridine series. 
Ligand Carboxylic acid Structure 
Secondary 
structural motif 
4-Cyanobenzoic acid 1a I 
4-Chlorobenzoic acid 1c II 
2,6-Diflurobenzoic acid 1g II 
Pentaflurobenzoic acid 1j II 
Suberic acid 1k I 
Succinic acid 1n III 
 
 
 
Sebacic acid 1o I 
4-Cyanobenzoic acid 2a II 
 
4-Nitrobenzoic acid 2e IV 
Fumaric acid 4m V 
 
Succinic acid 4n V 
3,5-Dinitrobenzoic acid 5i VI 
 
Fumaric acid 5m VII 
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2.5 Conclusions 
 
Our experimental results successfully demonstrated the relationship between the 
charge and the potential of a compound to form intermolecular hydrogen bonds. The 
higher charges in a molecule corresponded with the formation of salt via proton transfer, 
whereas the lower charges lead to interaction between neutral moieties to give co-
crystals, and the least charges resulted in no interaction between the moieties. It proves 
that charge in the molecule plays a huge role in their ability to exhibit intermolecular 
interactions. 
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CHAPTER 3 - Measuring binding energies in solution using 
Isothermal Titration Calorimetry (ITC) 
3.1 Introduction 
3.1.1 Correlating solid-state binding with solution behavior 
The formation of a co-crystal determines thermodynamic events that lead to an 
overall decrease in the energy (stabilization) of the system. The bringing together of two 
neutral molecular entities via weak non-covalent interactions may result in release of 
energy to give an energy-minimum stable compound. The amount of energy released 
may be correlated to the strength of the intermolecular interaction.1 The most 
experimentally observable thermodynamic quantity occurring during the conversion of a 
free (unbound) to the bound state is heat (enthalpy).2 Calorimetry is the measurement of 
energy changes that occur during a chemical process in the form of heat released 
(exothermic) or heat absorbed (endothermic).3 Various calorimetric methods have been 
devised to measure the energy change during a reaction, the most common being 
Differential Scanning calorimetry (DSC) and isothermal titration calorimetry (ITC).4 In 
DSC, the temperature of a sample is increased linearly as a function of time, whereas the 
sample is maintained at a constant temperature in ITC.  
In Chapter 2, we correlated the charges in a molecule to the capability to form co-
crystals in a range of pyridine compounds. In this chapter we tend to seek if this solid-
state behavior is reflected in solution as well. The study was carried out with 2-
acetamidopyridine as the model compound due to its highly effective co-crystallizing 
capability5 (Table 2.3 ‘c’) and good aqueous solubility. Three carboxylic acids with 
variable charges were chosen as co-crystallizing agents pertaining to the deduction that 
differences in charges relate to the differences in interactions.  
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3.1.2 Isothermal Titration Calorimetry 
 
Isothermal titration calorimetry (ITC) is a thermodynamic technique used in the 
study of intermolecular interactions between two species in solution. The interaction 
between two molecular species results in either gain or loss of energy (heat). The amount 
of heat lost during the process is a measure of strength of interaction between these 
species. This can be analyzed in terms of thermodynamic parameters like enthalpy 
change (∆H), entropy change (∆S), which further can be resolved into Gibbs free energy 
changes (∆G) of the system. The binding constants (Ka) and binding stoichiometry (N) 
can also be calculated.6, 7, 8 (Eq 3.1 – 3.2) 
 
∆G = - RTlnKa    (where, R = Gas constant, T = Absolute temperature)  Equation 3.1 
 
∆G = ∆H - T ∆S        Equation 3.2 
 
ITC experiments are more commonly used to determine thermodynamic 
parameters of biochemical interactions, usually in the study of small drug molecules with 
larger macromolecules like protein, DNA.9 Currently, it is also being used to study 
complex formation in pharmaceutical applications and binding reactions in biochemical 
systems.9, 10, 11  In our studies, we will employ ITC experiments2, 12 to determine the 
enthalpy change during the binding of different acids with our ligand, and hence 
interpreting the strength of binding. 
                                        
                  b        c       d 
Figure 3.1 The ligand and the acids under study (a) 2-acetamidopyridine (b) benzoic acid 
(c) 3-chlorobenzoic acid (d) 3-(N,N-dimethyl)aminobenzoic acid. 
 
Our study comprises:  a) dilution study of the ligand, b) dilution study of the acid, 
and c) titration of the ligand and acid.2 The calorimeter measures the extent of binding of 
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a molecule to another molecule using the heat of interaction as the probe. The binding of 
the ligand and the acid is thermodynamically favorable process.2 Energy is released 
during the titration in the form of heat, resulting in a more stable ligand-acid complex 
held together via hydrogen bonds. The magnitude of heat energy released during the 
titration is an indication of the stability of the complex, which will be measured by the 
calorimeter and expressed in thermodynamic terms. 
 
 
 
Figure 3.2 The hydrogen bonding interaction between 2-acetamidopyridine (ligand) and 
3-chlorobenzoic acid.  
3.2 Experimental  
3.2.1 Electrostatic charges calculations 
The magnitude of electrostatic charge on hydrogen-bond donors and acceptors in 
these molecules were obtained using semi-empirical AM1 calculations. Values for 
individual atoms are obtained by probing the MEPS (0.002 e/au isosurface, from AM1 
calculations) with a point charge.13   For example, 3-chlorobenzoic acid with its electron 
withdrawing chloro group has lower charge (-285 kJ/mol) on the carbonyl oxygen atom 
than that in benzoic acid (-298 kJ/mol). (Fig 3.3) 
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       2-acetamidopyridine 
 
   
     3-chlorobenzoic acid            benzoic acid   3-(N,N-dimethyl)aminobenzoic acid 
Figure 3.3 AM1 calculations of charges on 2-acetamidopyridine and the acids under 
study. 
 
Table 3.1 AM1 calculations on the hydroxyl group and the carbonyl group in the 
carboxylic acids. 
 
 AM1 calc. (kJ/mol) 
Carboxylic acid -OH C=O 
3-Chlorobenzoic acid 190 -285 
Benzoic acid 180 -298 
3-(N,N-dimethyl)aminobenzoic acid 171 -309 
 
The presence of an electron withdrawing chloro group in the benzene ring 
decreases the electron density on the carbonyl oxygen hence a lesser charge of -285 
kJ/mol is observed compared to -298 kJ/mol for unsubstituted benzoic acid. For the same 
reason, there is a higher positive charge on the acidic proton 190 kJ/mol compared to the 
180 kJ/mol in the benzoic acid. The opposite argument applies to 3-(N,N-
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dimethyl)aminobenzoic acid, where the electron donating effects of the methyl group 
increases the electron density in the ring and hence in the carbonyl oxygen where the 
charge on the oxygen is raised to -309 kJ/mol. The charge on hydroxyl proton however is 
reduced to 171 kJ/mol, making it a weaker acid compared to benzoic acid.  
3.2.2 Synthesis of 2-acetamidopyridine 
All three carboxylic acids used for our experiment were purchased from Aldrich 
and used without further purification. The ligand under study, 2-acetamidopyridine was 
synthesized according to the previous described method (section 2.2.1.1) 
 
3.2.3 Co-crystal screening via IR spectroscopy 
The ability of the carboxylic acids chosen for our study to form co-crystals was 
determined by screening via IR spectroscopy. All the acids formed co-crystal with 2-
acetamidopyridine as evidenced by the presence of broad stretches near 1950 and 2450 
cm-1, indicative of intermolecular O—H---N(heterocycle) hydrogen bonds and as a strong 
band for C=O near 1700 cm-1 indicative of an intact -COOH moiety and a weak C—O 
stretch near 1275 cm-1.14  
 
Table 3.2 IR stretching frequencies for three co-crystals of 2-acetamidopyridine. 
 
Ligand/3-chlorobenzoic acid (cm-1) 3219, 2390, 1883, 1700, 1584 
Ligand/benzoic acid (cm-1) 3224, 2410, 1855, 1699, 1609 
Ligand/3-(N,N-dimethyl) aminobenzoic acid (cm-1) 3007, 2472, 1871, 1699, 1610 
 
3.2.4 Single Crystal X-ray Crystallography 
X-ray data were collected on a Bruker SMART APEX or a SMART 1000 
diffractometer using Mo Kα radiation and, where noted, were corrected for absorption 
using the multiscan procedure implemented by SADABS.  Data were collected using 
SMART. 
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3.2.5 Instrumentation  
 
The titrations were performed on a VP-ITC isothermal titration calorimeter, 
(MicroCal Inc., Northampton, MA).  
 
 
 
Figure 3.4 An isothermal titration calorimeter. 
 
A typical isothermal titration calorimeter consists of an injector system, an 
adiabatic shield, and two identical cells as reference and sample cells made of a thermal 
conducting material. The cells are elongated tube-like with 1.4 ml bulbs where the 
samples are introduced via long-needled syringes. Heaters are arranged around the cells 
with special thermoelectric device to detect and measure the temperature differences 
between the two cells (∆T).8 (Figure 3.4) Both cells are maintained at a constant and 
identical temperature at least 5 ºC above that of the surroundings. The reference cell is 
filled with water and the sample cell is injected with the ligand solution. At the start of 
the experiment, a constant power of less than 1 milliwatt is applied to the reference cell. 
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This activates the cell feedback circuit (thermopile/thermocouple system) activating the 
heater in the sample cell and driving ∆T back to 0. Hence it insures that whatever change 
in temperature is seen in the sample cell, the heat is supplied or decreased accordingly to 
retain the thermal equilibrium between the two cells.2 Exothermic reactions result in an 
increase in the sample cell temperature, hence the feedback power needs to be decreased 
in the sample cell to maintain same temperature in both cells. Endothermic reactions 
decreases the sample cell temperature, hence feedback power needs to be increased.8, 15 
3.2.6 General experimental procedure for binding studies by ITC 
The samples were degassed at the start of the experiment to minimize any 
discrepancies resulting from the presence of air bubbles, as they may lead to abnormal 
data collection.2 The MicroCal instrument is allowed to warm up and then set at 30 ºC. 
The sample cell was filled with 1.3 mL of water or acid solution using a syringe with an 
elongated needle. The instrument was then allowed to stabilize for about 30 minutes. 
Then 100µL syringe was filled with the degassed ligand solution and fitted in the sample 
cell. The instrument is again allowed to stabilize, until the baseline is acceptable. The 
ligand solution is then injected into the sample cell in aliquots of 10µL for a total of 10 
injections. All the injections were carried out with automatically-set computerized 
instructions. Each aliquot of ligand solution is injected over a time span of 60 seconds 
with 300 seconds interval between injections to allow for the system to stabilize after 
each injection. High concentration of the ligand compared to the acid is used (50 times 
more ligand in terms of moles) so as to make sure that all of the acid molecules available 
are bonded to the ligand. The heat change patterns can then be analyzed to determine the 
ligand/acid binding ratio in terms of moles as well as the thermodynamic parameters to 
find the stability of the binding interaction. All reactions were performed at room 
temperature with the instrument set at 30 ºC. 
 
a) Dilution of the Ligand: The dilution effects on 2-acetamidopyridine was studied to 
adjust for the effect of ligand dilution on complexation with acid. The sample cell was 
filled with degassed water and the ligand solution was injected into the cell over time. 
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The reaction was found to be slightly endothermic and the data obtained was later 
subtracted from ligand-acid titration data to adjust for the dilution of ligand. 
 
b) Dilution of the Acid: The thermodynamics of dilution of benzoic acids were studied by 
injecting degassed pure water into the acid solution in the sample cell. Data obtained 
showed that the effect of dilution is minimal for the acid and hence neglected for further 
studies. 
 
c) Titration of Ligand with Acid: The aqueous substituted benzoic acid was filled into the 
sample cell. The system was then allowed to stabilize, after which the aqueous 2-
acetamidopyridine solution was injected into it. The data obtained showed that the 
ligand-acid binding is exothermic in nature.  The data was adjusted for dilution of ligand 
and analyzed using the software Origin ITC. 
 
Data analysis and data fit procedures were done using the software MicroCal 
Origin ITC. The signals from the experiment are plotted in µcal/sec as a function of time, 
interpreting the power needed to maintain the reference and sample cell at the same 
temperature. The number of pulses corresponds to the heat released/absorbed with 
injection of the ligand. These can be integrated to obtain the total heat change per 
injection. 
3.2.6.1 Binding study of 2-acetamidopyridine and benzoic acid 
1.3 mL of 0.044mM aqueous benzoic acid was filled into the sample cell. The 
instrument was allowed to stabilize and then 12mM aqueous 2-acetamidopyridine 
solution was injected into it in aliquots of 10µL for a total of 10 injections using the 
automatic computerized instructions. The heat change patterns were recorded and 
analyzed. 
3.2.6.2 Binding study of 2-acetamidopyridine and 3-chlorobenzoic acid 
1.3 mL of 0.044mM aqueous 3-chlorobenzoic acid was filled into the sample cell. 
The instrument was allowed to stabilize and then 12mM aqueous 2-acetamidopyridine 
solution was injected into it in aliquots of 10µL for a total of 10 injections using the 
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automatic computerized instructions. The heat change patterns were recorded and 
analyzed. 
3.2.6.3 Binding study of 2-acetamidopyridine and 3-(N,N-dimethyl)aminobenzoic acid  
1.3 mL of 0.044mM aqueous 3-(N,N-dimethyl)aminobenzoic acid was filled into 
the sample cell. The instrument was allowed to stabilize and then 12mM aqueous 2-
acetamidopyridine solution was injected into it in aliquots of 10µL for a total of 10 
injections using the automatic computerized instructions. The heat change patterns were 
recorded and analyzed. 
3.3 Results 
 
3.3.1 Single crystal X-ray analysis of 2-acetamidopyridine : 3-N,N-
dimethylbenzoic acid (1:1) 
 
 
Crystal structure of 2-acetamidopyridine:3-N,N-dimethylbenzoic acid (1:1) co-crystal 
showing the binding motif.16  
 
Crystal structure of 2-acetamidopyridine with 3-N,N-dimethylbenzoic acid shows 
the binding motif as N-H…O and O-H…N hydrogen bonds. Similar binding motifs can be 
expected for other two carboxylic acids used for our experiment. 
3.3.2 ITC spectra for thermodynamic study of dilution of 2-acetamidopyridine 
The dilution of the ligand, 2-acetamidopyridine was found to be slightly 
endothermic, the peaks of which remained constant through consecutive injections. This 
data was later subtracted from ligand-acid titration data to adjust for the dilution of 
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ligand. (Fig. 3.5) Similar but even less endothermic peaks were observed for dilution of 
the carboxylic acids, which are termed insignificant and are discarded. 
 
Figure 3.5 Spectrum showing endothermic nature of titration during the dilution of 
ligand.  
 
3.3.3 ITC spectra for thermodynamic study of 2-acetamidopyridine and various 
benzoic acids 
 
The ITC study comprises of titration, injection of 2-acetamidopyridine into the 
aqueous solution of the acid in the sample cell. The initial injection of the ligand results 
in the binding of most of the injected ligand, and hence maximum heat is generated in the 
process as seen by the exothermic nature of the curve. On subsequent injections of the 
ligand solutions, however less and less of the acid molecules are available for binding 
with the injected ligand and hence reduces the amount of heat liberated. Eventually, with 
continual injection of the ligand no more acid molecules are available for binding and no 
further heat release is observed. 
The heat exchange resulting from each individual injection is then integrated with 
respect to time and plotted against molar ratio of the two components. These are fitted 
using the appropriate binding models using the software OriginITC to calculate enthalpy 
change (∆H), equilibrium association or dissociation constant (K), entropy (∆S), and 
stoichiometry. The free energy change (∆G) can be calculated, from the values of ∆H and 
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∆S are known. (Equation 3.4) All the thermodynamic parameters obtained from the ITC 
experiment of 2-acetamidopyridine are given in Table 3.3. 
  
                      a             b 
Figure 3.6 (a) ITC titration curve of 2-acetamidopyridine vs. benzoic acid; (b) 
thermodynamic fit parameters. 
 
 
                 a     b 
Figure 3.7 (a) ITC titration curve of 2-acetamidopyridine vs. 3-chlorobenzoic acid; (b) 
thermodynamic fit parameters. 
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        a         b 
 
Figure 3.8  (a) ITC titration curve for thermodynamic study of 2-acetamidopyridine vs. 
3-(N,N-dimethyl)aminobenzoic acid; (b) thermodynamic fit parameters. 
 
 
3.4 Discussion 
3.4.1 Thermodynamic explanations for the co-crystal formation 
 
Table 3.3 Comparison of thermodynamic parameters for the complexation of three 
carboxylic acids co-crystallized with 2-acetamidopyridine 3. 
 
 3-Chlorobenzoic acid Benzoic acid 
3-(N,N)-dimethylbenzoic 
acid 
pKa17 3.83 4.20 5.10 
K 6895 ± 238 6570 ± 48 6623 ± 59 
∆H (cal/mol) -4740 ± 39 -4942 ± 9 -4902 ± 11 
∆S (cal/mol) 1.93 1.17 1.31 
∆G (cal/mol) -5324.3 -5295.7 -5299.3 
 
In solid state, the hydrogen-bonding patterns are well-defined; however in 
solutions the patterns are less-easily established. Studies show that in concentrated 
solutions, the molecules may occur as dimers whereas chains may be preferred in 
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concentrated solutions. The case is even more complicated for solvents with high 
dielectric constants like water that may favor more polar conformers.18 The formation of 
dimers is a hydrophobic effect. The non-polar compounds in aqueous solutions tend to 
aggregate as dimers or chains.  
Very few examples of benzoic acid dimers in aqueous solution19 are available in 
literature with inconsistent data for cyclic and non-cyclic species,20 whereas dimerization 
of benzoic acids is a common event in non-polar solvents and gaseous phase. Dimers of 
benzoic acid were reported in alcohol-water mixture.21 The binding energy in benzoic 
acids were found to be 5.0 (CCl4), 4-8 (benzene), and 6.3 kcal/mole (CHCl3) as cyclic 
dimers.20 Similarly, the amide-amide intermolecular hydrogen bond formation exists in 
aqueous solution22 with the intrinsic binding energy of 5.7 kcal/mol. This dimerization is 
driven by a favorable energy change associated with the release of water molecules from 
amide NH and CO groups which are involved during hydrogen bond formation.23, 24 
Hence both the ligand and benzoic acids are considered to exist as dimers in aqueous 
solutions.  
   
         (a)                 (b) 
 
                            (c) 
Figure 3.9 (a) Homodimer of benzoic acid. (b) Homodimer of ligand, 2-
acetamidopyridine. (c) Heterodimer between the benzoic acid and the ligand. 
 
The mixing together of these two 1:1 dimer solutions would result in the 
dissociation of the homomeric linkage in favor of the heteromeric dimers. Such structural 
binding motif is more robust than the homomeric binding motifs.25 Calorimetric binding 
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studies on antibiotic ristocetin showed that the ligand binding even induces the 
dissociation of antibiotic dimers.26 
In order for a hetermomeric dimer between 2-acetamidopyridine and benzoic 
acids to form, the water molecules surrounding the dimers need to be removed and the 
dimer has to be broken down into monomers. This process is endothermic and entropy 
favorable.  The formation of heteromeric dimer between the free ligand and acid occurs 
which again gets surrounded by the water molecules. This process involves formation of 
new bonds, an exothermic process and entropy unfavorable. The thermodynamic effects 
observed are the net effect of the breaking of old hydrogen bonds in homomeric dimer 
and formation of new hydrogen bonds in heteromeric dimers. We also need to understand 
that the heat studies for binding reactions is difficult and only qualitative studies can be 
found due to contributions from many equilibria conditions in the overall heat effect.27 
  The thermodynamic results obtained from our experiments showed the lowest 
enthalpy change value for 3-chlorobenzoic acid and comparable values for benzoic acid 
and 3-(N,N)-dimethylbenzoic acid. This is in contrast to our prediction of highest 
enthalpy value for 3-chlorobenzoic acid in part due to the electron-withdrawing effect 
imparted by the chloro group and hence stronger binding, with higher amount of energy 
release. Comparatively higher entropy change is observed for 3-chlorobenzoic acid which 
may account for the low enthalpic gain. However, the overall entropy effects is very 
small as the number of homodimers at the start and the number of heterodimers formed at 
the end stays the same during the process. The association constant (K) is highest for 3-
chlorobenzoic acid which supports our hypothesis. This factor may be taken as the major 
factor as other thermodynamic events entropy and free energy are dependent on the 
association constant. 
In these circumstances, the best thermodynamic parameter to study would be the 
Gibbs free energy of association which takes in consideration both enthalpic and entropic 
factors. Many physical properties of a compound like hydrophobic, electronic and steric 
substituent constants, as well as the biological activities themselves, are related to the 
Gibbs energy28. It seems logical therefore, to set up scales of hydrogen bonding strengths 
using Gibbs energies rather than enthalpies.1 The more negative the value of ∆G, the 
more favorable the process would be and more would be the energy release. Here, the 
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value of ∆G is lowest for 3-chlorobenzoic acid which is as expected whereas the values 
for other two acids are comparable. However, these values for all three carboxylic acids 
are still very close to each other. This suggests that the polarity of the solvent used may 
be playing a dominating role, as the polar solvent water with high dielectric constant 78 
(300K) is used as solvent,29  which itself competitively interact with the ligands/acids and 
the co-crystals. 
In addition, our experimental value of 5.3 kcal/mol fits well with the expected 
values for a normal hydrogen bond (ca 5 kcal/mol).30 The strength of heteromeric acid-
amide hydrogen bonding interaction is still dubious, whereas homodimeric N-H---O=C 
bond in urea is in the range of 4-15 kcal/mole.31 However it should be noted that very 
little work if any, has been done to investigate the thermodynamic properties of co-
crystallization of small molecules in aqueous medium. Our work may be the very first 
systematic work in investigating the solution behavior during co-crystallization of various 
benzoic acids with substituted pyridines. 
 
3.5 Conclusions 
 
The experimental results are consistent with the observations from the solid-state 
behavior (chapter 2). The strength and potential of co-crystallization is found to depend 
on the charges on the ligand and not on the co-crystallizing agents. There is a need to 
repeat the experiment with a single carboxylic acid and varying the ligands with different 
charges to further supplement our results. In our case, we were unable to do so due to 
solubility restrictions of the ligands. Also, the strength of the intermolecular interaction in 
terms of hydrogen bonding in co-crystals can be explained in thermodynamic terms to 
some extent. However, due to competitive contributions from the solvent, the solvation 
factors needs to be considered. However, due to experimental limitations, we were unable 
to run the experiment in different solvents to figure out the extent of solvent effects on 
the thermodynamics factors during co-crystallization.  
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CHAPTER 4 - Ditopic ligands as a probe to investigate 
selectivity in binary co-crystals/salts 
4.1 Introduction 
 
A co-crystallization1 process is an interplay between intermolecular interactions 
involving mainly hydrogen bonding,2 halogen bonding,3 and Π-Π interactions.4 The most 
common of these interactions remains the hydrogen bond which brings along its strength 
and directionality.5 Co-crystallization via hydrogen-bond interactions requires the 
interaction between two complementary hydrogen-bond donors and hydrogen-bond 
acceptors. During the process, commonly occurring synthons e.g. acid-acid and amide-
amide homosynthons are disrupted to form acid-amide heterosynthons.6 In the presence 
of a single acceptor and single donor molecule, the case is straightforward with 1:1 co-
crystal/salt formed. However, the presence of two acceptors complicates the case and 
predicting binding preferences becomes even more challenging, (Figure 4.1).  
 
 
 
Figure 4.1 Schematic of selectivity of hydrogen-bond donors for ditopic ligands. 
 
A systematic study of hydrogen bonding patterns in various crystal structures led 
Etter7 to suggest that in a mix of multiple hydrogen-bond donors and acceptors, the best 
hydrogen-bond donor will prefer the best hydrogen-bond acceptor and so on. Hence in 
our system with two acceptors and a single donor molecule, the interaction should occur 
Binding site 1 Binding site 2 
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selectively between the donor molecule and the better acceptor, (Figure 4.2). The 
reliability of this approach was tested with a series of new ditopic ligands comprising two 
competing acceptor sites equipped with pyridine, pyrimidine, and pyrazine moieties. 
These N-heterocycles have different strength and binding abilities which would probe the 
selectivity of the donor. To bring further variability in the choice of acceptors, the amino- 
and acetamido- substituents were equipped on these N-heterocyclic sites competing for a 
single donor. 
 
Figure 4.2 Schematic of a donor molecule (D) binding to the best acceptor (A1). 
 
4.1.1 Selectivity prediction via AM1calculations 
 
Electrostatic potential surface calculations provide important information 
regarding the binding strength of hydrogen-bonding entities.8 In Chapter 2, we have 
shown that the AM1-based electrostatic charge calculation is very successful in ranking 
binding potential of hydrogen-bond donors and acceptors.  This specificity observed for 
the small molecules is further extended to investigate the selectivity in ditopic molecules 
in this chapter. 
Our ditopic testing system consists of a combination of two entities selected from 
unsubstituted pyridyl and amino/acetamido-substituted N-heterocycles. These groups by 
themselves have the capability to engage in hydrogen-bond interactions with hydrogen-
bond donors like carboxylic acids via the commonly encountered N-heterocycle/ 
carboxylic acid heterosynthon.9 The assembly of these two moieties together within the 
same building block will test their comparative binding strengths against a single donor. 
A CSD search on the selectivity within the coupled N-heterocycles revealed that no such 
studies have been done to date.10  
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AM1 calculations of the electrostatic potential of the nitrogen atom in 
unsubstituted pyridines, pyrimidines, and pyrazines follow a decreasing trend, (Figure 
4.3). These charges can be enhanced by incorporating electron donating amino/acetamido 
groups in the ring; however this addition will also introduce complexity in our ligands by 
converting a one-point interacting group to two point interactions with probable 
contributions from auxiliary groups.   
 
                                               
   -275    -263               -245     -296          -276     -265 
 
Figure 4.3 Decreasing electrostatic potential in unsubstituted N-heterocycles and amino-
substituted N-heterocycles. 
 
 With the assumption that the two point donors like carboxylic acids might favor 
two-point interactions with the acceptor molecules, we set out to include the auxiliary 
group contributions in calculating the total charge on the acceptor sites as a measure of its 
binding potential. A combined hydrogen-bonding ability value, Q is introduced, which is 
the sum of the electrostatic potential surfaces for the hydrogen bonding entities in binding 
site.  
Q = A1 – (A2)   
Where A1 is the maximum positive potential and A2 is the minimum negative potential. 
 
 
 
 
 
 
Q1 = 69-(-283) 
    = 352 83 -241 162 
69 Q2 = 162-(-241) 
   = 403 
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For two point interactions, Q values were assigned to each binding site with the 
magnitude of the Q value reflecting the binding ability of a particular site. The 
comparison of the Q values for the two sites in the ditopic molecule is expected to act as 
a guideline in binding selectivity. Using 2-acetamido-5-(3-pyridyl) pyridine as an 
example, the two binding sites have either C-H or N-H as auxiliary groups.  Each site is 
assigned a Q value; and in this particular case, the acetamidopyridyl site with Q2 (403) is 
predicted to have higher binding over the site with Q1 (352).  
   
4.1.2 Research goals  
 
 We propose that electrostatic potentials may be used to determine selectivity in 
ditopic ligands containing two comparable binding sites. To investigate our hypothesis, 
we designed and synthesized a series of ditopic N-heterocyclic ligands (a combination of 
pyridine, pyrimidine, and pyrazine) capable of interacting with hydrogen bond donors, 
(Figure 4.4). The electrostatic potential of each binding sites in these ditopic ligands is 
calculated and ranked with the assumption that the donor will pair with the best hydrogen 
bond acceptor.  
               
      10          12         15 
 
           
         16          18 
 
        
  21          24 
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  27               29 
 
 
      32 
Figure 4.4 A series of bifunctional ligands with two different hydrogen-bonding sites 
have been synthesized. 
 
The hypothesis was tested with the introduction of a series of hydrogen bond 
donors ranging from monocarboxylic acids, dicarboxylic acids, and cyanoximes (Figure 
4.5) with the assumption that a donor should prefer to bind to the best acceptor site in the 
ditopic ligand.  
                                       
      a         b           c   d    e          f   
 
                             
      g        h      i        j   
 
                    
       k       l    m 
 83  
 
                
               n      o 
              
    p      q      r      s  
   
Figure 4.5 A series of nineteen hydrogen-bond acceptors used for the study; 
monocarboxylic acids (a – j), dicarboxylic acids (k - o), and cyanoximes (p - s). 
 
 
4.2 Experimental 
4.2.1 Synthesis of ligands 
 
All chemicals, unless otherwise noted, were purchased from Aldrich and used 
without further purification. Trimethylsilylacetylene was purchased from GFS chemicals. 
The catalysts, bis(triphenylphosphine)palladium(II) dichloride and 
Tetrakis(triphenylphosphine)palladium(0), were purchased from Strem chemicals. 
Column chromatography was carried out on silica gel (150 Å pore size) from Analtech 
Inc. Melting points were determined on a Fisher-Johns melting point apparatus and are 
uncorrected. 1H and 13C NMR spectra were collected on a Varian Unity plus 200 MHz or 
400 MHz spectrometer in CDCl3 or d6-DMSO. The infrared (IR) spectrum was collected 
on ThermoScientific Nicolet 380 FT-IR spectrometer, either directly or as a KBr mixture.  
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4.2.1.1 Synthesis of 3-pyridylboronic acid, 8
11
 
 
 
 
 
          8 
 Dry THF (200 mL) was added to a round-bottom flask kept in a dry ice/acetone 
bath (-78 ºC). Dinitrogen was bubbled through the solution and the flask closed with a 
rubber stopper. The dinitrogen atmosphere was maintained inside the flask along with 
continuous stirring.  3-Bromopyridine (9.65 mL, 0.10 mol) was added to it via syringe, 
followed by tri-isopropylborate (27.70 mL, 0.12 mol). Then n-butyllithium (75.00 mL, 
0.12 mol, ca. 1.6 M solution in hexanes) was added dropwise via syringe over 1 hr. The 
mixture was stirred for additional 30 mins with the temperature maintained at about -78 
ºC. The dry ice/acetone bath was then removed and the mixture allowed to warm to -20 
ºC when 2N HCl (200 mL) was added to it. When the mixture attained room temperature, 
the aqueous layer was separated using a separating funnel. The aqueous layer was stirred 
 And its pH adjusted to 7 by adding 5N NaOH, whereupon a white ppt. was obtained. It 
was filtered and air dried. (8.83 g, 72%). M. P. >250 ºC; 1H NMR (δH; 200 MHz, 
CD3OD): 8.52 (s, 1H), 8.43 (d, 1H), 8.22 (d, J = 8.0 Hz, 1H), 7.51 (d, J = 6.0 Hz, 1H). 
 
4.2.1.2 Synthesis of 2-amino-5-bromopyrimidine, 9 
 
 
                   9 
 A solution of N-bromosuccinimide (11.0 g, 61.8 mmol) in methylene chloride 
(200 mL) was added dropwise to the solution of 2-aminopyrimidine (5.0 g, 52.6 mmol) in 
methylene chloride (100 mL) kept over an ice bath.  After addition, the ice bath was 
removed and the reaction mixture was stirred at room temperature for 1 hr. The reaction 
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was monitored by TLC and upon completion, was quenched with 10% sodium 
bicarbonate and 10% sodium sulfite solution. The mixture was filtered and the precipitate 
washed with water twice and dried. The filtrate was extracted with methylene chloride 
and dried over anhydrous magnesium sulfate. The solvent was removed on a rotary 
evaporator to obtain the product as yellowish-white powder. (8.7 g, 95.6 %).  M.P. > 250 
ºC; 1H NMR (δH; 200 MHz, CDCl3): 8.31 (s, 2H), 5.09 (br, 2H). 
 
4.2.1.3 Synthesis of 2-amino-5-(3-pyridyl)pyrimidine, 10 
               
      9           8         10  
2-Amino-5-bromopyrimidine 9 (0.65 g, 3.74 mmol), 3-pyridylboronic acid 8 
(0.55 g, 4.47 mmol), and sodium carbonate (0.22 g, 2.08 mmol) were added to a round 
bottom flask. Acetonitrile (15 mL) and water (15 mL) were added and dinitrogen was 
bubbled through the mixture for 10 minutes. Bis(triphenylphosphine)palladium(II) 
dichloride (0.055 g, 0.078 mmol, 2.1 mol%) was added and dinitrogen bubbled through 
for 5 more minutes. The apparatus was fitted with a condenser and the mixture was 
refluxed at 80 ºC under dinitrogen atmosphere. The reaction was monitored by TLC and 
upon completion (36 hrs) was cooled to room temperature. The solution was then diluted 
with ethyl acetate (50 mL), washed with (3 x 50 mL) and saturated aqueous sodium 
chloride solution (1 x 50 mL). The organic layer was separated and dried over anhydrous 
magnesium sulfate. The solvent was removed on a rotary evaporator and the residue was 
chromatographed on silica with hexane: ethyl acetate (1:1) mixture as eluant.  The 
product was obtained as a yellowish white solid. The product was then recrystallized 
from ethyl acetate to obtain colorless block-shaped crystals. (0.48 g, 75 %).  M.P. 192 ‒ 
195 ºC; 1H NMR (δH; 400 MHz, CDCl3): 8.78 (s, 1H), 8.63 (s, 1H), 8.54 (s, 2H), 7.79 (d, 
J = 8.0 Hz, 1H), 7.39 (d, 1H), 5.31 (br, 2H); 13C NMR (δH; 200 MHz, CDCl3): 193.95, 
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156.73, 149.02, 147.39, 133.50, 131.30, 124.00, 121.96; FT-IR: υ 3313, 3150, 1659, 
1596 cm-1.     
4.2.1.4 Synthesis of 2-amino-4-methyl-5-bromopyrimidine, 11 
 
                11 
 N-bromosuccinimide (6.0 g, 33.7 mmol) in methylene chloride was added drop 
wise to 2-amino-4-methylpyrimidine (3.0 g, 27.5 mmol) dissolved in methylene chloride 
(100 mL), cooled in an ice bath.  The ice bath was removed and the reaction mixture was 
stirred at room temperature for 1 hr. The reaction was monitored by TLC and upon 
completion, was quenched with 10% sodium bicarbonate and 10% sodium sulfite 
solution. The mixture was filtered and the precipitate washed with water twice and dried. 
The filtrate was extracted with methylene chloride and dried over anhydrous magnesium 
sulfate. The solvent was removed on a rotary evaporator to obtain the product as 
yellowish-white powder. (4.50 g, 88 %).  M. P. 200 ‒ 202 ºC; 1H NMR (δH; 400 MHz, 
DMSO-d6): 8.206 (s, 1H), 6.783 (br, 2H), 2.312 (s, 3H); IR (cm-1): υ 3314, 3146, 1655, 
1548, 1473, 1209, 1041, 787.     
4.2.1.5 Synthesis of 2-amino-4-methyl-5-(3-pyridyl)pyrimidine, 12 
 
       11  8      12 
2-Amino-4-methyl-5-bromopyrimidine 11 (1.00 g, 5.32 mmol), 3-pyridylboronic 
acid 8 (0.8 g, 6.5 mmol), and sodium carbonate (0.7 g, 6.6 mmol) were added to a round 
bottom flask. Acetonitrile (35 mL) and water (35 mL) were added and dinitrogen was 
bubbled through the mixture for 10 minutes. Bis(triphenylphosphine)palladium(II) 
dichloride (0.09 mg, 0.13 mmol, 2.4 mol%) was added and dinitrogen bubbled through 
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for 5 more minutes. The apparatus was fitted with a condenser and the mixture was 
refluxed at 80 ºC under a dinitrogen atmosphere. The reaction was monitored by TLC and 
upon completion (36 hrs) was cooled to room temperature. The solution was diluted with 
ethyl acetate (100 mL), washed with (3 x 100 mL) and saturated aqueous sodium chloride 
solution (1 x 100 mL). The organic layer was separated and dried over anhydrous 
magnesium sulfate. The solvent was removed on a rotary evaporator and the residue was 
chromatographed on silica with hexane: ethyl acetate mixture as eluant.  The product was 
obtained as an off-white powder. The product is then recrystallized from ethyl acetate to 
obtain colorless flake-like crystals, (0.60 g, 61 %).  M. P. 202 ‒ 204 ºC; 1H NMR (δH; 
400 MHz, CDCl3): 8.63 (s, 1H), 8.58 (s, 1H), 8.14 (s, 2H), 7.62 (d, J = 8.0 Hz, 1H), 7.4 
(s, 1H), 5.26 (br, 2H), 2.35 (s, 3H); FT-IR (cm-1): υ 3284, 3126, 1660, 1581. 
 
4.2.1.6 Synthesis of 2-amino-5-bromopyrazine, 13 and 2-amino-3,5-dibromopyrazine, 
14 
 
       13    14 
A solution of N-bromosuccinimide (1.2 g, 6.7 mmol) in methylene chloride was 
added dropwise to 2-aminopyrazine (0.5 g, 5.3 mmol) dissolved in methylene chloride 
cooled at 0 ºC.  The reaction mixture was stirred at 5-10 ºC for 1 hr. The reaction was 
monitored by TLC and upon completion, was quenched with 10% sodium bicarbonate 
and 10% sodium sulfite solution. The mixture was filtered and the precipitate washed 
with water twice and dried. The filtrate was extracted with methylene chloride and dried 
over anhydrous magnesium sulfate. The solvent was removed on a rotary evaporator and 
the residue was chromatographed on silica with hexane: ethyl acetate 4:6 mixture as 
eluant.  The product 13 was isolated as a yellowish-white powder and the product 14 as a 
white powder. The products were then recrystallized from ethyl acetate.  
Product 13 (2-amino-5-bromopyrazine), (0.51 g, 56%). M. P. 105-107 ºC; 1H NMR (δH; 
200 MHz, CDCl3): 8.09 (s, 1H), 7.78 (s, 1H), 4.64 (br, 2H). 
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Product 14 (2-amino-3,5-dibromopyrazine), (0.12 g, 10%). M. P. 111-113 ºC; 1H NMR 
(δH; 200 MHz, CDCl3): 8.05 (s, 1H), 5.05 (br, 2H).  
4.2.1.7 Synthesis of 2-amino-5-(3-pyridyl)pyrazine, 15 
 
 
    13       8           15 
2-Amino-5-bromopyrazine 13 (1.00 g, 5.75 mmol), 3-pyridylboronic acid 8 (0.8 
g, 6.5 mmol), and sodium carbonate (0.7 g, 6.6 mmol) were added to a round bottom 
flask. Acetonitrile (35 mL) and water (35 mL) were added and dinitrogen was bubbled 
through the mixture for 10 minutes. Bis(triphenylphosphine)palladium(II) dichloride (90 
mg, 0.13 mmol, 2.3 mol%) was added and dinitrogen bubbled through for 5 more 
minutes. The apparatus was fitted with a condenser and the mixture was refluxed at 80 ºC 
under dinitrogen atmosphere. The reaction was monitored by TLC and upon completion 
(36 hrs) was cooled to room temperature. The solution was then diluted with ethyl acetate 
(100 mL), washed with (3 x 100 mL) and saturated aqueous sodium chloride solution (1 x 
100 mL). The organic layer was separated and dried over anhydrous magnesium sulfate. 
The solvent was removed on a rotary evaporator and the residue was chromatographed on 
silica with hexane: ethyl acetate (6:4) mixture as eluant.  The product was obtained as 
white powder. The product was recrystallized from ethyl acetate to give colorless 
crystals, (0.74 g, 75 %).  M. P. 210 ‒ 212 ºC; 1H NMR (δH; 400 MHz, CDCl3): 9.12 (s, 
1H), 8.61 (s, 1H), 8.49 (s, 1H), 8.18 (s, 1H), 8.10 (s, 1H), 7.38 (s, 1H), 4.75 (br, 2H); FT-
IR (cm-1): υ 3351, 3304, 3116, 1642, 1584.  
 
4.2.1.8 Synthesis of 2-acetamido-5-(3-pyridyl)pyridine, 16 
 
 
          6     8         16 
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2-Acetamido-5-bromopyridine, 6 (1.2 g, 5.5 mmol), 3-pyridylboronic acid 8 (0.8 
g, 6.5 mmol), and sodium carbonate (0.7 g, 6.6 mmol) were added to a round bottom 
flask. Acetonitrile (35 mL) and water (35 mL) were added and dinitrogen was bubbled 
through the mixture for 10 minutes. Bis(triphenylphosphine)palladium(II) dichloride (90 
mg, 0.13 mmol, 2.4 mol%) was added and dinitrogen bubbled for 5 more minutes. The 
apparatus was fitted with a condenser and the mixture was refluxed at 80 ºC under 
dinitrogen atmosphere. The reaction was monitored by TLC and upon completion (40 
hrs) was cooled to room temperature. The solution was then diluted with ethyl acetate 
(100 mL), washed with (3 x 100 mL) and saturated aqueous sodium chloride solution (1 x 
100 mL). The organic layer was separated and dried over anhydrous magnesium sulfate. 
The solvent was removed on a rotary evaporator and the residue was chromatographed on 
silica with hexane: ethyl acetate (6:4) mixture as eluant.  The product was obtained as  an 
off-white powder. The product was recrystallized from ethyl acetate to obtain colorless 
prism-shaped crystals, (0.45 g, 40 %).  M.p. 179 ‒ 181 ºC; 1H NMR (δH; 200 MHz, 
CDCl3): 8.85 (s, 1H), 8.64 (s, 1H), 8.51 (s, 1H), 8.31 (d, 1H), 8.07 (br, NH), 7.90 (t, 2H), 
7.41 (t, 1H), 2.26 (s, 3H); FT-IR (cm-1): υ 3176, 3002, 1688, 1568, 1523.  
 
4.2.1.9 Synthesis of 2-acetamido-5-bromopyrimidine, 17 
 
         9              17 
 
2-Amino-5-bromopyridine 9 (4 g, 23 mmol) was dissolved in acetic anhydride (20 
mL) added dropwise. The mixture was heated under reflux at 80°C for 2 hrs. Excess 
acetic anhydride and acetic acid produced were removed via vacuum distillation to obtain 
a white powder. Upon recrystallization from acetone, the product 17 was obtained as an 
off-white powder, (4.5 g, 91%,). Decomposed at 175 °C; 1H NMR (δH; 400 MHz, 
CDCl3): 8.63 (s, 2H), 8.52 (br, NH), 2.48 (s, 3H). FT-IR υ 3114 cm
-1 (N—H, br), 1695 
cm-1 (C=O, s), 1564 cm-1 (Amide II, s).  
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4.2.1.10 Synthesis of 2-acetamido-5-(3-pyridyl)pyrimidine, 18 
 
      10               18 
2-Amino-5-(3-pyridyl)pyrimidine 10 (1.0 g, 5.8 mmol) was dissolved in acetic 
anhydride (5 mL) which was added dropwise. The mixture was heated under reflux at 
80°C for 3 hrs with continuous monitoring by TLC. Excess acetic anhydride and acetic 
acid produced were removed via vacuum distillation to obtain a white powder. Upon 
recrystallization from ethyl acetate, the product 18 was obtained as colorless flake-like 
crystals, (0.8 g, 65%,). M. P. 240 ‒ 242 °C; 1H NMR (δH; 400 MHz, CDCl3): 9.02 (br, 
NH), 8.15 (br, 3H), 8.70 (d, 1H), 7.87 (d, 1H) 7.47 (s, 1H), 2.56 (s, 3H). 13C NMR (400 
MHz, CDCl3): 169.08, 157.35, 156.25, 149.23, 147.34, 133.91, 129.85, 125.31, 124.05, 
24.78; FT-IR (cm-1) υ 3208, 3123, 2977, 2934, 1681.  
 
4.2.1.11 Synthesis of 3-trimethylsilanylethynylpyridine, 19 
 
                   19 
3-Bromopyridine (5.00 g, 31.65 mmol), trimethylsilylacetylene (3.97 g, 40.40 
mmol), copper(I) iodide (0.17 g, 0.89 mmol), triphenylphosphine (0.60 g, 2.29 mmol), 
and bis(triphenylphosphine)palladium(II) dichloride (0.60 g, 0.86 mmol) were added to a 
round bottom flask. Tetrahydrofuran (65 mL) and triethylamine (65 mL) were added and 
dinitrogen bubbled through the resultant mixture for 10 minutes. The apparatus was fitted 
with a condenser and the mixture refluxed at 75 ˚C under dinitrogen atmosphere. The 
reaction was monitored by TLC and upon completion (48 hrs) was cooled to room 
temperature. The solution was then diluted with ethyl acetate (100 mL), washed with (3 x 
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100 mL) and saturated aqueous sodium chloride solution (1 x 100 mL). The organic layer 
was separated and dried over anhydrous magnesium sulfate. The solvent was removed on 
a rotary evaporator and the residue was chromatographed on silica with hexane: ethyl 
acetate (6:4) mixture as eluant.  The product was isolated as a light brown colored oil, 
(5.0 g, 91 %). 1H NMR (δH; 400 MHz, CDCl3): 8.66 (s, 1H), 8.48 (d, J = 4.2Hz, 1H), 
7.70 (d, J = 8.0 Hz, 1H), 7.19 (t, J = 6.8 Hz, 1H), 0.24 (s, 9H). 
 
4.2.1.12 Synthesis of 3-ethynylpyridine, 20 
 
        20 
3-trimethylsilanylethynylpyridine 19 (2.04 g, 11.66 mmol) and potassium 
carbonate (1.75 g, 17.85 mmol) were stirred in methanol (60 mL) at room temperature for 
2 hours. The solution was then diluted with ethyl ether (100 mL) and washed with water 
(4 x 100 mL). The solvent was removed on a rotary evaporator and the residue/product 
20 obtained as a light brown colored oil, (0.88 g, 74 %). 1H NMR (δH; 200 MHz, 
CDCl3): 8.73 (s, 1H), 8.57 (d, J = 2.4Hz, 1H), 7.77 (d, J =3.8Hz, 1H), 7.26 (t, J = 3.8Hz, 
1H), 3.22 (s, 1H). 
4.2.1.13 Synthesis of 2-acetamido-5-(3-pyridyl)ethynylpyridine, 21 
 
6  20      21 
2-Acetamido-5-bromopyridine 6 (1.09 g, 5.06 mmol), 3-ethynylpyridine (0.50 g,  
4.85 mmol) 20, copper(I) iodide (0.025 g, 0.131 mmol), triphenylphosphine (0.11 g, 0.42 
mmol), and bis(triphenylphosphine)palladium(II) dichloride (0.11 g, 0.16 mmol) were 
added to a round bottom flask. Tetrahydrofuran (15 mL) and triethylamine (15 mL) were 
added and dinitrogen bubbled through the resultant mixture for 10 minutes. The 
apparatus was fitted with a condenser and the mixture refluxed at 70 ˚C under a 
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dinitrogen atmosphere. The reaction was monitored by TLC and upon completion (36 
hrs) was cooled to room temperature. The solution was diluted with ethyl acetate (100 
mL), washed with (3 x 100 mL) and saturated aqueous sodium chloride solution (1 x 100 
mL). The organic layer was separated and dried over anhydrous magnesium sulfate. The 
solvent was removed on a rotary evaporator and the residue was chromatographed on 
silica with hexane: ethyl acetate (1:1) mixture as eluant.  The product 21 was isolated as  
a light brown colored solid, and recrystallized from ethyl acetate. (0.67 g, 65 %). M. P. 
195 ‒ 197 ºC; 1H NMR (δH; 400 MHz, DMSO-d6): 10.765 (s, NH), 8.760 (s, 1H), 8.602 
(s, 1H), 8.543 (s, 1H), 8.140 (s, 1H), 7.989 (s, 1H), 7.968 (s, 1H), 7. 480 (s, 1H), 2.117 (s, 
3H); FT-IR (cm-1): υ 3259, 3007, 2218, 1701, 1671, 1513, 1297. 
 
4.2.1.14 Synthesis of 2-amino-5-trimethylsilanylethynylpyridine, 22 
 
  2             22 
2-Amino-5-bromopyridine 2 (5.0 g, 28.9 mmol), trimethylsilylacetylene (3.97 g, 
40.4 mmol), copper(I) iodide (0.17 g, 0.89 mmol), triphenylphosphine (0.60 g, 2.29 
mmol), and bis(triphenylphosphine)palladium(II) dichloride (0.60 g, 0.86 mmol, 3 mol%) 
were added to a round bottom flask. Tetrahydrofuran (100 mL) and triethylamine (100 
mL) were added and dinitrogen bubbled through the resultant mixture for 10 minutes. 
The apparatus was fitted with a condenser and the mixture refluxed at 75 ˚C under a 
dinitrogen atmosphere. The reaction was monitored by TLC and upon completion (48 
hrs) was cooled to room temperature. The solution was then diluted with ethyl acetate 
(100 mL), washed with (3 x 100 mL) and saturated aqueous sodium chloride solution (1 x 
100 mL). The organic layer was separated and dried over anhydrous magnesium sulfate. 
The solvent was removed on a rotary evaporator and the residue was chromatographed on 
silica with hexane: ethyl acetate (1:1) mixture as eluant to obtain a light brown colored 
powder.  Upon recrystallization from methylene chloride, colorless crystals were 
 93  
obtained, (3.9 g, 71 %). 1H NMR (δH; 200 MHz, CDCl3): 8.21(s, 1H), 7.49 (d, J = 8.0 
Hz, 1H), 6.42 (d, J = 8.0 Hz, 1H), 4.61 (br, 2H), 0.24 (s, 9H). 
 
4.2.1.15 Synthesis of 2-amino-5-ethynylpyridine, 23 
 
       22       23 
2-Amino-5-trimethylsilanylethynylpyridine 22 (1.3 g, 6.8 mmol) and potassium 
carbonate (1.00 g, 7.23 mmol) were stirred in methanol (25 mL) at room temperature for 
2 hours. The solution was then diluted with ethyl ether (50 mL) and washed with water (4 
x 50 mL). The solvent was removed on a rotary evaporator and the residue/product 23 
was obtained as a light brown colored powder, (0.62 g, 79%). 1H NMR (δH; 200 MHz, 
CDCl3): 8.24 (s, 1H), 7.52 (d, J = 8.0 Hz, 1H), 6.44 (d, J = 8.0 Hz, 1H), 4.62 (br, 2H), 
3.07 (s, 1H). 
 
4.2.1.16 Synthesis of 2-acetamido-5-(3-(2-aminopyridyl))ethynylpyridine, 24 
 
        23     6            24 
2-Acetamido-5-bromopyridine 6 (0.55 g, 2.56 mmol), 2-amino-5-ethynylpyridine 
23 (0.35 g, 2.97 mmol), copper(I) iodide (0.013 g, 0.066 mmol), triphenylphosphine 
(0.055 g, 0.210 mmol), and bis(triphenylphosphine)palladium(II) dichloride (0.055 g, 
0.080 mmol) were added to a round bottom flask. Tetrahydrofuran (10 mL) and 
triethylamine (10 mL) were added and dinitrogen bubbled through the resultant mixture 
for 10 minutes. The apparatus was fitted with a condenser and the mixture refluxed at 70 
˚C under a dinitrogen atmosphere. The reaction was monitored by TLC and upon 
completion (36 hrs) was cooled to room temperature. The solution was then diluted with 
ethyl acetate (20 mL), washed with (3 x 20 mL) and saturated aqueous sodium chloride 
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solution (1 x 20 mL). The organic layer was separated and dried over anhydrous 
magnesium sulfate. The solvent was removed on a rotary evaporator and the residue was 
chromatographed on silica with hexane: ethyl acetate (1:1) mixture as eluant.  The 
product 24 was isolated as a light brown colored solid and recrystallized from ethyl 
acetate, (0.35 g, 55 %). M.P. 236 ‒ 238 ºC; 1H NMR (δH; 200 MHz, DMSO): 10.66 (br, 
1H), 8.43 (s, 1H), 8.13 (s, 2H), 7.85 (d, 1H), 7.48 (d, 2H), 6.45 (br, 2H), 2.10 (s, 3H); FT-
IR (cm-1): υ 3463, 3283, 3116, 1696, 1628, 1606. 
 
Alternate method 
 
 2       26            24 
2-Amino-5-bromopyridine 2 (0.35 g, 2.02 mmol), 2-acetamido-5-ethynylpyridine 
26 (0.25 g, 1.56 mmol), copper(I) iodide (0.009 g, 0.047 mmol), triphenylphosphine 
(0.04 g, 0.15 mmol), and bis(triphenylphosphine)palladium(II) dichloride (0.04 g, 0.06 
mmol) were added to a round bottom flask. Tetrahydrofuran (10 mL) and triethylamine 
(10 mL) were added and dinitrogen bubbled through the resultant mixture for 10 minutes. 
The apparatus was fitted with a condenser and the mixture refluxed at 70 ˚C under a 
dinitrogen atmosphere. The reaction was monitored by TLC and upon completion (36 
hrs) was cooled to room temperature. The solution was then diluted with ethyl acetate (50 
mL), washed with (3 x 50 mL) and saturated aqueous sodium chloride solution (1 x 50 
mL). The organic layer was separated and dried over anhydrous magnesium sulfate. The 
solvent was removed on a rotary evaporator and the residue was chromatographed on 
silica with hexane: ethyl acetate (1:1) mixture as eluant.  The product 24 was isolated as a 
light brown colored solid and recrystallized from ethyl acetate. (0.24 g, 60 %). 1H NMR 
(δH; 200 MHz, DMSO): 10.66 (br, 1H), 8.43 (s, 1H), 8.13 (s, 2H), 7.85 (d, 1H), 7.48 (d, 
2H), 6.45 (br, 2H), 2.10 (s, 3H). 
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4.2.1.17 Synthesis of 2-acetamido-5-trimethylsilanylethynylpyridine, 25 
 
   6              25 
2-Acetamido-5-bromopyridine 6 (4.14 g, 19.26 mmol), trimethylsilylacetylene 
(2.65 g, 26.93 mmol), copper(I) iodide (0.12 g, 0.63 mmol), triphenylphosphine (0.40 g, 
1.53 mmol), and bis(triphenylphosphine)palladium(II) dichloride (0.40 g, 0.57 mmol, 3 
mol%) were added to a round bottom flask. Tetrahydrofuran (50 mL) and triethylamine 
(50 mL) were added and dinitrogen bubbled through the resultant mixture for 10 minutes. 
The apparatus was fitted with a condenser and the mixture refluxed at 75 ˚C under 
dinitrogen atmosphere. The reaction was monitored by TLC and upon completion (48 
hrs) was cooled to room temperature. The solution was then diluted with ethyl acetate 
(100 mL), washed with (3 x 100 mL) and saturated aqueous sodium chloride solution (1 x 
100 mL). The organic layer was separated and dried over anhydrous magnesium sulfate. 
The solvent was removed on a rotary evaporator and the residue was chromatographed on 
silica with hexane: ethyl acetate (6:4) mixture as eluant to obtain a light brown colored 
powder.  Upon recrystallization from methylene chloride : hexane (1:2), colorless flaky 
crystals were obtained, (3.35 g, 75 %). 1H NMR (δH; 200 MHz, CDCl3): 8.36 (br, NH), 
8.12 (s, 2H), 7.75 (d, J = 10.0 Hz, 1H), 2.22 (s, 3H), 0.26 (s, 9H). 
 
4.2.1.18 Synthesis of 2-acetamido-5-ethynylpyridine, 26 
 
          25      26 
2-Acetamido-5-trimethylsilanylethynylpyridine 25 (1.69 g, 7.28 mmol) and 
potassium carbonate (1.05 g, 7.60 mmol) were stirred in methanol (30 mL) at room 
temperature for 2 hours. The solution was then diluted with ethyl ether (100 mL) and 
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washed with water (4 x 100 mL). The solvent was removed on a rotary evaporator and 
the product 26 was obtained as a light brown colored powder, (0.85 g, 73%). 1H NMR 
(δH; 200 MHz, CDCl3): 8.39 (s, 1H), 8.19 (d, J = 8.0 Hz, 1H), 8.02 (br, NH), 7.79 (dd, J 
= 12.0 Hz, 1H), 3.17 (s, 1H), 2.23 (s, 3H). 
 
4.2.1.19 Synthesis of 2-amino-5-(3-(2-acetamidopyridyl))ethynylpyrazine, 27 
 
         13             26            27 
A mixture of 2-amino-5-bromopyrazine 13 (0.52 g, 3.00 mmol), 2-acetamido-5-
ethynylpyridine 26 (0.50 g, 3.13 mmol), copper(I) iodide (0.018 g, 0.094 mmol), 
triphenylphosphine (0.08 g, 0.30 mmol), and bis(triphenylphosphine)palladium(II) 
dichloride (0.08 g, 0.12 mmol) were added to a round bottom flask. Tetrahydrofuran (20 
mL) and triethylamine (20 mL) were added and dinitrogen bubbled through the resultant 
mixture for 10 minutes. The apparatus was fitted with a condenser and the mixture 
refluxed at 70 ˚C under a dinitrogen atmosphere. The reaction was monitored by TLC 
and upon completion (48 hrs) was cooled to room temperature. The solution was then 
diluted with ethyl acetate (50 mL), washed with (3 x 50 mL) and saturated aqueous 
sodium chloride solution (1 x 50 mL). The organic layer was separated and dried over 
anhydrous magnesium sulfate. The solvent was removed on a rotary evaporator and the 
residue was chromatographed on silica with hexane: ethyl acetate (2:8) mixture as eluant.  
The product was washed with methanol and filtered to obtain a white solid, which was 
recrystallized from ethyl acetate. (0.64 g, 84 %). Decomposes at 200 ºC. 1H NMR (δH; 
200 MHz, DMSO): 10.69 (br, NH), 8.45 (s, 1H), 8.15 (s, 1H), 8.10 (s, 1H), 7.94 (s, 1H), 
7.89 (s, 1H), 6.94 (br, 2H), 2.12 (s, 3H); (δC; 400 MHz, DMSO-d6): 169.78, 154.91, 
151.66, 146.00, 140.76, 124.94, 114.33, 113.09, 112.47, 89.74, 85.88. FT-IR (cm-1): υ 
3390, 3294, 3125, 1688, 1666. 
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4.2.1.20 Synthesis of 2-acetamido-5-bromopyrazine, 28 
 
 
         13          28 
2-Amino-5-bromopyrazine 13 (2.0 g, 11.5 mmol) was dissolved in acetic 
anhydride (10 mL) which was added dropwise. The mixture was heated under reflux at 
80°C for 2 hrs. Excess acetic anhydride and acetic acid produced were removed via 
vacuum distillation to obtain a white powder. Upon recrystallization from ethyl acetate, 
the product 28 was obtained as a white powder, (2.0 g, 81%). M.P. 198 ‒ 201 °C; 1H 
NMR (δH; 200 MHz, CDCl3): 9.33 (s, 1H), 8.34 (s, 1H), 7.83 (br, NH), 2.27(s, 3H). FT-
IR υ 3273 cm-1 (N—H, br),  1671 cm-1 (C=O, s), 1528 cm-1 (Amide II, s). 
 
4.2.1.21 Synthesis of 2-acetamido-5-(3-(2-acetamidopyridyl))ethynylpyrazine, 29 
 
        28  26           29 
A mixture of 2-acetamido-5-bromopyrazine 28 (0.33 g, 1.52 mmol), 2-acetamido-
5-ethynylpyridine 26 (0.26 g, 1.63 mmol), copper(I) iodide (0.009 g, 0.047 mmol), 
triphenylphosphine (0.04 g, 0.15 mmol), and bis(triphenylphosphine)palladium(II) 
dichloride (0.04 g, 0.06 mmol) were added to a round bottom flask. Tetrahydrofuran (10 
mL) and triethylamine (10 mL) were added and dinitrogen bubbled through the resultant 
mixture for 10 minutes. The apparatus was fitted with a condenser and the mixture 
refluxed at 70 ˚C under a dinitrogen atmosphere. The reaction was monitored by TLC 
and upon completion (48 hrs) was cooled to room temperature. The solution was diluted 
with ethyl acetate (25 mL), washed with (3 x 25 mL) and saturated aqueous sodium 
chloride solution (1 x 25 mL). The organic layer was separated and dried over anhydrous 
magnesium sulfate. The solvent was removed on a rotary evaporator and the residue was 
chromatographed on silica with hexane: ethyl acetate (2:8) mixture as eluant.  The 
 98  
product was washed with methanol and filtered to obtain a white solid, which was 
recrystallized from ethyl acetate. (0.23 g, 53 %). M.P. 182 ‒ 184 ºC;  1H NMR (δH; 400 
MHz, DMSO-d6): 10.97 (br, NH), 10.66 (br, NH), 9.12 (s, 1H), 8.59 (s, 1H), 8.41 (s, 
1H), 8.04 (s, 1H), 7.98 (s, 1H), 2.13 (s, 3H), 2.08 (s, 3H); (δC; 400 MHz, DMSO-d6): 
169.45, 155.30, 150.87, 147.91, 140.40, 131.92, 114.76, 112.98, 104.19. FT-IR (cm-1): υ 
3230, 3068, 1660, 1571. 
 
4.2.1.23 Synthesis of 2-amino-5-trimethylsilanylethynylpyrimidine, 30 
 
  9           30 
A mixture of 2-amino-5-bromopyrimidine 9 (2.5 g, 14.5 mmol), 
trimethylsilylacetylene (2.0 g, 20.3 mmol), copper(I) iodide (0.085 g, 0.45 mmol), 
triphenylphosphine (0.30 g, 1.15 mmol), and bis(triphenylphosphine)palladium(II) 
dichloride (0.30 g, 0.43 mmol, 3 mol%) were added to a round bottom flask. 
Tetrahydrofuran (50 mL) and triethylamine (50 mL) were added and dinitrogen bubbled 
through the resultant mixture for 10 minutes. The apparatus was fitted with a condenser 
and the mixture refluxed at 75 ˚C under dinitrogen atmosphere. The reaction was 
monitored by TLC and upon completion (48 hrs) was cooled to room temperature. The 
solution was then diluted with ethyl acetate (50 mL), washed with (3 x 50 mL) and 
saturated aqueous sodium chloride solution (1 x 50 mL). The organic layer was separated 
and dried over anhydrous magnesium sulfate. The solvent was removed on a rotary 
evaporator and the residue was chromatographed on silica with hexane: ethyl acetate 
mixture as eluant to obtain a light brown colored powder.  Upon recrystallization from 
methylene chloride, colorless crystals were obtained, (2.2 g, 80 %). 1H NMR (δH; 400 
MHz, CDCl3): 8.40 (s, 2H), 5.21 (br, 2H), 0.26 (s, 9H). 
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4.2.1.24 Synthesis of 2-amino-5-trimethylsilanylethynylpyrazine, 31 
 
  13          31 
A mixture of 2-amino-5-bromopyrazine 13 (2.5 g, 14.5 mmol), 
trimethylsilylacetylene (2.0 g, 20.3 mmol), copper(I) iodide (0.085 g, 0.45 mmol), 
triphenylphosphine (0.30 g, 1.15 mmol), and bis(triphenylphosphine)palladium(II) 
dichloride (0.30 g, 0.43 mmol, 3 mol%) were added to a round bottom flask. 
Tetrahydrofuran (50 mL) and triethylamine (50 mL) were added and dinitrogen bubbled 
through the resultant mixture for 10 minutes. The apparatus was fitted with a condenser 
and the mixture refluxed at 75 ˚C under dinitrogen atmosphere. The reaction was 
monitored by TLC and upon completion (48 hrs) was cooled to room temperature. The 
solution was then diluted with ethyl acetate (50 mL), washed with water (3 x 50 mL) and 
saturated aqueous sodium chloride solution (1 x 50 mL). The organic layer was separated 
and dried over anhydrous magnesium sulfate. The solvent was removed on a rotary 
evaporator and the residue was chromatographed on silica with hexane: ethyl acetate 
mixture as eluant to obtain a dark brown colored powder, (2.4 g, 87 %). 1H NMR (δH; 
200 MHz, CDCl3): 8.16 (s, 1H), 7.94 (s, 1H), 4.80 (br, 2H), 0.26 (s, 9H). 
 
4.2.1.25 Synthesis of 2-amino-5-(3-(2-aminopyrazino))ethynylpyrimidine, 32
12
 
 
 9  31       32 
A mixture of 2-amino-5-trimethylsilanylethynylpyrazine, 31 (1.30 g, 6.95 mmol), 
2-amino-5-bromopyrimidine, 9 (1.21 g, 6.95 mmol),  copper (I) iodide (0.131 g, 0.689 
mmol), triethylamine (1.39 g, 14.47 mmol), and ethylene glycol dimethyl ether (145 mL) 
was placed in a round bottom flask. Tetrakis(triphenylphosphine)palladium (0) (0.413 g, 
0.358 mmol) was added and dinitrogen bubbled through for 10 mins. The solution was 
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then heated to 80 ºC and tetrabutylammonium fluoride (14.5 ml, 1M/THF) was added 
dropwise to it in a dinitrogen atmosphere. The apparatus was fitted with a condenser and 
the mixture refluxed at 80 ºC for 12 hours under dinitrogen, and then quenched with 
water (200 mL). The solution was extracted with ethyl acetate (3 x 100 mL) and the 
organic extracts were washed with saturated aqueous sodium chloride solution (1 x 50 
mL). The organic layer was separated and dried over anhydrous magnesium sulfate. The 
solvent was removed on a rotary evaporator and the residue was chromatographed on 
silica with hexane: ethyl acetate: methanol mixture as eluant to obtain a light brown 
colored powder. It was washed with hot water (3 x 100 mL) and then dried, (0.8 g, 55 %). 
M. P. >280 ºC. 1H NMR (δH; 200 MHz, DMSO-d6): 8.40 (s, 2H), 8.08 (s, 1H), 7.85 (s, 
1H), 7.16 (br, 2H), 6.89 (br, 2H); 13C NMR (δC; 400 MHz, DMSO-d6): 161.89, 160.14, 
154.50, 145.34, 132.48, 125.18, 105.75, 89.94, 84.08, 57.52, 23.09, 19.23. FT-IR (cm-1): 
υ 3300, 3150, 1636, 1593, 1522. 
 
Alternate method 
 
 13  30       32 
A mixture of 2-amino-5-trimethylsilanylethynylpyrimidine, 30 (1.30 g, 6.95 
mmol), 2-amino-5-bromopyrazine, 13 (1.21 g, 6.95 mmol), copper (I) iodide (0.131 g, 
0.689 mmol), triethylamine (1.39 g, 14.47 mmol), and ethylene glycol dimethyl ether 
(145 mL) was placed in a round bottom flask. Tetrakis(triphenylphosphine)palladium (0) 
(0.413 g, 0.358 mmol) was added and dinitrogen bubbled through for 10 mins. The 
solution was then heated to 80 ºC and tetrabutylammonium fluoride (14.5 ml, 1M/THF) 
was added dropwise to it in dinitrogen atmosphere. The apparatus was fitted with a 
condenser and the mixture refluxed at 80 ºC for 12 hours under dinitrogen, and then 
quenched with water (200 mL). The solution was extracted with ethyl acetate (3 x 100 
mL) and the organic extracts were washed with saturated aqueous sodium chloride 
solution (1 x 50 mL). The organic layer was separated and dried over anhydrous 
magnesium sulfate. The solvent was removed on a rotary evaporator and the residue was 
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chromatographed on silica with hexane: ethyl acetate: methanol mixture as eluant to 
obtain light brown colored powder. It was washed with hot water (3 x 100 mL) and then 
dried, (1.5 g, 95 %). M. P. >280 ºC. 1H NMR (δH; 200 MHz, DMSO-d6): 8.40 (s, 2H), 
8.08 (s, 1H), 7.85 (s, 1H), 7.16 (br, 2H), 6.89 (br, 2H); 13C NMR (δC; 400 MHz, DMSO-
d6): 161.89, 160.14, 154.50, 145.34, 132.48, 125.18, 105.75, 89.94, 84.08, 57.52, 23.09, 
19.23. 
4.2.2 Synthesis of co-crystals and salts  
 
Each of the ten ligands under study was allowed to react with the same set of 19 
co-crystallizing agents comprising of ten monocarboxylic acids, five dicarboxylic acids 
and four cyanoximes. The solubility of the ligands range from highly soluble to very 
poorly soluble in a variety of solvents including ethyl acetate, nitrobenzene, methylene 
chloride, chloroform, acetonitrile, ethanol, and methanol. The low solubility of some of 
the ligands prompted the change of co-crystallization technique from slow evaporation at 
room temperature to methanol-assisted solvent-drop grinding (18, 27, 29, and 32). 
4.2.2.1 Synthesis of 2-amino-5-(3-pyridyl)pyrimidine/4-chlorobenzoic acid (1:1), 10c  
2-amino-5-(3-pyridyl)pyrimidine (0.010 g, 0.058 mmol) was dissolved in 5mL of 
ethyl acetate. To this solution was added 4-chlorobenzoic acid (0.009 g, 0.058 mmol) in 5 
mL of ethyl acetate. The resulting solution was warmed and allowed to stand for slow 
evaporation at room temperature. Colorless, plate-like crystals were obtained after 3 days. 
M. P. 160─162°C; FT-IR (cm-1) υ 3298, 2375, 1830, 1691. 
4.2.2.2 Synthesis of 2-amino-5-(3-pyridinium)pyrimidine pentaflurobenzoate, 10j 
2-amino-5-(3-pyridyl)pyrimidine (0.010 g, 0.058 mmol) was dissolved in 5mL of 
ethyl acetate. To this solution was added pentafluorobenzoic acid (0.012 g, 0.058 mmol) 
in 5 mL of ethyl acetate. The resulting solution was warmed and allowed to stand for 
slow evaporation at room temperature. Colorless, plate-like crystals were obtained after 3 
days. M. P. 156─158°C; FT-IR (cm-1) υ 3092, 2446, 1930, 1695. 
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4.2.2.3 Synthesis of 2-amino-5-(3-pyridyl)pyrimidine/suberic acid (2:1), 10k 
2-amino-5-(3-pyridyl)pyrimidine (0.010 g, 0.058 mmol) was dissolved in 5mL of 
ethyl acetate. To this solution was added suberic acid (0.005 g, 0.029 mmol) in 5 mL of 
ethyl acetate. The resulting solution was warmed and allowed to stand for slow 
evaporation at room temperature. Colorless crystals were obtained after 3 days. M. P. 
150°C; FT-IR (cm-1) υ 3301, 3150, 2410, 1912, 1687. 
4.2.2.4 Synthesis of 2-amino-5-(3-pyridyl)pyrimidine/succinic acid (2:1), 10n 
2-amino-5-(3-pyridyl)pyrimidine (0.010 g, 0.058 mmol) was dissolved in 5mL of 
ethyl acetate. To this solution was added succinic acid (0.004 g, 0.029 mmol) in 5 mL of 
ethyl acetate. The resulting solution was warmed and allowed to stand for slow 
evaporation at room temperature. Colorless rod-like crystals were obtained after 3 days. 
M. P. 188─189°C; FT-IR (cm-1) υ 3325, 3163, 2387, 1871, 1697. 
4.2.2.5 Synthesis of 2-amino-5-(3-pyridyl)pyrimidine/sebacic acid (2:1), 10o 
2-amino-5-(3-pyridyl)pyrimidine (0.010 g, 0.058 mmol) was dissolved in 5mL of 
ethyl acetate. To this solution was added sebacic acid (0.006 g, 0.029 mmol) in 5 mL of 
ethyl acetate. The resulting solution was warmed and allowed to stand for slow 
evaporation at room temperature. Colorless, rod-like crystals were obtained after 3 days. 
M. P. 143─145°C; FT-IR (cm-1) υ 3325, 3137, 2475, 1947, 1688. 
4.2.2.6 Synthesis of 2-amino-5-(3-pyridyl)pyrimidine/2-chlorocyanoxime (1:1), 10r 
2-amino-5-(3-pyridyl)pyrimidine (0.010 g, 0.058 mmol) was dissolved in 5mL of 
ethyl acetate. To this solution was added 2-chlorocyanoxime (0.010 g, 0.058 mmol) in 5 
mL of ethyl acetate. The resulting solution was warmed and allowed to stand for slow 
evaporation at room temperature. Light yellow colored, block-like crystals were obtained 
after 3 days. M. P. 175─177°C; FT-IR (υ, cm-1) 3299, 3147, 2462, 1861, 1661. 
4.2.2.7 Synthesis of 2-amino-4-methyl-5-(3-pyridyl)pyrimidine/succinic acid (2:1), 12n 
2-amino-4-methyl-5-(3-pyridyl)pyrimidine (0.004 g, 0.021 mmol) was dissolved 
in 5mL of ethyl acetate/acetonitrile/ethanol (1:1:1). To this solution was added succinic 
acid (0.002 g, 0.011 mmol) in 5 mL of ethyl acetate. The resulting solution was warmed 
and allowed to stand for slow evaporation at room temperature. Yellowish plate-like 
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crystals were obtained after 3 days. M. P. 160─162°C; FT-IR (υ, cm-1) 3291, 3122, 2472, 
1877, 1703. 
4.2.2.8 Synthesis of 2-amino-5-(3-pyridyl)pyrazine/4-nitrobenzoic acid (1:1), 15e 
2-amino-5-(3-pyridyl)pyrazine (0.010 g, 0.058 mmol) was dissolved in 5mL of 
ethyl acetate/methanol (1:1). To this solution was added 4-nitrobenzoic acid (0.010 g, 
0.058 mmol) in 5 mL of ethyl acetate. The resulting solution was warmed and allowed to 
stand for slow evaporation at room temperature. Yellowish needle-shaped crystals were 
obtained after 3 days. M. P. 208─210°C; FT-IR (υ, cm-1) 3445, 3343, 2435, 1928, 1689. 
4.2.2.9 Synthesis of 2-acetamido-5-(3-pyridyl)pyridine/cyanoxime (1:1), 16p 
2-acetamido-5-(3-pyridyl)pyridine (0.030 g, 0.141 mmol) was dissolved in 5mL 
of ethyl acetate. To this solution was added cyanoxime (0.021 g, 0.141 mmol) in 5 mL of 
ethyl acetate. The resulting solution was warmed and allowed to stand for slow 
evaporation at room temperature. Colorless crystals were obtained after 3 days. M. P. 
140─142°C; IR (KBr pellet) υ cm-1 3263, 2452, 1896, 1696. 
4.2.2.10 Synthesis of 2-amino-5-(3-(2-acetamido)pyridyl)ethynylpyridinium 3,5-
dimethyl benzoate/ 3,5-dimethylbenzoic acid (1:1), 24h 
 
2-amino-5-(3-(2-acetamido)pyridyl)ethynylpyridine (0.030 g, 0.119 mmol) was 
dissolved in 5mL of ethyl acetate. To this solution was added 3,5-dimethylbenzoic acid, 
(0.018 g, 0.119 mmol) in 5 mL of ethyl acetate. The resulting solution was warmed and 
allowed to stand for slow evaporation at room temperature. Colorless crystals were 
obtained after 3 days. M. P. 177─180°C; IR (KBr pellet) υ cm-1 3340, 3034, 2504, 1885, 
1678. 
4.2.2.11 Synthesis of 2-amino-5-(3-(2-acetamido)pyridyl)ethynylpyridinium phthalate, 
24l 
2-amino-5-(3-(2-acetamido)pyridyl)ethynylpyridine (0.030 g, 0.119 mmol) was 
dissolved in 5mL of ethyl acetate. To this solution was added phthalic acid (0.010 g, 
0.059 mmol) in 5 mL of ethyl acetate. The resulting solution was warmed and allowed to 
stand for slow evaporation at room temperature. Colorless crystals were obtained after 3 
days. M. P. 175─176°C; IR (KBr pellet) υ cm-1 3199, 3010, 2474, 2003, 1690. 
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4.2.2.12 Synthesis of 2-amino-5-(3-(2-acetamido)pyridyl)ethynylpyrazine/3,5-
dinitrobenzoic acid (1:1), 27i 
 
2-amino-5-(3-(2-acetamido)pyridyl)ethynylpyrazine (0.010 g, 0.040 mmol) was 
dissolved in 5mL of ethyl acetate/ethanol/DMSO (1:1:0.5). To this solution was added 
3,5-dinitrobenzoic acid (0.008 g, 0.040 mmol) in 5 mL of ethyl acetate. The resulting 
solution was warmed and allowed to stand for slow evaporation at room temperature. 
Yellowish needle-shaped crystals were obtained after 3 days. Decomposed at 180 °C; IR 
(KBr pellet) υ cm-1 3375, 3094, 2435, 1871, 1687. 
 
4.2.3 Electrostatic charges calculations 
The magnitude of the electrostatic potential on the hydrogen-bond donors and 
acceptors in these molecules were obtained using semi-empirical AM1 calculations.13 
Values for individual atoms are obtained by probing the MEPS (0.002 e/au isosurface, 
from AM1 calculations) with a point charge. Depending upon the values obtained for the 
nitrogen atoms in the pyridine/pyrimidine/pyrazine molecules, the best hydrogen acceptor 
and second best hydrogen acceptor was assigned to be the one with the highest charge 
and second highest charge respectively. For example, the 2-amino-5-(3-
pyridyl)pyrimidine 10  has one pyridyl-N and two pyrimidyl-N atoms. The two highest 
charges on the nitrogen atoms were identified using the software and duly assigned best 
hydrogen bond acceptor and second best acceptor. Hence the pyridyl-N with the highest 
charge (-277 kJ/mol) was assigned the best hydrogen bond acceptor and pyrimidyl-N 
with the second higher charge (-260 kJ/mol) was assigned second best acceptor.  
 
4.2.4 Single Crystal X-ray Crystallography 
X-ray data were collected on a Bruker SMART APEX or a SMART 1000 
diffractometer using Mo Kα radiation and, where noted, were corrected for absorption 
using the multiscan procedure implemented by SADABS.  Data were collected using 
SMART.  The relevant X-ray data are summarized in Table 4.4 and labeling schemes and 
thermal ellipsoids for all structures are shown in Figures 4.6, 4.14, and 4.21.   
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4.3 Results and Discussion 
4.3.1 Characterization by FT-IR 
 
The solids obtained from the co-crystallization of each of the ten ligands with 19 
co-crystallizing agents (ten monocarboxylic acids, five dicarboxylic acids and four 
cyanoximes), a total of 190 (10 x 19), were screened using IR spectroscopy. The outcome 
of this analysis is displayed in Table 4.1. The IR stretching frequencies of interest of all 
the salts and co-crystals under study is listed in Table 4.1 and 4.2.   
The distinction between the salt, neutral co-crystal, and no reaction was done by 
identifying the characteristics band stretches and shifting of carbonyl stretches in free and 
bonded acids via IR spectroscopy. The presence/absence of broad absorption bands in the 
regions near 1950 and 2450 cm-1 indicates intermolecular O—H---N(heterocycle) 
hydrogen bonds. The appearance of a sharp stretch around 1700 cm-1and a weak stretch 
near 1275 cm-1 indicates intact C=O in co-crystals, whereas a strong stretch around 1650-
1550 cm-1 and a weaker symmetrical stretch around 1400 cm-1 indicates COO- in salts.14  
Table 4.1 Results in attempted co-crystallization reactions in pyridine series 
 
Ligands 10 12 15 16 18 21 24 27 29 32 
Salt & 
co-crystal 
19/19 16/19 15/19 19/19 6/19 14/19 17/19 9/19 5/19 6/19 
Yield % 100 84 79 100 32 74 89 47 26 32 
 
The results indicate high supramolecular yields in terms of formation of salts and 
co-crystals for the ligands 10, 12, 15, 16, 21 and 24; whereas for the remaining ligands 
the yield is poor. This may have been due to the poor solubility of the ligands themselves. 
The co-crystallization for the ligands 18, 27, 29 and 32 were carried out via solvent-drop 
grinding due to their minimal solubility in traditional solvents, hence could not be carried 
out via evaporation at room temperature. In addition, the carboxylic acid/carboxylate 
stretching which is the basis of differentiation between salts and co-crystals is very 
elusive here. The salts 10j, 24h, and 24l display carbonyl stretching at 1695, 1678, 1690 
cm-1 instead of the expected carboxylate stretching at 1650-1550 cm-1. Hence, within this 
system of coupled ditopic heterocyclic ligands, the IR data is inconclusive in 
distinguishing between the salts and the co-crystals formed. 
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Table 4.2 IR stretching frequencies (cm-1) of salts and co-crystals of the ligands 10, 
12, 15, 16, and 18. 
  10 12 15 16 18 
a 4-cyanobenzoic acid 
3449, 3311, 
2370, 1888, 
1701 
3304, 3152, 
2491, 1905,  
1701 
3420, 3201, 
2374, 1882, 
1699 
3449, 3254, 
2408, 1936, 
1694 
3309, 2930, 
2441, 1939, 
1683 
b 
3-hydroxybenzoic 
acid 
3477, 3346, 
2457, 1949, 
1692 
3305, 3171, 
2477, 1880, 
1686 
n/a 
3422, 3255, 
2496, 1844, 
1701 
3312, 2934, 
2469, 1934, 
1681 
c 4-chlorobenzoic acid 
3298, 2375, 
1830, 1691 
n/a 
3383, 3201, 
2368, 1869, 
1687 
3435, 3255, 
2439, 1879, 
1695 
n/a 
d 4-fluorobenzoic acid 
3400, 3321, 
2459, 1920, 
1700 
3317, 3132, 
2558, 1878, 
1670 
3380, 3204, 
2418, 1923, 
1686 
3435, 3256, 
2443, 1918, 
1694 
n/a 
e 4-nitrobenzoic acid 
3414. 3318, 
2370, 1920, 
1701 
3415, 3117, 
2391, 1900, 
1701 
3445, 3343, 
2435, 1928, 
1689 
3449, 3299, 
2448, 1945, 
1699 
3116, 2924, 
2366, 1940, 
1692 
f 
3,4-dichlorobenzoic 
acid 
3330, 3184, 
2373, 1922, 
1699 
3280, 3117, 
2422, 1896, 
1656 
3315, 3202, 
2362, 1869, 
1693 
3440, 3255, 
2439, 1905, 
1698 
n/a 
g 
2,6-difluorobenzoic 
acid 
3293, 3163, 
2492, 1942, 
1716 
3300, 3156, 
2479, 1922, 
1720 
3323, 3212, 
2360, 1900, 
1701 
3422, 3249, 
2521, 1884, 
1697 
n/a 
h 
3,5-dimethylbenzoic 
acid 
3322, 3154, 
2607, 1811, 
1683 
3320, 3192, 
2532, 1812, 
1683 
n/a 
3444, 2496, 
1892, 1707 
n/a 
i 
3,5-dinitrobenzoic 
acid 
3280, 3118, 
2484, 1938, 
1716 
3262, 2988, 
2370, 1968, 
1680 
n/a 
3445, 3217, 
2453, 1961, 
1679 
n/a 
j 
pentafluorobenzoic 
acid 
3092, 2446, 
1930, 1695 
3326, 2918, 
2468, 1928, 
1682 
n/a 
3431, 3043, 
2448, 1879, 
1707 
n/a 
k suberic acid 
3303, 3166, 
2413, 1904, 
1687 
3310, 3134, 
2493, 1901, 
1701 
3433, 3309, 
2437, 1871, 
1693 
3457, 3255, 
2474, 1923, 
1698 
n/a 
l phthalic acid 
3309, 3140, 
2480, 1869, 
1694 
3445, 3332, 
2366, 1845, 
1686 
3311, 3119, 
2435, 1865, 
1688 
3431, 3241, 
2505, 1874, 
1695 
3295, 2940, 
2509, 1920, 
1684 
m fumaric acid 
3463, 3319, 
2394, 1864, 
1683 
3290, 3121, 
2429, 1866, 
1699 
3343, 3172, 
2541, 1928, 
1725 
3422, 3255, 
2527, 1888, 
1698 
3388, 2926, 
2492, 1965, 
1684 
n succinic acid 
3325, 3163, 
2387, 1871, 
1697 
3291, 3122, 
2472, 1877, 
1703 
3414, 3336, 
2456, 1905, 
1725 
3479, 3246, 
2448, 1923, 
1698 
3362, 2925, 
2524, 1948, 
1685 
o sebacic acid 
3325, 3137, 
2475, 1947, 
1688 
3307, 3147, 
2492, 1925, 
1693 
3405, 3310, 
2458, 1871, 
1692 
3259, 2487, 
1918, 1702 
n/a 
p cyanoxime 
3416, 3323, 
2562, 1781, 
1667 
3419, 3329, 
2534, 1627 
3335, 3212, 
2439, 1867, 
1682 
3263, 2452, 
1896, 1696 
n/a 
q 2-fluorocyanoxime 
3414, 3326, 
2530, 1777, 
1668 
3418, 3332, 
2534, 1776, 
1629 
3321, 3214, 
2432, 1789, 
1634 
3475, 3294, 
2474, 1861, 
1702 
n/a 
r 2-chlorocyanoxime 
3299, 3147, 
2462, 1861, 
1661 
n/a 
3332, 3111, 
2395, 1826, 
1627 
3431, 3250, 
2452, 1918, 
1694 
n/a 
s 4-bromocyanoxime 
3304, 3156, 
2455, 1888, 
1661 
n/a 
3337, 3207, 
2438, 1900, 
1644 
3444, 3285, 
2487, 1866, 
1698 
n/a 
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Table 4.3 IR stretching frequencies (cm-1) of salts and co-crystals of the ligands 21, 
24, 27, 29, and 32. 
  21 24 27 29 32 
a 4-cyanobenzoic acid 
3422, 3056, 
2474, 1905, 
1702 
3282, 2745, 
1973, 1681 
3304, 2944, 
2513, 1939, 
1687 
3242, 3057, 
2548, 1953, 
1686 
n/a 
b 3-hydroxybenzoic acid 
3249, 3053, 
2607, 1870, 
1693 
3464, 3116, 
2492, 1843, 
1695 
n/a n/a n/a 
c 4-chlorobenzoic acid 
3440, 3030, 
2439, 1893, 
1714 
3423, 3217, 
2533, 1873, 
1696 
n/a n/a n/a 
d 4-fluorobenzoic acid 
3427, 3074, 
2540, 1914, 
1699 
3423, 3199, 
2498, 1902, 
1692 
3301, 2943, 
2556, 1924, 
1674 
n/a n/a 
e 4-nitrobenzoic acid 
3435, 3052, 
2417, 1905, 
1707 
3255, 2363, 
1941, 1696 
3387, 3296, 
2552, 1959, 
1687 
n/a 
3016, 2411, 
1939, 1702 
f 3,4-dichlorobenzoic acid 
3435, 3065, 
2465, 1888, 
1716 
3393, 2486, 
1926, 1690 
3315, 2943, 
2509, 1871, 
1691 
3240, 3091, 
2570, 1930, 
1673 
n/a 
g 2,6-difluorobenzoic acid 
3440, 3065, 
2470, 1888, 
1702 
3415, 2461, 
1919, 1690 
n/a n/a n/a 
h 
3,5-dimethylbenzoic 
acid 
3436, 3035, 
2512, 1856, 
1706 
3340, 3034, 
2504, 1885, 
1678 
n/a 
3228, 3042, 
2519, 1851, 
1703 
n/a 
i 3,5-dinitrobenzoic acid 
3413, 2465, 
1932, 1716 
3340, 3075, 
2515, 1979, 
1673 
3375, 3094, 
2435, 1871, 
1687 
3093, 2829, 
2539, 1851, 
1699 
3312, 3091, 
2463, 1855, 
1702 
j pentafluorobenzoic acid n/a 
3325, 3075, 
2509, 2032, 
1684 
3390, 3296, 
2455, 1912, 
1686 
3241, 3066, 
2521, 1887, 
1696 
n/a 
k suberic acid n/a 
3464, 3193, 
2486, 1932, 
1696 
n/a n/a 
3310, 3152, 
2500, 1904, 
1704 
l phthalic acid n/a 
3199, 3010, 
2474, 2003, 
1690 
3389, 3157, 
2615, 1924, 
1687 
n/a 
3313, 2944, 
2504, 1990, 
1703 
m fumaric acid 
3440, 3049, 
2489, 1875, 
1706 
3323, 3034, 
2439, 1985, 
1684 
3390, 3155, 
2536, 1900, 
1667 
n/a 
3307, 3161, 
2464, 1882, 
1702 
n succinic acid n/a 
3235, 2384, 
2002, 1674 
3390, 3160, 
2525, 1932, 
1687 
n/a 
3307, 2963, 
2533, 1900, 
1693 
o sebacic acid n/a 
3452, 3211, 
2474, 1908, 
1702 
n/a n/a n/a 
p cyanoxime 
3368, 2525, 
1911, 1707 
3455, 3180, 
2530, 1810, 
1685 
n/a n/a n/a 
q 4-fluorocyanoxime 
3450, 3063, 
2471, 1902, 
1707 
3420, 3222, 
2547, 1856, 
1713 
n/a n/a n/a 
r 4-chlorocyanoxime 
3436, 2471, 
1911, 1702 
n/a n/a n/a n/a 
s 4-bromocyanoxime 
3444, 2536, 
1839, 1702 
n/a n/a n/a n/a 
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4.3.2 Crystal Structures  
 
A total of 19 crystal structures were obtained, out of which seven are of the 
ligands by themselves, nine are co-crystals, and three are salts. Out of twelve co-
crystals/salts, ten were obtained with carboxylic acids and two with cyanoximes. The co-
crystals and salts with the dicarboxylic acids are in 2:1 stoichiometry, while 
monocarboxylic acids and cyanoximes display 1:1 stoichiometry.  
 
A summary of the crystallographic information for the salts and co-crystals are 
presented in the Appendix A and all the hydrogen-bond geometries are listed in Table 
4.4. 
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Table 4.4 Hydrogen-bond geometries for the ditopic ligands, and their salts and co-
crystals. 
______________________________________________________________________________________ 
Structure D-H...A d(D-H)/Å           d(H...A)/Å d(D...A)/Å <(DHA)/º 
______________________________________________________________________________________  
10i    N121-H12A1...N132  0.90(2)  2.15(2)  3.0507(17) 174(2) 
  N122-H12A2...N131  0.90(2)  2.13(2)  3.0288(17) 174(2) 
N121-H12B1...N112#1  0.91(2)  2.12(2)  3.0301(17) 176(2) 
N122-H12B2...N111#2  0.87(2)  2.18(2)  3.0466(17) 175(2) 
 
12ii   N(12)-H(12A)...N(13)#1  0.876(14) 2.124(14) 2.9948(12) 172.4(13) 
 N(12)-H(12B)...N(11)#2  0.889(14) 2.145(14) 3.0278(12) 171.6(12) 
 
15iii N(12)-H(12A)...N(21)#1  0.885(19) 2.13(2)  3.0067(18) 172.9(17) 
 N(12)-H(12B)...N(14)#2  0.87(2)  2.40(2)  3.239(2)  162.7(16) 
 
16iv  N371-H371...N212#1  0.88  2.19  3.064(2)  169.4 
  N372-H372...N211  0.88  2.20  3.071(3)  171.6 
 
21v  N(32)-H(32)...O(18)  0.83(3)  2.07(3)  2.879(3)  166(3) 
  N(12)-H(12)...N(41)#1  0.87(3)  2.14(3)  3.007(3)  176(3) 
 
24vi N221-H22A1...O(1S)  0.894(16) 2.133(16) 2.9502(13) 151.6(13) 
N222-H22A2...O(1S)  0.895(15) 2.107(16) 2.9953(12) 172.1(14) 
N221-H22B1...N112#1  0.895(16) 2.169(16) 3.0625(13) 176.2(14) 
N222-H22B2...N111#2  0.904(16) 2.122(16) 3.0253(13) 176.3(13) 
N121-H121...N212#2  0.894(16) 2.220(16) 3.1055(13) 170.4(13) 
N122-H122...N211#1  0.882(15) 2.213(15) 3.0899(13) 172.6(13) 
O(1S)-H(1A)...O182#3  0.889(16) 1.884(17) 2.7661(12) 171.2(15) 
O(1S)-H(1B)...O181#4  0.852(17) 1.958(17) 2.8073(12) 174.1(15) 
 
27vii  N(22)-H(22A)...N(11)#1  0.932(14) 2.132(14) 3.0615(11) 174.9(12) 
 N(22)-H(22B)...O(18)#2  0.938(13) 2.145(13) 3.0117(11) 153.0(11) 
   N(12)-H(12)...N(21)#3  0.922(13) 2.185(13) 3.1010(11) 171.8(11) 
 
10cviii   O(31)-H(31)...N(21)   0.96(2)  1.67(2)  2.6274(16) 179(2) 
  N(12)-H(12A)...N(11)#1  0.92(2)  2.19(2)  3.0998(16) 172.9(15) 
 N(12)-H(12B)...N(13)#2  0.912(19) 2.05(2)  2.9650(16) 176.1(15) 
 
10jix   N(21)-H(21)...O(31)  1.022(16) 2.690(15) 3.3299(12) 120.7(11) 
  N(12)-H(12A)...N(11)#1  0.860(16) 2.122(16) 2.9778(12) 173.4(15) 
 N(12)-H(12B)...N(13)#2  0.897(16) 2.094(17) 2.9848(13) 172.4(15) 
 
10kx  O(31)-H(31)...N(21)  0.95(2)  1.70(2)  2.6516(16) 174.9(17) 
  N(12)-H(12A)...N(13)#2  0.873(18) 2.188(19) 3.0603(18) 177.7(17) 
  N(12)-H(12B)...N(11)#3   0.903(19) 2.120(19) 3.0222(18)   176.1(15) 
 
10nxi  O(51)-H(51)...N(11)  0.98(3)  1.64(3)  2.618(2)  174(3) 
  O(54)-H(54)...N(31)  0.98(3)  1.69(3)  2.662(2)  171(3) 
  N(12)-H(12A)...O(52)  0.92(3)  1.96(3)  2.873(3)  171(3) 
  N(12)-H(12B)...N(41)#1  0.97(3)  2.01(3)  2.973(3)  173(2) 
  N(32)-H(32A)...O(55)  1.03(3)  1.86(3)  2.871(3)  168(2) 
  N(32)-H(32B)...N(21)#2  0.93(3)  2.12(3)  3.038(3)  171(3) 
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______________________________________________________________________________________ 
Structure D-H...A d(D-H)/Å           d(H...A)/Å d(D...A)/Å <(DHA)/º 
______________________________________________________________________________________  
10oxii  O(31)-H(31)...N(21)  0.919(19) 1.741(19) 2.6509(13) 170.2(16) 
  N(12)-H(12A)...N(11)#2  0.907(15) 2.150(15) 3.0546(13) 175.3(13) 
  N(12)-H(12B)...N(13)#3  0.917(16) 2.101(16) 3.0176(14) 177.6(14) 
 
10pxiii  O(37)-H(37)...N(21)  0.94(3)  1.72(3)  2.644(2)  169(2) 
  N(12)-H(12A)...N(11)#1  0.89(2)  2.16(2)  3.045(2)  173(2) 
  N(12)-H(12B)...N(13)#2  0.92(2)  2.13(2)  3.041(2)  175(2) 
 
12nxiv  O(31)-H(31)...N(21)  0.999(17) 1.698(17) 2.6910(14) 171.7(15) 
 N(12)-H(12A)...N(11)#2  0.924(16) 2.167(16) 3.0789(15) 168.9(13) 
  N(12)-H(12B)...N(13)#3  0.889(16) 2.096(17) 2.9779(15) 171.3(14) 
 
15exv O(31)-H(31)...N(21)  0.84  1.73  2.566(4)  175.1 
  N(12)-H(12A)...O(31)#1  0.88  2.12  2.981(4)  165.4 
  N(12)-H(12B)...O(34)#2  0.88  2.18  3.051(4)  168.3 
 
16pxvi O(37)-H(37)...N(21)  0.994(15) 1.610(15) 2.6037(11) 178.0(13) 
  N(12)-H(12)...N(11)#1  0.903(13) 2.327(13) 3.2280(11) 175.0(11) 
 
24hxvii  N(12)-H(12)...O(32)  0.904(19) 1.92(2)  2.8212(17) 173.6(17) 
  N(21)-H(21)...O(41)  0.96(2)  1.58(2)  2.532(2)  173(2) 
  N(22)-H(22A)...O(42)  0.90(2)  1.97(2)  2.867(2)  173.6(19) 
  O(31)-H(31)...N(11)  0.82(2)  1.90(2)  2.7067(17) 171(2) 
  N(22)-H(22B)...O(42)#1  0.89(2)  1.98(2)  2.863(2)  169.4(19) 
 
24lxviii N(12)-H(12)...O(38)#1  0.88  2.05  2.916(2)  166.2 
  N(21)-H(21)...O(51)  0.99(2)  1.64(2)  2.592(2)  160(2) 
  N(22)-H(22A)...O(52)  0.88  2.01  2.848(2)  157.9 
  N(22)-H(22B)...O(54)#2  0.88  2.06  2.877(2)  154.1 
  N(32)-H(32)...O(53)#3  0.88  2.18  3.035(2)  165.0 
  N(41)-H(41)...O(53)  0.87(3)  1.76(3)  2.622(2)  173(3) 
 N(42)-H(42A)...O(52)  0.88  2.15  2.973(2)  155.4 
  N(42)-H(42B)...O(54)#2  0.88  2.32  3.181(3)  166.4 
 
27ixix  N(22)-H(22A)...N(11)#1  0.97(3)  1.98(3)  2.957(3)  177(2) 
  O(31)-H(31)...N(24)  0.98(3)  1.63(3)  2.599(3)  166(2) 
  N(12)-H(12)...N(21)#2  0.89(3)  2.22(3)  3.108(3)  177(2) 
 
 
 (i) #1 x+1,y,z+1  #2 x-1,y,z-1  (ii) #1 -x+1,y-1/2,-z+3/2  #2 -x+1,y+1/2,-z+3/2  (iii) #1 x,y-1,z    #2 x-1/2,-
y+1/2,z-1/2  (iv) #1 x+1,y,z-1  (v) #1 -x+1,-y,-z+1  (vi) #1 -x,-y,-z  #2 -x+2,-y+1,-z+2  #3 -x-1,-y,-z  #4 x-
1,y,z-1  (vii) #1 x,y-1,z  #2 x,-y+1,z-1/2  #3 x,y+1,z  (viii) #1 -x,y-1/2,-z+3/2  #2 -x,y+1/2,-z+3/2  (ix) #1 -
x+3,-y,-z+1  #2 -x+3,-y-1,-z+1  (x) #1 -x-1,-y-1,-z    #2 -x+2,-y,-z+1    #3 -x+3,-y+1,-z+1  (xi) #1 x-1,-
y+1/2,z-1/2  #2 x+1,-y+3/2,z+1/2  (xii) #1 -x+3,-y-1,-z  #2 -x,-y,-z+1  #3 -x-1,-y+1,-z+1  (xiii) #1 -
x+1,y+1/2,-z+5/2  #2 -x+1,y-1/2,-z+5/2  (xiv) #1 -x+1,-y+2,-z+1  #2 -x,y-1/2,-z+3/2  #3 -x,y+1/2,-z+3/2  
(xv) #1 -x,-y,-z  #2 x-1,y-2,z-1  (xvi) #1 -x+1,-y,-z+1  (xvii) #1 x+1/2,-y+3/2,z+1/2  (xviii) #1 x+2,y+1,z-1  
#2 -x,-y,-z+1  #3 -x,-y,-z+2  (xix) #1 x-2,y,z-1  #2 x+2,y,z+1      
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Figure 4.6 Thermal ellipsoid plots (50 % probabilities) and labeling schemes for the ditopic 
ligands 10, 12, 15, 16, 21, 24, and 27. 
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4.3.2.1 Crystal structure of 10 and 12 
 
 The crystal structures of the ditopic ligands 2-amino-5-(3-pyridyl)pyrimidine 10 
and 2-amino-4-methyl-5-(3-pyridyl)pyrimidine 12 show similar packing with 1-D chains 
resulting from two self-complementary N-H···N hydrogen bonds between the amino 
groups and the pyrimidinyl nitrogens on either side. The consecutive pyridyl-N atoms on 
the chains are positioned in anti- arrangement in 10 and syn- arrangement in 12, (Figure 
4.7 – 4.8). 
 
 
Figure 4.7 1-D arrangement in 10 formed via N-H···N hydrogen bonds. 
 
 
 
 
Figure 4.8 1-D arrangement of 12 formed via N-H···N hydrogen bonds. 
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4.3.2.2 Crystal structure of 2-amino-5-(3-pyridyl)pyrazine, 15 
 
The crystal structure of 15 shows 1-D strands formed via two self-complementary 
N-H···N hydrogen bonds (N(12)-H(12A)...N(21), 3.0067(18) Å) and (N(12)-
H(12B)...N(14), 3.239(2) Å) between the pyridyl-N and the amino N-H in the 
neighboring ligands arranged in a parallel manner, (Figure 4.9). 
 
 
 
Figure 4.9 1-D chain in 15 formed via N-H···N hydrogen bonds. 
 
4.3.2.3 Crystal structure of 2-acetamido-5-(3-pyridyl)pyridine, 16 
 
The crystal structure of 16 shows zigzag 1-D strands formed via two self-
complementary N-H···N hydrogen bonds (N371-H371...N212, 3.064(2) Å) and (N372-
H372...N211, 3.071(3) Å) between the pyridyl-N and the acetamido N-H in the 
neighboring ligands, (Figure 4.10).  
  
 
 
Figure 4.10 1-D strand of 16 connected via N-H···N hydrogen bonds. 
 
4.3.2.4 Crystal structure of 2-acetamido-5-(3-pyridyl)ethynylpyridine, 21 
 
The crystal structure of 21 shows a four-component assembly linked via N-H···O 
hydrogen bonds (N(32)-H(32)...O(18), 2.879(3) Å) and N-H···N hydrogen bonds N(12)-
H(12)...N(41)1, 3.007(3) Å) between the acetamido N-H and carbonyl oxygen, and the 
acetamido N-H and pyridyl-N respectively, (Figure 4.11). 
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Figure 4.11 Four-component arrangement in the structure of 21 formed via N-H···O and 
N-H···N hydrogen bonds. 
 
4.3.2.5 Crystal structure of 2-amino-5-(3-(2-acetamido)pyridyl)ethynylpyridine, 24 
 
The crystal structure of 24 consists of primary motif formed via three N-H···N 
interactions; two resulting from amino N-H and pyridyl-N interactions, and one from 
acetamido N-H and pyridyl-N interaction with two of its neighbors to give a 1-D chain.  
The chain is further extended by water molecules via two N-H···O between the amino N-
H and water molecules, and two O-H···O interactions between carbonyl oxygens and 
water molecules to form a 2-D network, (Figure 4.12). 
  
 
 
Figure 4.12 2-D network of 24 formed via a series of N-H···N, N-H···O, and O-H···O 
hydrogen bonds. 
 
4.3.2.6 Crystal structure of 2-amino-5-(3-(2-acetamido)pyridyl)ethynylpyrazine, 27 
 
 The crystal structure of 27 consists of primary motif formed via two N-H···N 
hydrogen bonds between amino N-H and pyridyl-N (N(22)-H(22A)...N(11), 174.9(12) 
Å); and acetamido N-H and pyridyl-N (N(12)-H(12)...N(21), 3.1010(11) Å). In addition, 
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two N-H···O hydrogen bonds between amino N-H and carbonyl oxygen (N(22)-
H(22B)...O(18), 3.0117(11) Å) are also present, (Figure 4.13). 
 
 
 
Figure 4.13 2-D arrangement of 27 formed via N-H···N and N-H···O hydrogen bonds. 
 
 
 
 
  
      10c       10j 
 
      
        10k         10n   
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        10o       10p 
 
Figure 4.14 Thermal ellipsoid plots (50 % probabilities) and labeling schemes for the co-
crystals (10c, 10k, 10n, 10o, and 10p) and salt (10j) of 2-amino-5-(3-pyridyl)pyrimidine 10. 
 
4.3.2.7 Crystal structure of 2-amino-5-(3-pyridyl)pyrimidine/4-chlorobenzoic acid (1:1), 
10c 
 
The crystal structure of 10c shows a 1:1 co-crystal with 2-amino-5-(3-
pyridyl)pyrimidine and 4-chlorobenzoic acid connected via O-H···N hydrogen bonds 
(O(31)-H(31)...N(21), 2.6274(16) Å) between the hydroxyl group of the acid and the 
pyridyl-N of 10. The aminopyrimidine moiety is engaged in N-H···N interactions with its 
neighboring ligands to give a 1-D ribbon, (Figure 4.15).  
 
 
 
Figure 4.15 1-D ribbon of 10c formed via O-H···N and N-H···N interactions. 
 
4.3.2.8 Crystal structure of 2-amino-5-(3-pyridinium)pyrimidine pentaflurobenzoate, 
10j 
 
The crystal structure of 10j displays a similar 1:1 architecture as observed for 10c. 
However, the loss of proton from the pentaflurobenzoic acid gives rise to a ionic salt with 
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N-H+···O+ interactions (N(21)-H(21)...O(31), 3.3299(12) Å) between the pyridinium and 
the carboxylate oxygen. The aminopyrimidine moiety is engaged in N-H···N interactions 
with its neighboring ligands to give a 1-D ribbon, (Figure 4.16).  
 
 
Figure 4.16 1-D ribbon of 10j formed via N-H+···O- and N-H···N interactions. 
 
4.3.2.9 Crystal structure of 10k and 10o  
 
The crystal structures of 10k and 10o show 2:1 co-crystals comprising of the 
neutral ligand 10 and suberic acid or sebacic acid molecule connected via hydrogen 
bonding interactions. The primary synthons in these structures are O–H···N hydrogen 
bonds which are extended into interlinking ribbon to give a 2-D network via N–H···N 
interactions between the aminopyrimidine moieties, (Figure 4.17 - 4.18).  
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Figure 4.17 2-D ribbon of 10k formed via O-H···N and N-H···N interactions. 
 
 
 
Figure 4.18 2-D ribbon of 10o formed via O-H···N and N-H···N interactions. 
 
4.3.2.10 Crystal structure of 2-amino-5-(3-pyridyl)pyrimidine/2-chlorocyanoxime (1:1), 
10r 
 
The crystal structure of 10p shows a 1:1 co-crystal similar to 10c, with the ligand 
2-amino-5-(3-pyridyl)pyrimidine 10 and chlorocyanoxime connected via O-H···N 
hydrogen bonds (O(37)-H(37)...N(21), 2.644(2) Å) between the hydroxyl group of the 
cyanoxime and the pyridyl-N of 10. The aminopyrimidine moiety is engaged in N-H···N 
interactions with its neighboring ligands to give a 1-D ribbon, (Figure 4.19).  
 
 
 
Figure 4.19 1-D ribbon of 10p formed via O-H···N and N-H···N interactions. 
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4.3.2.11 Crystal structure of 2-amino-5-(3-pyridyl)pyrimidine/succinic acid (2:1), 10n 
 
 The crystal structure of 10n shows a 2:1 co-crystal comprising of the 
neutral ligand 10 and succinic acid molecule connected via hydrogen bonding 
interactions. This structure is different from other co-crystals/salts structure of 10 in the 
binding mode of the co-crystallizing agent. Here, the acid binds with the 
aminopyrimidine moiety rather than with the pyridine. The primary synthons in these 
structures are O–H···N and N–H···O hydrogen bonds between the succinic acid and the 
aminopyrimidinium-NH moieties. The architecture is extended into 2-D ribbons via N–
H···N interactions between the anti-proton of the aminopyrimidine and the pyridyl-N, 
(Figure 4.20).  
 
 
 
Figure 4.20 2-D ribbon of 10n connected via O-H···N and N-H···N interactions. 
 
 
 
  
   12n      15e 
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24h      24l                
     
Figure 4.21 Thermal ellipsoid plots (50 % probabilities) and labeling schemes for the co-
crystals (12n, 15e, 16p and 27i) and salts (24h and 24l). 
 
4.3.2.12 Crystal structure of 2-amino-4-methyl-5-(3-pyridyl)pyrimidine/succinic acid 
(2:1), 12n 
The crystal structure of 12n shows a 2:1 co-crystal comprising of the neutral 
ligand 12 and succinic acid molecule connected via hydrogen bonding interactions. The 
primary synthons in these structures are O–H···N hydrogen bonds (O(31)-H(31)...N(21), 
2.6910(14) Å). The architecture is extended into chains, which are interlinked to give a 2-
D network via N–H···N interactions between the aminopyrimidine moieties, (Figure 
4.22). 
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Figure 4.22 2-D ribbon of 12n formed via O-H···N and N-H···N interactions. 
 
4.3.2.13 Crystal structure of 2-amino-5-(3-pyridyl)pyrazine/4-nitrobenzoic acid (1:1), 
15e 
 
The crystal structure of 15e shows a 1:1 co-crystal with the ligand 2-amino-5-(3-
pyridyl)pyrazine and 4-nitrobenzoic acid connected via O-H···N hydrogen bond (O(31)-
H(31)...N(21), 2.566(4) Å) between the hydroxyl group of the acid and the pyridyl-N of 
15 as the primary motif. The amino group of the aminopyrazine moiety is engaged in two 
N-H···O interactions with hydroxyl oxygen and the nitro-oxygen of the nitrobenzoic acid, 
resulting in a four-component ribbon-like chain, (Figure 4.23).  
 
 
 
Figure 4.23 1-D ribbon of 15e formed via O-H···N and N-H···O interactions. 
 
4.3.2.14 Crystal structure of 2-acetamido-5-(3-pyridyl)pyridine/cyanoxime (1:1), 16p 
 
The crystal structure of 16p shows a 1:1 co-crystal with the ligand 2-aceatamido-
5-(3-pyridyl)pyridine 16 and cyanoxime connected via O-H···N hydrogen bonds (O(37)-
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H(37)...N(21), 2.6037(11) Å) between the hydroxyl group of the cyanoxime and the 
pyridyl-N of 16, (Figure 4.24).  
 
 
 
Figure 4.24 Co-crystal of 16p with O-H···N interaction between cyanoxime and 16. 
 
4.3.2.15 Crystal structure of 2-amino-5-(3-(2-acetamido)pyridyl)ethynylpyridinium 3,5-
dimethylbenzoate/3,5-dimethylbenzoic acid (1:1), 24h 
 
The crystal structure of 24h show a 1:1:1 salt/co-crystal complex of 2-amino-5-
(3-(2-acetamido)pyridyl)ethynylpyridinium with one molecule of 3,5-dimethylbenzoate 
and one molecule of 3,5-dimethylbenzoic acid. The primary motifs are, (i) charged N-
H+···O- and N-H···O- interactions between the aminopyridinium moiety of the ligand and 
3,5-dimethylbenzoate ion; (ii) neutral O-H···N and  N-H···O interactions between the 
acetamidopyridyl moiety of the ligand and 3,5-dimethylbenzoic acid. These trimers are 
further linked to neighboring complexes via N-H···O- interactions between the anti-
proton of the aminopyridine moiety and the neighboring carboxylate ion, (Figure 4.25).  
 
 
 
Figure 4.25 Two trimers of 24h linked via N-H···O- interactions.  
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4.3.2.16 Crystal structure of 2-amino-5-(3-(2-acetamido)pyridyl)ethynylpyridinium 
phthalate, 24l 
 
The crystal structure of 24l display a 2:1 salt with two molecules of  2-amino-5-
(3-(2-acetamido)pyridyl)ethynylpyridinium with one phthalate ion. The primary motifs 
are N-H+···O- and N-H···O- interactions between the aminopyridinium moiety of the 
ligand and phthalate ion. These ionic complexes are extended into a 1-D network via 
neutral N-H···O interactions between the acetamidopyridyl moieties of two neighboring 
ligands, (Figure 4.26).  
 
 
 
Figure 4.26 1-D chain in 24l formed via a series of N-H+···O-, N-H···O-, and N-H···O 
interactions. 
 
4.3.2.17 Crystal structure of 2-amino-5-(3-(2-acetamido)pyridyl)ethynylpyrazine /3,5-
dinitrobenzoic acid (1:1), 27i 
 
The crystal structure of 27i show a 1:1 co-crystal with the ligand 2-amino-5-(3-(2-
acetamido)pyridyl)ethynylpyrazine 27 and 3,5-dinitrobenzoic acid connected via O-H···N 
hydrogen bond (O(31)-H(31)...N(24), 2.599(3) Å) between the hydroxyl group of the 
acid and the pyrazinyl-N of 27 as the primary motif. The N-H···N interactions between 
the amino-NH of the aminopyrazine moiety and the pyridyl-N results in 1-D extension of 
the network. In addition, an interesting O···O interaction is seen between the carboxyl-O 
and nitro-O of two neighboring dinitrobenzoic acids, (Figure 4.27).  
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Figure 4.27 1-D network in 27i formed via O-H···N and N-H···N interactions. 
 
4.3.3 Selectivity in the context of electrostatic potentials 
 
The charges on the heterocyclic nitrogen atoms in pyridine, pyrimidine, and/or 
pyrazine moieties in each ligand were used to rank the best hydrogen bond acceptor and 
second best hydrogen bond acceptor.  
 
 
               
    10        12         15 
 
           
       16                   18 
 
         
         21           24 
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        27        32 
 
 
      29 
Figure 4.28 Electrostatic potential (kJ mol-1) calculations on hydrogen-bond acceptors 
within the ditopic N-heterocycles.  
 
 Out of the 12 crystal structures analyzed, the hydrogen bond donor was found to  
selectively bind with the best hydrogen bond acceptor in ten cases (supramolecular yield, 
83%), with the second best acceptor in one case 10n (supramolecular yield, 9%), and one 
case 24h the donors could not distinguish between the two acceptor sites and binds with 
both acceptors, (Table 4.5).  
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Table 4.5 Charges on the nitrogen atoms assigned as the best hydrogen bond acceptor 
and second best acceptor in the ligands under study. 
 
#  A1 A2 ∆A √ % Yield 
10 2-amino-5-(3-pyridyl)pyrimidine -277 -260 17 5/6 83 
12 2-amino-4-methyl-5-(3-pyridyl) pyrimidine -276 -264 12 1/1 100 
15 2-amino-5-(3-pyridyl)pyrazine -292 -254 38 1/1 100 
16 2-acetamido-5-(3-pyridyl)pyridine -283 -241 42 1/1 100 
18 2-acetamido-5-(3-pyridyl)pyrimidine -252 -227 25 n/a - 
21 2-acetamido-5-(3-pyridyl)ethynylpyridine -256 -238 18 n/a - 
24 
2-acetamido-5-(3-(2-
aminopyridyl))ethynylpyridine 
-253 -247 6 1/2 50 
27 
2-amino-5-(3-(2-
acetamidopyridyl))ethynylpyrazine 
-247 -237 10 1/1 100 
29 
2-acetamido-5-(3-(2-
acetamidopyridyl))ethynylpyrazine 
-257 -243 14 n/a - 
32 
2-amino-5-(3-(2-
aminopyrazino))ethynylpyrimidine 
-272 -263 9 n/a - 
 
All electrostatic potential charges are in kJ mol-1 
A1 (best hydrogen bond acceptor) 
A2 (second best hydrogen bond acceptor) 
∆A |A1 – A2| 
√ Donors binding with best hydrogen-bond acceptors. 
% Yield (supramolecular yield) 
 
The first six ligands (10, 12, 15, 16, 18, and 21) consist of two unequal acceptor 
sites; the pyridyl binding site is a one-point acceptor, whereas the amino/acetamido 
substituted pyridyl, pyrimidyl, or pyrazinyl binding sites are two-point acceptors. This 
may lead to an assumption that the one-point donors like cyanoximes would favor the 
one-point acceptors in the pyridyl moiety, and the two-point donors like carboxylic acids 
would favor the second binding site. However it was found that the donor, irrespective of 
their “binding-points” largely prefers the acceptor site (the pyridyl group in this case) 
with the higher electrostatic potential.  
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          a               b 
Figure 4.29 Hydrogen-bonding interactions with the ligand in (a) 10o (b) 10n 
 
The selectivity for the pyridyl group may have arisen due to the advantage in the 
overall number of hydrogen bonds achieved with the choice of the best acceptor. The 
analysis can be done by comparing the co-crystals of 2-amino-5-(3-pyridyl)pyrimidine 10 
which displayed both binding to the best acceptor (5 instances) and second best acceptor 
(1 instance). In the co-crystals 10k and 10o with suberic acid and sebacic acid, the ligand 
10 is involved in the formation of five hydrogen bonds (one with the carboxylic acid, four 
with the neighboring ligands), (Figure 4.29a). However, in the co-crystal 10n with 
succinic acid, the ligand 10 is involved in four hydrogen bonds only (two with the 
carboxylic acid, two with the neighboring ligands), (Figure 4.29b). This extra stability 
furnished by the additional hydrogen bond on binding to the best acceptor might have 
favored the binding of the hydrogen bond donors to the best acceptors. 
 
   
     (a)         (b) 
Figure 4.30 Hydrogen-bonding interactions with the ligand in (a) 24h (b) 24l 
 
Out of the twelve crystal structures, nine were co-crystals, two were salts and one 
a salt-co-crystal complex. The cyanoximes with higher potential to form co-crystals than 
salts gave co-crystals with the expected binding to the best hydrogen bond acceptor in 
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both cases (10r and 16p). The two salts were obtained with pentaflurobenzoic acid (10j) 
and phthalic acid (24l). Out of the six complexes obtained from 10, the high tendency of 
pentaflurobenzoic acid to lose proton resulted in the formation of salt 10j, whereas the 
remaining five complexes are co-crystals. Both solids obtained with 24 are salts. The salt 
24l contains two protonated ligands with aminopyridinium ions bound with a phthalate 
ion via N-H+···O- and N-H···O- interactions. The free acetamidopyridyl moiety in the 
ligand interacts via neutral N-H···O bonds with the acetamido group of a neighboring 
ligand, (Figure 4.30a). Another complex 24h of the same ligand with 3,5-
dimethylbenzoic acid displays an ionic interaction on one side with the aminopyridinium 
ion binding with the dimethylbenzoate ion, whereas the other side consisting of 
acetamidopyridine moiety forms a co-crystal with the neutral acid, hence resulting in an 
interesting salt-co-crystal complex, (4.30b). This type of behavior at the aminopyridine 
site is not completely unexpected, as the CSD database15 search shows that out of 105 
structures containing the aminopyridyl moiety and carboxylic acid/carboxylate ion only 
five structures are co-crystals whereas 100/105 are salts. This observation in 24h may 
also be influenced by the small difference (6 kJ mol-1) in the electrostatic potential 
between these two acceptor sites, which may be too small to be distinguish between the 
two binding sites, (Table 4.5). 
4.3.4 Validity of Q values 
 
The Q values for the two individual hydrogen binding sites in the ligands are 
calculated by including the participation of the groups adjacent to the heterocycle-N 
atom. The electrostatic contribution from the adjacent N-H or C-H groups in addition that 
of the pyridyl/pyrimidyl/pyrazinyl nitrogen atom itself is used for the calculation of the Q 
value. The larger value of Q may implicate the higher ability to binding, and hence the 
particular site may be considered as the better hydrogen bonding site. 
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Table 4.6 Calculation of Q values from the combination of electrostatic potential of 
heterocyclic nitrogen and adjacent groups 
 
 
Q1  (sum of charges on Het-N and C-H at site 1) 
Q1’ (sum of charges on Het-N and N-H at site 1) 
Q2  (sum of charges on Het-N and N-H at site 2) 
√    (number of times the donor binded with best hydrogen bond donor in accordance to Q values) 
 
The Q values at both ends of the ligand were calculated. For pyrimidine and 
pyrazine moieties with two heterocyclic nitrogens, two different Q values were assigned 
based on the nature of the adjacent groups (C-H or N-H), (Table 4.6). Hence for each 
ditopic ligand two Q values are assigned (Q1/Q1’ and Q2) and based on these values the 
best hydrogen bond acceptor and second best acceptor were identified. However, the 
results show that the selectivity based on Q values is only followed for the ligand 10. The 
six crystal structures obtained for co-crystals/salts of 10 reveals that at five instances the 
hydrogen bond donor binds with the best hydrogen bond acceptor as assigned by the Q 
  Het-
N/CH 
Q1 Het-N/NH Q1' Het-N/NH Q2 √ 
10 2-amino-5-(3-pyridyl)pyrimidine 277/66 343 x x 260/48 308 5/6 
12 
2-amino-4-methyl-5-(3-
pyridyl)pyrimidine 
276/71 347 x x 264/144 408 0/1 
15 2-amino-5-(3-pyridyl)pyrazine 292/59 351 x x 254/146 400 0/1 
16 2-acetamido-5-(3-pyridyl)pyridine 283/69 352 x x 241/162 403 0/1 
18 
2-acetamido-5-(3-
pyridyl)pyrimidine 
252/77 329 x x 227/104 331 n/a 
21 
2-acetamido-5-(3-
pyridyl)ethynylpyridine 
256/82 338 x x 238/99 337 n/a 
24 
2-acetamido-5-(3-(2-
aminopyridyl))ethynylpyridine 
x x 253/145 398 247/89 336 1/2 
27 
2-amino-5-(3-(2-acetamido) 
pyridyl)ethynylpyrazine 
247/124 371 238/170 408 237/90 327 1/1 
29 
2-acetamido-5-(3-(2-acetamido) 
pyridyl)ethynylpyrazine 
257/7 264 241/185 426 243/94 337 n/a 
32 
2-amino-5-(3-(2-aminopyrazino)) 
ethynylpyrimidine 
272/104 376 255/158 413 263/140 403 n/a 
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value, which consists of four carboxylic acids and one cyanoxime (one-point donor).  The 
crystal structure of 24h has the donor acid binding with both acceptor sites, which can be 
better explained by the minimal charge differences between the acceptor nitrogen atoms 
rather than by the differences between the Q values. The co-crystal 27i displayed the acid 
binding with the Q value-assigned better hydrogen bond donor; however it failed to 
distinguish between the two Q1 values (Q1 and Q1’ for two heterocyclic nitrogens in 
pyrazine) and was found to bind with Q1 (371) over Q1’ (408). This shows that Q values 
are not suitable for determining the selectivity in these ditopic ligands.  
 
4.5 Conclusions 
 
The results showed that the selectivity of hydrogen bond donors in the choice of 
hydrogen bond acceptors can be exploited by using the electrostatic potential calculations 
as shown by the overall supramolecular yield of 83% (10/12) in terms of best 
acceptor/donor approach. Hence electrostatic potential charges can be used as reliable 
guidelines in the prediction of binding preferences in the presence of two or more 
different binding sites. 
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CHAPTER 5 - Solubility enhancement via co-
crystallization/salt-formation 
5.1 Introduction 
 
One of the major challenges in the pharmaceutical industry during drug 
development and formulation is the need to optimize poor biopharmaceutical properties 
of an active pharmaceutical ingredient (API). The identification of the optimum solid 
form in terms of solubility, dissolution rate, mechanical properties, thermal stability etc. 
is essential before it can be marketed.1, 2 Due to these problems, very few drugs being 
discovered every year actually make it to the market (1/10,000).3 One of the major 
challenges is the improvement of the solubility of these pharmaceutical drug candidates.4, 
5 Various techniques are in use to enhance the solubility of a pharmaceutical drug 
candidate including salt formation,6 reduced particle size,7 cosolvents,8 micronization,9 
micellar solutions,10 lipid-based systems11 etc. Another approach gaining attention is 
pharmaceutical co-crystallizations,12 where the API is allowed to complex with one or 
more molecules in the crystal lattice via non-covalent interactions.13, 14 
Co-crystallization techniques have a proven ability to improve the 
physicochemical properties of a drug molecule such as solubility15, 16 and stability17.  
However, this technique differs from the more widely used salt formation technique in 
that no ionic species are formed during the process. The neutral molecules used are held 
together via non-covalent interactions without making or breaking of covalent bonds.18 In 
brief, no proton transfer occurs during co-crystallization process and hence it may be a 
significant factor in improving the solubility of neutral compounds and weak acids and 
bases which lack the potential to form a salt.19  
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5.1.1 Co-crystal solubility (Scc) and solubility product (Ksp) 
 
 Co-crystal solubility (Scc) is a function of the solubility product (Ksp), which is the 
product of the concentration of API and co-crystallizing agent in solution.20 For a binary 
co-crystal AaBb that does not ionize or form complexes in the solution, the solubility of 
the co-crystal is defined by the chemical equilibrium of the solid co-crystal with the 
solution.5 
AaBb(solid) ↔ aA(solution) + bB(solution)       Equation 5.1 
  
Where A is the API, B is the co-crystallizing agent, and subscripts ‘a’ and ‘b’ are the 
stoichiometric number of molecules of A and B in the complex. 
 
The corresponding equilibrium constant is given by 
 
Keq =           Equation 5.2 
Keq is proportional to the thermodynamic activity product of the co-crystal components. 
 Taking solid co-crystal activity as unity (aAB(s) = 1) and assuming the activity 
coefficients of A and B equal unity for low solute levels, the co-crystal solubility can be 
described by the solubility product. 
Ksp = aA
a aB
b ~ [A]a [B]b        Equation 5.3 
Where Ksp is the solubility product of the co-crystal, [A] and [B] are the molar 
concentration of the co-crystal components at equilibrium.  
 
On dissolution of a 1:1 co-crystal in a pure solvent into individual components 
without complexation or ionization to form a saturated solution. Considering the 
equilibrium reaction above, the mass balance for [A] = aSAaBb and [B] = bSAaBb can be 
substituted in Equation 6.3 to provide the co-crystal solubility. 
 
SAaBb = 
a+b√(Ksp/a
abb)       Equation 5.4 
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5.1.2 Research Goals  
 
The melting points and enthalpies of pharmaceutical crystals are the indicators of 
their ideal solubility. These readily measurable properties are associated with crystal 
lattice energy that must be overcome for dissolution to occur.5, 21  The incorporation of 
compounds with predictable properties and crystal packing into the crystal lattice of an 
API should bring a predictable change in the properties of the API.  
 
 
 
 
 
 
 
 
 
Figure 5.1 Variation of melting points of even chain aliphatic dicarboxylic acids, (n =  
number of methylene groups in the chain) 
 
A series of 5 aliphatic dicarboxylic acids with even number of carbon chains were 
chosen for our study, (Table 5.1). The choice of even-chain dicarboxylic acids was done 
on the basis of their systematic change in physical properties compared to their odd-chain 
analogues.22 The melting points of these even-numbered aliphatic dicarboxylic acids 
decreases with the increasing number of methylene groups in the chain (Figure 5.1); 
whereas for the odd-numbered diacids the melting points are significantly lower due to 
the differences in crystal structure/packing.23 Since the crystal structure translates to the 
physical properties of a compound, this might be beneficial for fine-tuning the solubility 
behavior of our API mimics.  
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Table 5.1 Physical properties of dicarboxylic acids with even number carbon atoms 
 
Diacids Formula M.W. λmax (nm) M.P. (ºC) Aq. Solubility pKa1/pKa2 
Succinic Acid C4H6O4 118.09 203.4 185 – 187 76.6 mg/mL
24 4.16/5.61 
Adipic Acid C6H10O4 146.14 208 151-154 22.1 mg/mL
25 4.43/5.41 
Suberic Acid C8H14O4 174.20 206.6 141-144 8.9 mg/mL
24 4.53/5.526 
Sebacic Acid C10H18O4 202.25 255.6 131-135 0.25 mg/mL
26 4.72/5.4526 
Dodecanedioic Acid C12H22O4 230.3 261.4 128 0.004 mg/mL
24 - 
 
 
Four API mimics were chosen for our study; 3 small molecules with pyridine and 
pyrimidine backbone and one known-pharmaceutical drug. Pyridines are used as 
precursors to agrochemicals and pharmaceuticals in view of their high biological 
activities,27 whereas pyrimidines are present as nucleobases in RNA and DNA. All these 
molecules are known to form co-crystals.28 Haloperidol is an antipsychotic drug used for 
the treatment of acute psychosis, delirium, and schizophrenia.29 The presence of the 
acetamido and propiamido group in 2-acetamido/propiamido-5-bromopyridine with an 
N/N-H hydrogen-bond donor/acceptor site provide them with better potential to form 
hydrogen bonds with various co-crystallizing agents. The presence of pyridyl and 
pyrimidyl nitrogen, amino group in 2-amino-5-(3-pyridyl)pyrimidine; and the 
piperidinyl-N and hydroxyl group in haloperidol also have hydrogen-bond forming 
ability. We expect that the predictable pattern exhibited by the chosen series of 
dicarboxylic acids will be reflected in the properties of the co-crystals upon their 
incorporation in the crystal lattice of the API mimics. 
 
Our studies have three main objectives:  
1) Alter the API solubility via co-crystallization.  
2) Measure equilibrium solubility changes in co-crystals against the API mimics in water  
    and pH 6.8 buffer.  
3) Determine solubility changes upon salt formation. 
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5.2 Experimental 
 
All five aliphatic dicarboxylic acids and the drug haloperidol were purchased 
from Aldrich and used without further purification. The pH 6.8 buffer solution was 
prepared by dissolving calculated weights of sodium hydrogen phosphate, sodium 
dihydrogen phosphate, and sodium chloride in deionized water. The determinations of 
melting points were carried out on Fisher-Johns melting point apparatus and are 
uncorrected. 
5.2.1 Synthesis of APIs  
The molecules under study range from small-molecule API mimics (2-acetamido-
5-bromopyridine, 2-propiamido-5-bromopyridine) to larger 2-amino-5-(3-pyridyl) 
pyrimidine and haloperidol. 2-acetamido-5-bromopyridine SR1, 2-propiamido-5-
bromopyridine SR2, and 2-amino-5-(3-pyridyl)pyrimidine SR3 were synthesized as 
described in the section 2.2.1.1 (ligand 6), 2.2.1.2 (ligand 4), and 4.2.1.3 (ligand 10) 
respectively. 1H NMR and 13C NMR spectra were recorded on a Varian Unity plus 200 
MHz and 400 MHz spectrometer in CDCl3 and DMSO.  
 
         
            SR1                  SR2       SR3 
 
 
                           SR4 
Figure 5.2 The API mimics (Supramolecular reagents, SR) under study for solubility 
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5.2.2 Synthesis of co-crystals and salts 
All API mimics 2-acetamido-5-bromopyridine SR1, 2-propiamido-5-
bromopyridine SR2, 2-amino-5-(3-pyridyl)pyrimidine SR3 and the drug haloperidol SR4 
were allowed to co-crystallize with the five aliphatic dicarboxylic acids with even 
number of carbon atoms; succinic acid (C4H6O4) a, adipic acid (C6H10O4) b, suberic acid 
(C8H14O4) c, sebacic acid (C10H18O4) d, and dodecanedioic acid (C12H22O4) e.  
 
            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
Figure 5.3 List of aliphatic dicarboxylic acids used in the study. 
 
 The general procedure followed for the synthesis of co-crystals/salts involves 
refluxing stoichiometric amounts of ligand and acid in a suitable solvent, which was 
immediately cooled, the product filtered, dried and then subjected to IR screening. For 
structure and binding preferences determination, single crystals were grown from suitable 
solvents via slow evaporation at room temperature and were characterized using single-
crystal X-ray diffraction. 
5.2.2.1 Synthesis of 2-acetamido-5-bromopyridine/succinic acid (2:1), SR1-a 
A mixture of 2-acetamido-5-bromopyridine (0.20 g, 0.93 mmol) and succinic acid 
(0.055 g, 0.465 mmol) in ethanol was refluxed at 40 ºC for 1 hr. The solution was 
immediately cooled to room temperature, whereupon the product crystallizes out. It was 
filtered and dried. For X-ray diffraction purposes, single crystals were grown by slow 
evaporation of an ethanolic solution at room temperature. Colorless, thin, rod-shaped 
a c b 
d e 
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crystals were obtained after 4 days. M. P. 158—161°C; IR υ 2452 cm-1, 1870 cm-1 (O—
H…N, br), 1707 cm-1 (C=O, s), 1560 cm-1 (Amide II, s). 
5.2.2.2 Synthesis of 2-acetamido-5-bromopyridine/dodecanedioic acid (2:1), SR1-e 
A mixture of 2-acetamido-5-bromopyridine (0.20 g, 0.93 mmol) and 
dodecanedioic acid (0.107 g, 0.465 mmol) in ethanol was refluxed at 40 ºC for 1 hr. The 
solution was immediately cooled to room temperature, whereupon the product 
crystallizes out. It was filtered and dried. For X-ray diffraction purposes, single crystals 
were grown by slow evaporation of an ethanolic solution at room temperature. Colorless, 
rod-shaped crystals were obtained after 4 days. M. P. 118—120°C; IR υ 2496 cm-1, 1847 
cm-1 (O—H…N, br), 1699 cm-1 (C=O, s), 1577 cm-1 (Amide II, s). 
5.2.2.3 Synthesis of 2-propiamido-5-bromopyridine/succinic acid (2:1), SR2-a 
A mixture of 2-propiamido-5-bromopyridine (0.20 g, 0.87 mmol) and succinic 
acid (0.052 g, 0.437 mmol) in ethanol was refluxed at 40 ºC for 1 hr. The solution was 
immediately cooled to room temperature, whereupon the product crystallizes out. It was 
filtered and dried. For X-ray diffraction purposes, single crystals were grown by slow 
evaporation of an ethanolic solution at room temperature. Colorless, rod-shaped crystals 
were obtained after 3 days. M. P. 150°C; IR υ 2529 cm-1, 1863 cm-1 (O—H…N, br), 1702 
cm-1 (C=O, s), 3259 cm-1 (N—H amide, s),  1580 cm-1 (Amide II, s). 
5.2.2.4 Synthesis of 2-propiamido-5-bromopyridine/adipic acid (2:1), SR2-b 
A mixture of 2-propiamido-5-bromopyridine (0.20 g, 0.87 mmol) and adipic acid 
(0.064 g, 0.437 mmol) in ethanol was refluxed at 40 ºC for 1 hr. The solution was 
immediately cooled to room temperature, whereupon the product crystallizes out. It was 
filtered and dried. For X-ray diffraction purposes, single crystals were grown by slow 
evaporation of an ethanolic solution at room temperature. Colorless, rod-shaped crystals 
were obtained after 3 days. M. P. 132—134°C; IR υ 2476 cm-1, 1904 cm-1 (O—H…N, br), 
1687 cm-1 (C=O, s), 3260 cm-1 (N—H amide, s),  1536 cm-1 (Amide II, s). 
5.2.2.5 Synthesis of 2-propiamido-5-bromopyridine/suberic acid (2:1), SR2-c 
A mixture of 2-propiamido-5-bromopyridine (0.20 g, 0.87 mmol) and suberic acid 
(0.076 g, 0.437 mmol) in ethanol was refluxed at 40 ºC for 1 hr. The solution was 
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immediately cooled to room temperature, whereupon the product crystallizes out. It was 
filtered and dried. For X-ray diffraction purposes, single crystals were grown by slow 
evaporation of an ethanolic solution at room temperature. Colorless crystals were 
obtained after 3 days. M. P. 120°C; IR υ 2597 cm-1, 1816 cm-1 (O—H…N, br), 1700 cm-1 
(C=O, s), 3255 cm-1 (N—H amide, s),  1565 cm-1 (Amide II, s). 
5.2.2.6 Synthesis of 2-propiamido-5-bromopyridine/sebacic acid (2:1), SR2-d 
A mixture of 2-propiamido-5-bromopyridine (0.20 g, 0.87 mmol) and sebacic 
acid (0.088 g, 0.437 mmol) in ethanol was refluxed at 40 ºC for 1 hr. The solution was 
immediately cooled to room temperature, whereupon the product crystallizes out. It was 
filtered and dried. For X-ray diffraction purposes, single crystals were grown by slow 
evaporation of an ethanolic solution at room temperature. Colorless, block-shaped 
crystals were obtained after 3 days. M. P. 115—117°C; IR υ 2609 cm-1, 1901 cm-1 (O—
H…N, br), 1697 cm-1 (C=O, s), 3250 cm-1 (N—H amide, s),  1560 cm-1 (Amide II, s). 
5.2.2.7 Synthesis of 2-propiamido-5-bromopyridine/dodecanedioic acid (2:1), SR2-e 
A mixture of 2-propiamido-5-bromopyridine (0.20 g, 0.87 mmol) and 
dodecanedioic acid (0.101 g, 0.437 mmol) in ethanol was refluxed at 40 ºC for 1 hr. The 
solution was immediately cooled to room temperature, whereupon the product 
crystallizes out. It was filtered and dried. For X-ray diffraction purposes, single crystals 
were grown by slow evaporation of an ethanolic solution at room temperature. Colorless, 
block-shaped crystals were obtained after 3 days. M. P. 108—110°C; IR υ 2533 cm-1, 
1847 cm-1 (O—H…N, br), 1697 cm-1 (C=O, s), 1534 cm-1 (Amide II, s). 
5.2.2.8 Synthesis of 2-amino-5-(3-pyridyl)pyrimidine/succinic acid (2:1), SR3-a 
A mixture of 2-propiamido-5-bromopyridine (0.20 g, 1.16 mmol) and succinic 
acid (0.069 g, 0.581 mmol) in ethanol was refluxed at 40 ºC for 1 hr. The solution was 
immediately cooled to room temperature, whereupon the product crystallizes out. It was 
filtered and dried. For X-ray diffraction purposes, single crystals were grown by slow 
evaporation of an ethanolic solution at room temperature. Colorless, block-shaped 
crystals were obtained after 3 days. M. P. 188—189°C; IR υ 2378 cm-1, 1887 cm-1 (O—
H…N, br), 1697 cm-1 (C=O, s), 3166 cm-1 (N—H amide, s),  1605 cm-1 (Amide II, s). 
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5.2.2.9 Synthesis of 2-amino-5-(3-pyridyl)pyrimidine/adipic acid (2:1), SR3-b 
A mixture of 2-propiamido-5-bromopyridine (0.20 g, 1.16 mmol) and adipic acid 
(0.085 g, 0.581 mmol) in ethanol was refluxed at 40 ºC for 1 hr. The solution was 
immediately cooled to room temperature, whereupon the product crystallizes out. It was 
filtered and dried. For X-ray diffraction purposes, single crystals were grown by slow 
evaporation of an ethanolic solution at room temperature. Colorless, block-shaped 
crystals were obtained after 3 days. M. P. 160—161°C; IR υ 2476 cm-1, 1892 cm-1 (O—
H…N, br), 1695 cm-1 (C=O, s), 1596 cm-1 (Amide II, s). 
5.2.2.10 Synthesis of 2-amino-5-(3-pyridyl)pyrimidine/suberic acid (2:1), SR3-c 
A mixture of 2-propiamido-5-bromopyridine (0.20 g, 1.16 mmol) and sebacic 
acid (0.102 g, 0.581 mmol) in ethanol was refluxed at 40 ºC for 1 hr. The solution was 
immediately cooled to room temperature, whereupon the product crystallizes out. It was 
filtered and dried. For X-ray diffraction purposes, single crystals were grown by slow 
evaporation of an ethanolic solution at room temperature. Colorless crystals were 
obtained after 3 days. M. P. 150°C; IR υ 2410 cm-1, 1912 cm-1 (O—H…N, br), 1687 cm-1 
(C=O, s), 1593 cm-1 (Amide II, s). 
5.2.2.10 Synthesis of 2-amino-5-(3-pyridyl)pyrimidine/sebacic acid (2:1), SR3-d 
A mixture of 2-propiamido-5-bromopyridine (0.20 g, 1.16 mmol) and sebacic 
acid (0.118 g, 0.581 mmol) in ethanol was refluxed at 40 ºC for 1 hr. The solution was 
immediately cooled to room temperature, whereupon the product crystallizes out. It was 
filtered and dried. For X-ray diffraction purposes, single crystals were grown by slow 
evaporation of an ethanolic solution at room temperature. Colorless, rod-shaped crystals 
were obtained after 3 days. M. P. 143—145°C; IR υ 2406 cm-1, 1904 cm-1 (O—H…N, br), 
1695 cm-1 (C=O, s), 1557 cm-1 (Amide II, s). 
5.2.2.11 Synthesis of 2-amino-5-(3-pyridyl)pyrimidine/dodecanedioic acid (2:1), SR3-e 
A mixture of 2-propiamido-5-bromopyridine (0.20 g, 1.16 mmol) and 
dodecanedioic acid (0.134 g, 0.581 mmol) in ethanol was refluxed at 40 ºC for 1 hr. The 
solution was immediately cooled to room temperature, whereupon the product 
crystallizes out. It was filtered and dried. For X-ray diffraction purposes, single crystals 
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were grown by slow evaporation of an ethanolic solution at room temperature. Colorless, 
block-shaped crystals were obtained after 3 days. M. P. 140—142°C; IR υ 2415 cm-1, 
1904 cm-1 (O—H…N, br), 1695 cm-1 (C=O, s), 1590 cm-1 (Amide II, s). 
5.2.2.12 Synthesis of haloperidol/succinate-suberic acid (1:1:1), SR4-c 
A mixture of haloperidol (0.50 g, 1.33 mmol) and suberic acid (0.232 g, 0.437 
mmol) in methylene chloride was refluxed at 50 ºC for 1 hr. The solution was 
immediately cooled to room temperature, whereupon the product crystallizes out. It was 
filtered and dried. For X-ray diffraction purposes, single crystals were grown by slow 
evaporation of an ethyl acetate solution at room temperature. Colorless, block-shaped 
crystals were obtained after 3 days. M. P. 130—132°C; IR υ 3322 cm-1,  2525 cm-1, 1932 
cm-1, 1704 cm-1, 1679 cm-1, 1544 cm-1. 
 
5.2.3 Solubility studies 
Solubility studies involve the determination of a solubility standard curve of the 
ligand using UV spectroscopy and then calculating the concentration of the ligand on 
dissolution of the co-crystal. Studies were carried out in a neutral aqueous medium as 
well as in pH 6.8 buffer solution. 
5.2.3.1 Determination of solubility standard curve for the ligand 
A known mass of the API mimic was allowed to stir in a known volume of 
deionized water/buffer solution kept over a water bath at room temperature (20-22 ºC) for 
24 hrs, 48 hrs, and 72 hrs to determine the time for dissolution to reach equilibrium. After 
each trial, the stirred solution was filtered and the solution concentration was calculated. 
The solubility was found to increase from 24 hrs to 48 hrs, but no significant difference is 
noted between 48 hrs and 72 hrs. Hence it was assumed that the solution attained 
equilibrium concentration at 48 hrs, and so all studies were performed at 48 hrs. 
The filtered equilibrium solution of the ligand was subjected to serial dilutions 
and the absorbance recorded via UV spectroscopy. Absorbance data at λmax were then 
plotted against the corresponding concentrations to obtain the standard curve for the 
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ligand. While choosing the λmax for the ligand, care was taken as not to overlap it with the 
λmax from the aliphatic dicarboxylic acids used as co-crystallizing agents.  
5.2.3.2 Determination of solubility of co-crystals/salts 
The co-crystals/salts of each API mimic was stirred separately in deionized 
water/buffer solution over water bath at room temp. Aliquots were drawn at 48 hrs, 
filtered, and the filtrate subjected to UV analysis. The absorbance of the solution at the 
wavelength corresponding to the λmax for the ligand is noted and the standard curve for 
the ligand is employed to calculate the equilibrium concentration of the ligand. The 
concentrations obtained were plotted for comparative study of solubility. 
 
5.2.4 Single crystal X-ray crystallography 
X-ray data were collected on a Bruker SMART APEX or a SMART 1000 
diffractometer using Mo Kα radiation and, where noted, were corrected for absorption 
using the multiscan procedure implemented by SADABS.  Data were collected using 
SMART.  The relevant X-ray data are summarized in Table 5.3 and labeling schemes and 
thermal ellipsoids for all structures are shown in Figures 5.3, 5.6, 5.7, 5.15, and 5.20.   
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5.3 Results and Discussion 
 
Table 5.2 IR stretching frequencies (cm-1) of salts and co-crystals under study. 
 Acids co-crystals   salt 
  SR1 SR2 SR3 SR4 
  
2-acetamido-5-
bromopyridine 
2-propiamido-5-
bromopyridine 
2-amino-5-(3-
pyridyl)pyrimidine 
haloperidol 
a Succinic acid 
3237, 2452, 1870, 
1707, 1520 
3259, 2529, 1863, 
1702, 1580 
3322, 3166, 2378, 
1887, 1697, 1605 
3281, 2431, 
1904, 1679, 
1589 
b Adipic acid 
3241, 2556, 1831, 
1687,  1515 
3260, 2476, 1904, 
1687, 1536 
3301, 3126, 2476, 
1892, 1695, 1596 
3154, 2443, 
1945, 1703, 
1687, 1573 
c Suberic acid 
3248, 2513, 1851, 
1704, 1531 
3255, 2597, 1816, 
1700, 1565 
3301, 3150, 2410, 
1912, 1687, 1593 
3322, 2525, 
1932, 1704, 
1679, 1544 
d Sebacic acid 
3256, 2484, 1863, 
1704, 1536 
3250, 2609, 1901, 
1697, 1560 
3289, 3150, 2406, 
1904, 1695, 1557 
3334, 2521, 
1928, 1711, 
1683, 1507 
e 
Dodecanedioic 
acid 
3244, 2496, 1847, 
1699, 1520 
3269, 2512, 1863, 
1704, 1531 
3305, 3146, 2415, 
1904, 1695,  1590 
3204, 2509, 
1894, 1700, 
1691, 1587 
 
 
5.3.1 Crystal Structures 
A summary of the crystallographic information for the salts and co-crystals are 
presented in the Appendix A and all the hydrogen-bond geometries are listed in Table 
5.3. 
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Table 5.3 Hydrogen-bond geometries for the ligands, salts, and co-crystals under study. 
____________________________________________________________________________________ 
Structure D-H...A d(D-H)/Å           d(H...A)/Å d(D...A)/Å <(DHA)/º 
____________________________________________________________________________________ 
  
SR1i N172-H172...O171#1  0.86(3)  2.10(2)  2.946(2)  167(2) 
  N171-H171...O172  0.80(3)  2.13(3)  2.925(2)  174(2) 
 
SR2ii N(17)-H(17)...O(17)#1 0.84(4)  2.05(4)  2.858(3)  161(3) 
 
SR3iii N121-H12A1...N132  0.90(2)  2.15(2)  3.0507(17) 174(2) 
 N122-H12A2...N131  0.90(2)  2.13(2)  3.0288(17) 174(2) 
 N121-H12B1...N112#1 0.91(2)  2.12(2)  3.0301(17) 176(2) 
 N122-H12B2...N111#2 0.87(2)  2.18(2)  3.0466(17) 175(2) 
 
 
SR1-aiv  O(21)-H(21)...N(11) 0.73(4) 1.99(4) 2.716(4) 174(5) 
  N(12)-H(12)...O(22)  0.77(4)  2.13(4)  2.900(4)  171(4) 
 
SR1-ev N(12)-H(12)...O(22)  0.97(4)  1.91(4)  2.870(3)  173(3) 
  O(21)-H(21)...N(11)   0.83(4)  1.94(4)  2.737(3)  159(4) 
 
SR2-avi O311-H311...N111  0.84   1.87   2.705(12)  171.6 
  O312-H312...N112  0.84   1.87  2.705(12)  174.1 
 O313-H313...N113  0.84  1.85 2.689(14)  172.9 
  O314-H314...N114  0.84  1.84  2.677(13)  177.8 
  N171-H171...O321  0.88   2.02   2.874(17)  162.3 
  N172-H172...O322  0.88   2.06   2.887(15)  156.7 
  N173-H173...O323  0.88   2.06   2.917(18)  163.0 
  N174-H174...O324  0.88   2.06   2.921(18)  166.2 
  O341-H341...N211  0.84   1.84   2.672(12)  169.5 
  O342-H342...N212  0.84   1.88   2.711(11)  171.2 
  O343-H343...N213  0.84   1.88   2.714(12)  173.1 
  O344-H344...N214  0.84   1.86   2.699(13)  176.2 
  N271-H271...O331  0.88   2.02   2.878(16)  164.8 
  N272-H272...O332  0.88   2.00   2.867(16)  169.3 
  N273-H273...O333  0.88   2.03   2.900(18)  170.1 
  N274-H274...O334   0.88   2.07  2.926(18) 163.1 
 
SR2-bvii N(12)-H(12)...O(21)  0.86(2)  2.01(2)  2.8720(19) 173(2) 
O(22)-H(22)...N(11)  0.74(3)  1.94(3)  2.6697(19) 170(3) 
 
SR2-cviii O(21)-H(21)...N(11) 0.77(2) 1.98(2) 2.7538(19) 174(2) 
  N(12)-H(12)...O(22)  0.75(2)  2.12(2)  2.8686(19) 177(2) 
 
SR2-dix O(31)-H(31)...N(11) 0.77(2) 1.99(2) 2.7522(17) 174(2) 
  N(12)-H(12)...O(32)  0.82(2)  2.01(2)  2.8209(17) 169(2) 
 
SR2-ex N(12)-H(12A)...O(32) 0.81(2)  2.04(2)  2.8561(17) 178(2) 
 O(31)-H(31)...N(11)  0.71(3)  2.03(3)  2.7405(17) 173(3) 
 
SR3-axi O(51)-H(51)...N(11)  0.98(3)  1.64(3)  2.618(2)  174(3) 
O(54)-H(54)...N(31)  0.98(3)  1.69(3)  2.662(2)  171(3) 
N(12)-H(12A)...O(52) 0.92(3)  1.96(3)  2.873(3)  171(3) 
N(12)-H(12B)...N(41)#1 0.97(3)  2.01(3)  2.973(3)  173(2) 
N(32)-H(32A)...O(55) 1.03(3)  1.86(3)  2.871(3)  168(2) 
N(32)-H(32B)...N(21)#2 0.93(3)  2.12(3)  3.038(3)  171(3) 
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____________________________________________________________________________________ 
Structure D-H...A d(D-H)/Å           d(H...A)/Å d(D...A)/Å <(DHA)/º 
______________________________________________________________________________________ 
 
SR3-bxii O(31)-H(31)...N(21)  0.91(2)  1.76(2)  2.6714(15) 174.8(19) 
  N(12)-H(12B)...N(13)#2 0.885(18) 2.113(18) 2.9965(16) 176.2(16) 
 N(12)-H(12A)...N(11)#3 0.896(18) 2.161(18) 3.0554(16) 176.6(16) 
 
SR3-cxiii  O(31)-H(31)...N(21)  0.95(2)  1.70(2)  2.6516(16) 174.9(17) 
   N(12)-H(12A)...N(13)#2 0.873(18) 2.188(19) 3.0603(18) 177.7(17) 
   N(12)-H(12B)...N(11)#3  0.903(19) 2.120(19) 3.0222(18)   176.1(15) 
 
SR3-dxiv O(31)-H(31)...N(21)  0.919(19) 1.741(19) 2.6509(13) 170.2(16) 
 N(12)-H(12A)...N(11)#2 0.907(15) 2.150(15) 3.0546(13) 175.3(13) 
  N(12)-H(12B)...N(13)#3 0.917(16) 2.101(16) 3.0176(14) 177.6(14) 
 
SR3-exv O(31)-H(31)...N(21)  0.90(2)  1.76(2)  2.6486(13) 169.4(19) 
  N(12)-H(12A)...N(11)#2 0.864(15) 2.179(16) 3.0400(14) 173.9(15) 
  N(12)-H(12B)...N(13)#3 0.891(16) 2.118(16) 3.0095(14) 178.5(14) 
 
SR4-cxvi N(21)-H(21)...O(51)  0.905(13) 1.825(14) 2.7120(11) 165.7(12) 
  O(41)-H(41)...O(52)  0.883(16) 1.749(16) 2.5730(11) 154.2(14) 
  O(24)-H(24)...O(52)#3 0.793(16) 2.030(16) 2.7661(11) 154.2(15) 
 
 
i) #1 x+1,y+1,z  ii) #1 x-1/2,y,-z+3/2  iii) #1 x+1,y,z+1  #2 x-1,y,z-1  iv) #1 -x-1,-y,-z  v) #1 -x+3,-y+2,-z  
vi) n/a  vii) #1 -x+2,-y,-z+2  viii) #1 -x-1,-y+1,-z  ix) #1 -x,-y+1,-z+1  x) #1 -x-2,-y,-z+1  xi) #1 x-1,-
y+1/2,z-1/2  #2 x+1,-y+3/2,z+1/2  xii) #1 -x+1,-y+2,-z+1  #2 -x,y-1/2,-z+3/2  #3 -x,y+1/2,-z+3/2  xiii) #1 -
x-1,-y-1,-z  #2 -x+2,-y,-z+1  #3 -x+3,-y+1,-z+1  xiv) #1 -x+3,-y-1,-z  #2 -x,-y,-z+1  #3 -x-1,-y+1,-z+1  xv) 
#1 -x-1,-y+3,-z  #2 -x+2,-y+1,-z+1  #3 -x+3,-y,-z+1  xvi) #1 -x,-y+2,-z+1  #2 -x+1,-y,-z  #3 x+1,y,z  
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   SR1      SR2 
 
SR3 
Figure 5.4 Thermal ellipsoid plots (50 % probabilities) and labeling schemes for 2-
acetamido-5-bromopyridine SR1, 2-propiamido-5-bromopyridine SR2, and 2-amino-5-(3-
pyridyl)pyrimidine SR3. 
 
5.3.1.1 Crystal structure of APIs SR1, SR2, and SR3. 
The crystal structures of the APIs 2-acetamido-5-bromopyridine SR1, 2-
propiamido-5-bromopyridine SR2, 2-amino-5-(3-pyridyl)pyridine SR3 are described in 
the sections 2.3.1, 2.3.2, and 4.3.2.1 respectively, (Figure 5.5). 
 
   
1 2 
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3 
Figure 5.5 1-D strands of ligands connected via N-H---O (SR1 and SR2) and N-H---N 
(SR3) hydrogen bonds. 
 
5.3.1.2 Crystal structure of haloperidol, SR4
30
 
The crystal structure of SR4 shows the molecules of haloperidol connected via 
intermolecular interaction between the hydroxyl group of one haloperidol to piperidinyl-
N of neighboring haloperidol through O-H---N hydrogen bonds giving rise to stacked 1-
D strands, (Figure 5.6).  
 
 
Figure 5.6 1-D strands of haloperidol SR4 connected via O-H···N hydrogen bonding. 
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              SR1-a           SR1-e  
Figure 5.7 Thermal ellipsoid plots (50 % probabilities) and labeling schemes for SR1-a and 
SR1-e. 
 
 
   
      SR2-a                SR2-b 
 
   
       SR2-c             SR2-d 
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         SR2-e 
 
Figure 5.8 Thermal ellipsoid plots (50 % probabilities) and labeling schemes for co-
crystals of 2-propiamido-5-bromopyridine SR2. 
 
5.3.1.3 Crystal structures of SR1-a, SR1-e, SR2-c, SR2-d, and SR2-e 
The crystal structures of SR1-a, SR1-e, SR2-c, SR2-d and SR2-e show 2:1 co-
crystals comprising of the neutral API mimic and one diacid connected via the primary 
synthons N–H···O and N···H–O hydrogen bonds. The bromine atom present in the ligand 
does not contribute in any significant interaction, Figure 5.9 – 5.13.  
 
 
 Figure 5.9 Primary hydrogen bonding in the crystal structure of SR1-a. 
 
 
Figure 5.10 Primary hydrogen bonding in the crystal structure of SR1-e. 
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Figure 5.11 Primary hydrogen bonding in the crystal structure of SR2-c. 
 
 
Figure 5.12 Primary hydrogen bonding in the crystal structure of SR2-d. 
 
 
Figure 5.13 Primary hydrogen bonding in the crystal structure of SR2-e. 
 
5.3.1.4 Crystal structures of SR2-a and SR2-b 
The crystal structures of SR2-a and SR2-b display primary motifs composed of 
the ligand 2-propiamido-5-bromopyridine and the succinic acid or adipic acid in a 2:1 
ratio. The primary synthons in these structures are N–H···O and N···H–O hydrogen bonds 
between the propiamidopyridine moieties and the carboxylic acid. The secondary Br···O–
H interaction between the carboxylic O-H and the bromine atom from the ligand extend 
the architecture into a ribbon-like structure, (Figure 5.14 – 5.15). 
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Figure 5.14 1-D chain comprising of four component square-like architecture in SR2-a. 
 
 
Figure 5.15 1-D chain comprising of four component square-like architecture in SR2-b. 
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            SR3-a             SR3-b 
 
  
SR3-c     SR3-d  
 
 
     SR3-e 
Figure 5.16 Thermal ellipsoid plots (50 % probabilities) and labeling schemes for SR3-a-e. 
 
5.3.1.5 Crystal structures of SR3-a 
The crystal structure of SR3-a displays a primary motif composed of the ligand 2-
amino-5-(3-pyridyl)pyrimidine and succinic acid. The primary synthons are the O–H···N 
interaction between the hydroxyl proton of the acid and the pyrimidyl-N of the ligand, 
and a N–H···O interaction between the amino proton of the pyrimidine moiety and the 
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carbonyl oxygen of the acid. The motif is extended via N–H···N interactions between the 
anti-amino N-H and pyridyl-N to give a zigzag network, (Figure 5.17). 
 
 
Figure 5.17 1-D sheets of SR3-a showing N-H---O, O-H---N, and N-H---N binding 
motifs. 
  
5.3.1.6 Crystal structures of SR3-b, SR3-c, SR3-d, and SR3-e 
The crystal structure of SR3-b, SR3-c, SR3-d and SR3-e displays a primary motif 
composed of the ligand 2-amino-5-(3-pyridyl)pyrimidine and adipic acid, suberic acid, 
sebacic acid, or dodecanedioic acid. The primary synthons in these structures are O–
H···N hydrogen bond between the hydroxyl proton of the acid and the pyridyl-N of the 
ligand. The motif is extended into 2-D network via self-complementary N–H···N 
interactions between the amino N-H and pyrimidyl-N of neighboring aminopyrimidine 
moieties, (Figure 5.18 – 5.20). 
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Figure 5.18 2-D zigzag sheets of SR3-b showing O-H---N and N-H---N binding motifs.  
 
 
 
Figure 5.19 2-D zigzag sheets of SR3-c showing O-H---N and N-H---N binding motifs. 
 
 
 
Figure 5.20  2-D zigzag sheets of SR3-d showing O-H---N and N-H---N binding motifs.  
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Figure 5.21  2-D zigzag sheets of SR3-e showing O-H---N and N-H---N binding motifs.  
 
 
 
Figure 5.22 Thermal ellipsoid plots (50 % probabilities) and labeling schemes for SR4-c. 
 
5.3.1.7 Crystal structures of SR4-c 
The crystal structure of SR4-c displays a primary motif composed of protonated 
haloperidol linked with a succinate ion via charge-assisted N–H+···O- and O–H···O- 
hydrogen bonds with N(21)-H(21)...O(51) and O(24)-H(24)...O(52) distances of 
2.7120(11) and 2.7661(11) Å, respectively. In addition, there is a free carboxylic acid 
which is connected to the carboxylate ion moiety via complementary O–H···O- hydrogen-
bond interactions producing a 2-D network, (Figure 5.23). 
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Figure 5.23  2-D network of SR4-c showing N–H+···O-, O–H···O- and O-H---O- binding 
motifs.  
 
 
5.3.2 Standard curves for the dissolution of API mimics 
5.3.2.1 Standard curve for dissolution of SR1 in deionized water 
The equilibrium solubility of 2-acetamido-5-bromopyridine SR1 in deionized 
water at 48 hrs was found to be 0.5100 mg/mL (±0.0091). 
 
   (a)      (b) 
Figure 5.24 Solubility curves for dissolution of 2-acetamido-5-bromopyridine SR1 in 
water after 48 hrs. (a) Wavelength vs. absorbance curve @244 nm in different 
concentrations (mM). (b) Standard curve for equilibrium solubility. 
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5.3.2.2 Standard curve for dissolution of SR2 in deionized water 
The equilibrium solubility of 2-propiamido-5-bromopyridine SR2 in deionized 
water at 48 hrs is found to be 0.3395 mg/mL (±0.0139). 
0
0.5
1
1.5
190 240 290 340
Wavelength (nm)
A
b
s
o
rb
a
n
c
e
y = 23.24x + 0.0195
R2 = 0.9992
0
0.5
1
1.5
0 0.01 0.02 0.03 0.04 0.05
Concentration (mM)
A
b
s
o
rb
a
n
c
e
 
        (a)                 (b) 
Figure 5.25 Solubility curves for dissolution of 2-propiamido-5-bromopyridine SR2 in 
water after 48 hrs. (a) Wavelength vs. absorbance curve @244 nm in different 
concentrations (mM). (b) Standard curve for equilibrium solubility.        
 
5.3.2.3 Standard curve for dissolution of SR3 in pH 6.8 buffer 
The equilibrium solubility of 2-amino-5-(3-pyridyl)pyrimidine SR3 in pH 6.8 
buffer solution at 48 hrs is found to be 3.7540 mg/mL (±0.1018). 
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  (a)      (b) 
Figure 5.26 Solubility curves for dissolution of 2-amino-5-(3-pyridyl)pyrimidine SR3 in 
pH 6.8 buffer water after 48 hrs. (a) Wavelength vs. absorbance curve @244 nm in 
different concentrations (mM). (b) Standard curve for equilibrium solubility.        
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5.3.2.4 Standard curve for dissolution of SR4 in pH 6.8 buffer solution 
The equilibrium solubility of haloperidol SR4 in pH 6.8 buffer solution at 48 hrs 
is found to be 0.0738 mg/mL (±0.0039). 
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  (a)      (b) 
Figure 5.27 Solubility curves for dissolution of haloperidol SR4 in pH 6.8 buffer 
solution after 48 hrs. (a) Wavelength vs. absorbance curve @248 nm in different 
concentrations (mM). (b) Standard curve for equilibrium solubility.        
 
5.3.3 Equilibrium dissolution studies 
5.3.3.1 Equilibrium dissolution of 2-acetamido-5-bromopyridine (SR1) co-crystals in 
water 
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Figure 5.28 Comparative equilibrium solubilities of SR1 and its co-crystals. 
 
The results show that there is slight change in solubility of 2-acetamido-5-
bromopyridine upon co-crystallization with succinic and adipic acid, whereas a decrease 
in solubility is observed with sebacic acid and dodecanedioic acid, (Table 5.4). This 
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minimal solubility change can be explained on the basis of the crystal packing of these 
co-crystals. Both crystal structures of SR1-a and SR1-e show similar crystal packing 
with each of the acid binding with two APIs in a zero-dimensional architecture, (Figure 
5.9-5.10). Since there is no extension of network beyond the periphery of these three 
molecules, the solubility enhancement is not expected to change much.   
 
Table 5.4 Comparative solubilities of SR1 and its co-crystals. 
Key Sample Solubility (mg/mL) Change in solubility 
API SR1 0.510 ± 0.0091 - 
API + Succnic acid SR1-a 0.5872 ± 0.0107  +15% 
API + Adipic acid SR1-b 0.5703± 0.0059 +12% 
API + Suberic acid SR1-c 0.5071± 0.0058 -6% 
API + Sebacic acid SR1-d 0.2903± 0.0073 -43% 
API + Dodecanedioic acid SR1-e 0.3387± 0.0161 -34% 
 
5.3.3.2 Equilibrium dissolution of 2-propiamido-5-bromopyridine (SR2) co-crystals in 
water 
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Figure 5.29 Comparative equilibrium solubilities of SR2 and its co-crystals. 
 
The solubility of the API mimic 2-propiamido-5-bromopyridine itself is almost 
half compared to the solubility of homologous API 2-acetamido-5-bromopyridine. This 
might be due to the presence of a methylene group which reduces its solubility in an 
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aqueous environment. There is slight increase in solubility (+46%) of co-crystals of 2-
propiamido-5-bromopyridine compared to that of 2-acetamido-5-bromopyridine (+15%). 
Again, the solubility gain is seen with co-crystallizing agents succinic and adipic acid, 
whereas with sebacic acid and dodecanedioic acid a decrease in solubility is noted, (Table 
5.5). Upon investigation of the crystal structures, a crystal packing similar to the ones 
observed for the co-crystals of 2-acetamido-5-bromopyridine is seen for the co-crystals 
SR2-c, SR2-d, and SR2-e, a zero-dimensional architecture with no propagation of 
network in space, (Figure 5.11-5.13). However for the co-crystals SR2-a and SR2-b there 
is extension of network in one-dimensional space (Figure 5.14-5.15), which might have 
contributed to a slightly higher aqueous solubility. The lower solubility seen for the co-
crystals with sebacic acid and dodecanedioic acid is attributed to the lower aqueous 
solubility of the co-crystallizing agents themselves. 
 
Table 5.5 Comparative solubilities of SR2 and its co-crystals. 
Key Sample Solubility (mg/mL) Change in solubility 
API SR2 0.3395± 0.0111 - 
API + Succnic acid SR2-a 0.4073± 0.0113 +20% 
API + Adipic acid SR2-b 0.4939± 0.0028 +46% 
API + Suberic acid SR2-c 0.3143± 0.0166 -7% 
API + Sebacic acid SR2-d 0.2378± 0.0296 -30% 
API + Dodecanedioic acid SR2-e 0.2433± 0.0033 -28% 
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5.3.3.3 Equilibrium dissolution of 2-amino-5-(3-pyridyl)pyrimidine (SR3) co-crystals in 
pH 6.8 buffer solution  
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Figure 5.30 Comparative equilibrium solubilities of SR3 and its co-crystals. 
 
The slight improvement in aqueous solubility for the co-crystals observed for one-
dimensional network over zero-dimensional network for the previous APIs prompted us 
to choose an API capable of propagating the network into 1D or 2D space. The choice of 
the API 2-amino-5-(3-pyridyl)pyrimidine was made on the basis of its observed ability to 
form extended 1D networks, hence it may play a role in determining whether the network 
extension would actually help in altering the aqueous solubility of an API. In addition, 
the experiments were run in a pH 6.8 buffer solution to cancel out any change in 
acidity/basicity during the studies. 
For the co-crystals of 2-amino-5-(3-pyridyl)pyrimidine, an overall decrease in 
solubility is observed, (Table 5.6). A decreasing trend in aqueous solubility is seen in the 
co-crystal series from adipic acid to dodecanedioic acid (-13% to -81%). The succinic 
acid co-crystal shows an offset from this trend, possibly due to its different crystal 
packing compared to the ones from the other carboxylic acids, (Figure 5.17). This again, 
highlights the role of crystal packing in the overall solubility of a compound. The 
decrease in solubility observed for the co-crystals may be due to the high solubility of the 
API (3.75 mg/mL) itself.  Hence, a proper choice of API with lower solubility and proper 
co-crystallizing agents may give co-crystals with an extended 1D or 2D network. 
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Table 5.6 Comparative solubilities of SR3 and its co-crystals. 
 
Key Sample Solubility (mg/mL) Change in solubility 
API SR3 3.7540 ±  0.1018 - 
API + Succnic acid SR3-a 2.9578 ± 0.0897 -21% 
API + Adipic acid SR3-b 3.2723 ± 0.0430 -13% 
API + Suberic acid SR3-c 2.6382 ± 0.0646 -30% 
API + Sebacic acid SR3-d 1.2481 ± 0.0502 -67% 
API + Dodecanedioic acid SR3-e 0.6976 ± 0.0789 -81% 
 
5.3.3.4 Equilibrium dissolution of haloperidol (SR4) salts in pH 6.8 buffer solution  
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Figure 5.31 Comparative equilibrium solubilities of SR4 and its salts. 
 
The solubility experiments were carried out with an API with the least solubility 
(0.0738 mg/mL) among all the API mimics tried so far. Co-crystallization was attempted 
with this API with the same series of co-crystallizing agents. Haloperidol has a highly 
basic piperidine-N and a hydroxyl group capable of hydrogen bonding. Out of the three 
haloperidol complexes (all salts) in the CSD search, one is with an organic compound 
(saccharin), whereas the remaining were with HCl and HBr. The co-crystallization was 
carried out in chloroform in a effort to limit proton transfer during the process, however 
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the results show that the piperidine-N is basic enough to pull the proton from the 
carboxylic acid even in non-polar chloroform as solvent to give salts/complexes. 
Almost all salt/complexes show considerable increase in aqueous solubility 
compared to the API, (Table 5.7). The highest increase is seen for the complex of the API 
with suberic acid (867%) whereas for dodecanedioic acid the solubility remained similar 
to that of API. A parabolic curve is observed for the solubility of the complexes with the 
solubility increasing from succinic to suberic acid along the series and then decreasing to 
dodecanedioic acid. This observation may be explained considering the solubility of the 
co-crystallizing agents complexed with haloperidol (0.0738 mg/mL). From Table 5.1, we 
see that the solubility of aliphatic dicarboxylic acids decreases from succinic acid (76.6 
mg/mL) to suberic acid (8.9 mg/mL) and dodecanedioic acid (0.004 mg/mL). The high 
solubility difference between succinic acid and the API (haloperidol) may have triggered 
rapid dissociation of the complex in water. This might have perturbed the equilibrium 
between the undissociated complex and the dissociated moieties, hence tilting the 
equilibrium toward more undissociated complex and hence lower solubility is observed 
for succinic acid complex. The suberic acid with intermediate aqueous solubility might 
be the right fit on sustaining the equilibrium hence resulting in the highest solubility.  
 
Table 5.7 Comparative solubilities of SR4 and its salts. 
Key Sample Solubility (mg/mL) Change in solubility 
API (Haloperidol) SR4 0.0738 ± 0.0039 - 
API + Succnic acid SR4-a 0.3665 ± 0.0126 +397% 
API + Adipic acid SR4-b 0.5192 ± 0.0237 +604% 
API + Suberic acid SR4-c 0.7133 ± 0.0237 +867% 
API + Sebacic acid SR4-d 0.1952 ± 0.0107 +165% 
API + Dodecanedioic acid SR4-e 0.0759 ± 0.0069 +3% 
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5.3.4 Effect of co-crystallizing agent properties on co-crystals and salts 
 
 The solubility and thermal behavior of co-crystals and salts were found to reflect 
the properties of the co-crystallizing agent they were complexed with. A successful 
translation of the co-crystallizing agent properties into the API mimics is achieved by 
their incorporation into their crystalline lattice of the API mimics. 
 The solubility of the co-crystallizing agents decrease with the increase in 
molecular weight, the succinic acid having the highest and the dodecanedioic acid having 
the lowest solubility. The co-crystals of SR1 and SR2 with these co-crystallizing acids 
follow a similar trend with the solubilities decreasing from the co-crystals generated from 
succinic acid to the dodecanedioic acid. A slight decrease in solubility of succinic acid 
co-crystal with SR3 resulting from a different crystal packing compared to other co-
crystal in the series. The salts generated from haloperidol SR4 with the co-crystallizing 
agent sing a completely different tune, marking the unpredictability of the salt properties, 
(Figure 5.32). 
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Figure 5.32 Dependence of co-crystal/salt solubility on the solubility of co-crystallizing 
agents. 
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Table 5.8 Comparative solubilities of co-crystallizing agents and its co-crystals/salts 
 
Diacids  SR1 SR2 SR3 SR4 
Dodecanedioic acid 0.004 0.3387 0.2433 0.6976 0.0759 
Sebacic acid 0.25 0.2903 0.2378 1.2481 0.1952 
Suberic acid 8.9 0.5071 0.3143 2.6382 0.7133 
Adipic acid 22.1 0.5703 0.4939 3.2723 0.5192 
Succinic acid 76.6 0.5872 0.4073 2.9578 0.3665 
 
Similarly, the melting points of the co-crystallizing agent decreases with the 
increase in the molecular weight, the succinic acid having the highest and the 
dodecanedioic acid having the lowest melting point in the series. The co-crystals of the 
SR1, SR2, and SR3 depict the same trend with the co-crystal generated from succinic 
acid having the highest melting point and that from dodecanedioic acid having the lowest 
melting point. The salts however, again show an unpredictable behavior, failing to show 
any relationship with the properties of the co-crystallizing agents from which they are 
generated, (Figure 5.33).  
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Figure 5.33 Dependence of thermal behavior of co-crystal (SR1-SR3) and salt (SR4) on 
the melting points of the co-crystallizing agents. 
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Table 5.9 Comparative melting points (ºC) of co-crystallizing agents and its co-
crystals/salts 
 
Diacids  SR1 SR2 SR3 SR4 
Dodecanedoic acid 129 120 109 141 117 
Sebacic acid 137 128 115 145 104 
Suberic acid 144 130 120 150 131 
Adipic acid 154 143 132 160 149 
Succinic acid 186 159 150 189 132 
 
 
5.4 Conclusions  
 
Our experimental results successfully show that the solubility of an API can be 
altered via co-crystallization. The co-crystallizing agents and the crystal packing are 
found be the major determinants in altering the solubility.  Higher aqueous solubility was 
observed for the co-crystals obtained from the co-crystallizing agent with higher 
solubility (Figure 5.32), as long as the solubility difference between the co-crystallizing 
agent and the API is not large enough to disturb the equilibrium (as seen for haloperidol). 
Also, the extension of network in the co-crystals showed higher alteration in solubility 
(SR2-a-b and SR3-a-e). Hence if we need higher solubility enhancement for an API 
(desired by pharmaceutical industries), the co-crystallizing agents with higher solubility 
needs to be chosen whereas for decreasing the solubility (desired by agrochemicals), the 
co-crystallizing agents with lower solubility needs to be chosen.  Similarly, to generate 
co-crystals with higher melting point requires co-crystallizing agents to have higher 
melting points.  
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CHAPTER 6 - From molecular recognition in cavitands to 
hydrogen and halogen-bonded capsules 
6.1 Introduction 
 
Molecular recognition processes are common in nature and are responsible for the 
formation of complex biological structures as well as for their unique behavior.1 This 
process is a delicate balance between shape, size, and functional complementarities and 
governs whether any individual molecules can self-assemble to give larger architectures.2 
An understanding of molecular recognition and self-assembly processes is vital in the 
development of new strategies in supramolecular chemistry.1,3 Utilization of self-
assembly processes in designing strategies to bring together two self-complementary 
architectures to form a capsular structure has gained extensive attention in the past two 
decades.4  Nano-sized molecular capsules with a well-defined inner cavity find 
applications in various fields including selective binding, separation, and sensing of small 
molecules and ions,5 use as reaction chamber,6 control of reactivity,7 in catalysis, 
stabilization of reactive intermediates,8 as chiral receptor,9 gas encapsulation,10 social 
isomerization11 etc. 
Various molecular capsules have been synthesized employing a range of 
molecular interactions such as strong ionic interactions,12 covalent interaction to give 
rigid covalent capsules,13 weaker non-covalent intermolecular interaction especially 
hydrogen bonds,14 metal-ligand interactions,15 combination of covalent and hydrogen 
bonds,16 combination of metal ion coordination and intermolecular interaction, and 
hydrophobic effects.17 The use of non-covalent interactions like hydrogen bonding (HB) 
or halogen bonding (XB) has an advantage in the ease of formation and the reversibility 
of the capsule. This expands the applications of molecular capsules in selective delivery 
of drugs where the relative ease of closing and opening of the capsular framework 
simplifies the drug delivery in a controlled manner. 
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The most common reversible-capsule synthesis is based on the self-assembly of 
resorcinarenes.18,19  The incorporation of appropriate molecular recognition entities on 
these structures leads to self-assembly to form capsules of different shapes and sizes. The 
incorporation of self-complementary entities may result in the formation of a homomeric 
capsule, whereas two complementary entities on two different hosts may give a 
heteromeric capsule. The two containers can also be brought together into the formation 
of a capsule using a linker with a complementary functionality, (Figure 6.1). 
 
 
Figure 6.1 Schematic representation of the formation of functional capsules. 
 
Molecular capsules can also encapsulate two or more similar guests within the 
cavity of homodimeric (symmetrical) capsule and two or more different guests within the 
cavity of heterodimeric (asymmetrical) capsule. However, heterodimeric assembly 
requires two halves to be complementary with different inner environments in order to 
selectively incorporate different guests. 
Cavitand 
Homodimeric capsule 
Homodimeric capsule 
(connected by linker) 
Heterodimeric capsule 
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Figure 6.2 Structural difference between resorcinarenes and cavitands. 
 
Resorcinarene-based cavitands were introduced by Cram in the early 1980s.19, 20 Its 
bowl-shaped curvature, large extended surfaces for intermolecular interactions is a 
suitable for the incorporation of guest molecules with different shapes and sizes. The 
rigidity garnered by the condensation of the hydroxyl groups provides a stable wall to 
keep the guest molecules inside the cavity, (Figure 6.3). In addition, the potential to 
functionalize as well as to deepen the cavity makes it a desirable choice for host-guest 
chemistry. 
 
 
Figure 6.3 Structure of a resorcin[4]arene-based cavitand outlining its four parts of 
interest. 
A typical resorcinarene-based cavitand is broadly composed of four parts. The 
four evenly-placed sterically hindered aromatic positions at the rim of the cavity, termed 
the ‘upper rim’21 and the methylene bridge22 between the adjacent benzene rings, are 
suitable locales for functionalization. Both areas can be decorated with various functional 
moieties to vary the depth of the cavity as well as to impart specific properties to the 
cavitands. The ‘bridging groups’ are responsible for reducing flexibility of the molecule, 
hence erasing the possibility of different conformations. The middle part comprising the 
‘upper rim’ 
‘body’ 
‘feet’ 
‘bridging groups’ 
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cavity is termed ‘body’. It consists of an inner cavity lined with sp2-hybridized atoms 
(benzene) with Π-bonds coating the surface. It hence behaves like a thin layer of negative 
charge which is suitable for trapping electron deficient guests.23 The lower end, termed 
‘feet’, is usually the place where modifications are carried out to alter the solubility.24 
Our synthetic focus will be on functionalizing the ‘upper rim’ and incorporating pentyl 
‘feet’ for solubilization in organic solvents. 
 
6.1.1 Hydrogen bonded cavitands 
Hydrogen bonding is the major non-covalent interaction employed in self-
assembly studies.14 Current approaches towards the synthesis of hydrogen bonded 
cavitands involve functionalizing the methylene bridge25, 26 or the aromatic ring27 to 
impart the hydrogen bonding capabilities to the cavitand. Homodimeric,25 
heterodimeric27 and linker-assisted homomeric25 hydrogen-bonded capsules with various 
shapes and sizes were reported. The hydrogen bond donors like –COOH, -OH, -NH2, -
NOH, -NHCOR and the hydrogen bond acceptors pyridyl-N, OCOOR are being used in 
the capsules with the major binding motifs as O-H---N,  N-H---O, O-H---O bonding 
interactions.  
6.1.2 Halogen bonded cavitands 
Halogen bonding28 has emerged as a promising supramolecular synthetic tool in 
the field of noncovalent synthesis because of its high strength, specificity, and 
directionality.29 It consists of a halogen atom acting as electron pair acceptor 
(electrophilic species) and an electron rich moiety as the electron pair donor, with the 
strength of the halogen bond increasing in the order Cl<Br<I.30  Halogen bonds are 
equipped with comparable binding strengths and directionality and pH endurance 
advantages over the better-known hydrogen bond.31 It has applications in the self-
assembly in liquid crystals,32 controlling properties of conducting and magnetic 
molecular materials33, separating enantiomeric mixtures and isomers,34 controlling solid 
state reactivity,35 molecular folding and other biopharmacological properties,36 and anion 
binding.37 Halogen bonding also has the potential to form molecular capsules, however 
there are no known examples of halogen bonded capsules in the literature to date.  
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6.1.3 Research Goals 
 
 Our studies employ resorcinarene-based cavitands and probe their potential to 
form self-assembled or linker-assisted hydrogen and halogen-bond directed molecular 
capsules. By incorporating suitable/complementary hydrogen-bonding motifs on a 
cavitand, self-assembly can bring the two cavitands together with or without a linker into 
a dimeric hydrogen-bonded capsular assembly. 2-acetamidopyridine and 2-
aminopyrazine moieties with a known potential to self-assemble were decorated on the 
upper rim of a cavitand and their potential to self-assemble via hydrogen bond to form 
capsular structures were probed. 
   
          (a)      (b) 
Figure 6.4 (a) A complementary pair of 2-acetamido-5-bromopyridine in self-assembling 
hydrogen-bonding interaction. (b) Linker-assisted assembly.  
 
 Similarly, the formation of a halogen-bonding capsule requires halogen bond 
donors and halogen bond acceptors. The incorporation of a pyridyl group with a proven 
potential to act as halogen bond acceptor onto the ‘upper rim’ provides an opportunity to 
bring together two cavitands with the help of a halogen-bond donor linker. The 
tetrafluorobromobenzene38 and tetrafluorodiiodobenzene39 moieties are known to form 
robust halogen bonding with nitrogen in pyridine and piperazine moieties. Hence, the use 
of tetrafluorodiiodobenzene as a linker should enable the two pyridyl-substituted 
cavitands to come together via N---I halogen bonding into a capsular framework given 
the appropriate geometry of the molecules. 3-Pyridyl and 4-pyridyl moieties were 
decorated on the upper rim of the cavitand via standard Suzuki Miyaura cross-coupling 
reactions and tested for their ability to form co-crystals as well as linker-assisted 
homodimeric capsules with 1,4-diiodo-tetrafluorobenzene. In addition, the possibility of 
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formation of a heterodimeric halogen-bonded capsule was studied with pyridylcavitands 
and a halogen-substituted calixarene molecule.  
   
Figure 6.5 N---I halogen bonding between 1,4-diiodotetraflurobenzene and 4,4’-
bipyridyl-N-oxide.40 
 
6.2 Experimental 
6.2.1 Synthesis 
All chemicals were purchased from Aldrich and Strem chemicals and used 
without further purification. The determinations of melting points were carried out on 
Fisher-Johns melting point apparatus and are uncorrected. 1H NMR and 13C NMR spectra 
were recorded on a Varian Unity plus 200 MHz or 400 MHz spectrometer in CDCl3 or 
D6-DMSO. Compounds were prepared for infrared spectroscopic (IR) analysis as a 
mixture in KBr. MALDI-TOF / TOF-MS was carried out on a Bruker Daltonics Ultraflex 
TOF/TOF. 
6.2.1.1 Synthesis of C-pentylcalix[4]resorcinarene, 33
41
 
 
              R = (CH2)4CH3 
             33 
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A mixture of resorcinol (5.100 g, 0.045 mol), hexanal (4.550 g, 0.045 mol) and 
ethanol (45 mL) was placed in a round bottom flask. Conc. HCl (7.25 mL) was added to 
it at 0 ºC under dinitrogen atmosphere.  The apparatus was fitted with a condenser and the 
mixture was refluxed at 70 ºC for 10 hours. The reaction was monitored by TLC and 
upon completion was cooled to room temperature. It was then diluted with water to 
obtain a yellowish precipitate with a sweet, fruity smell. It was filtered and the precipitate 
washed with warm water until the filtrate is pH neutral. The white precipitate obtained 
was then dried, (8 g, 91%). M.P. >280 ºC. 
1
H NMR (δH; 400 MHz, DMSO-d6): 8.86 (s, 
8H), 7.15 (s, 4H), 6.14 (s, 4H), 4.21 (t, J = 7.6Hz, 4H), 2.00 – 2.02 (m, 8H), 1.16 – 1.25 
(m, 24H), 0.83 (t, J = 6.4Hz, 12H). 
 
6.2.1.2 Synthesis of C-pentyltetrabromocalix[4]resorcinarene, 34
42, 43
 
 
 
R = (CH2)4CH3            R = (CH2)4CH3 
                     33        34 
C-Pentylcalix[4]resorcinarene 33 (5.0 g, 6.5 mmol) was placed in a round bottom 
flask and 2-butanone (40 mL) was added to it. The reaction mixture was stirred until all 
of 33 was dissolved.  The solution was cooled below 10 ºC by keeping over ice bath. The 
reaction flask was wrapped with aluminum foil, and under dark conditions N-
bromosuccinimide (6.9 g, 39 mmol) was added to it in small portions so that the 
temperature of the reaction mixture remained below 10 ºC. After the addition of NBS, the 
reaction mixture was allowed to stir at room temperature for 12 hrs. The precipitate 
obtained was filtered, washed with cold acetone (25 mL), then cold water (3 x 50 mL), 
and again with cold acetone (25 mL). The product was then dried in oven overnight to 
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obtain a white solid.  (5.7 g, 81%) M. P. >300 ºC; 1H NMR (δH; 200 MHz, DMSO-d6): 
9.10 (s, 8H), 7.35 (s, 4H), 4.34 (t, J = 8.0Hz, 4H), 2.17 (br, 8H), 1.27 (br, 24H), 0.84 (br, 
12H).  
 
6.2.1.3 Synthesis of C-pentyltetrabromocavitand, 35
42
 
 
 R = (CH2)4CH3          R = (CH2)4CH3 
          34                35 
 
C-Pentyltetrabromocalix[4]resorcinarene, 34 (15.0 g, 13.8 mmol) was placed in a 
three-necked round-bottomed flask fitted with a mechanical stirrer and a reflux 
condenser. Anhydrous DMF (225 mL) was added and the mixture was stirred under 
dinitrogen until all of 34 was dissolved. K2CO3 (30.0 g, 215.5 mmol) was added to the 
reaction mixture and was further stirred. The first portion of bromochloromethane (4.0 
mL, 63 mmol) was then added carefully into the reaction mixture. It was refluxed at 40 
ºC under a dinitrogen atmosphere for 24 hrs with vigorous stirring. The second portion of 
bromochloromethane (4.0 mL) was added into the reaction mixture and refluxed at 65 ºC 
for another 24 hrs. Similarly, the third and fourth portion of bromochloromethane (4.0 
mL) was added after every 24 hrs under reflux. After 24 hrs of reflux after addition of the 
fourth portion, the mechanical stirrer and the heating were turned off and the reaction 
mixture allowed to cool to room temperature for additional 48 hrs. The product was then 
filtered and the precipitate washed with DMF (2 x 25 mL) followed by water (3 x 100 
mL) and methanol (2 x 30 mL) and dried to obtain white powder, (11.75 g, 75 %). M. P. 
>280 ºC; 1H NMR (δH; 200 MHz, CDCl3): 7.04 (s, 4H), 5.97 (d, J = 8.0Hz, 4H), 4.86 (t, 
J = 8.0Hz, 4H), 4.40 (d, J = 8.0Hz, 4H), 2.19 – 2.22 (br, 8H), 1.39 (br, 24H), 0.92 (m, 
12H). 
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6.2.1.4 Synthesis of C-pentyltetraiodocavitand, 36 
 
    R = (CH2)4CH3               R = (CH2)4CH3 
        35            36 
C-Pentryltetrabromocavitand 35 (2.0 g, 1.8 mmol) was placed in a round 
bottomed flask and warmed to 50 ºC with stirring for about 30 mins. Dry, freshly distilled 
THF (50 mL) was added to it and the solution cooled to -78 ºC using dry ice/acetone 
bath. The reaction mixture was stirred under dinitrogen and n-butyllithium (6.0 equiv., 
6.6 mL, ca. 1.6 M solution in hexanes) was rapidly added using syringe. After stirring for 
1 hr, iodine (3.6 g, 14.2 mmol in THF (5 mL)) was added. The cooling bath was removed 
and the reaction mixture was allowed to warm to room temperature. The stirring was 
continued for 2 hrs and then the reaction mixture was cooled to 0 ºC using ice bath and 
quenched with a saturated aqueous sodium thiosulfate solution. The aqueous phase was 
extracted with ethyl acetate (3 x 75 mL), washed with brine and dried with magnesium 
sulfate. The solvent was removed on a rotary evaporator to obtain a white residue. It was 
purified by column chromatography using a hexanes/dichloromethane mixture as the 
eluent, whereupon small amounts of C-pentyl-1,3-dibromo-2,4-diiodocavitand, 36’ was 
also isolated. The product 36 was further purified by recrystallization with 
dichloromethane yielding a white powder, (1.70 g, 73 %). M. P. >280 ˚C; 1H NMR (δH; 
200 MHz, CDCl3): 7.07 (s, 4H), 5.98 (d, J = 6.0Hz, 4H), 4.86 (t, J = 8.0 Hz, 4H), 4.32 (d, 
6.0Hz, 4H), 2.22 – 2.19 (m, 8H), 1.39 (br, 24H), 0.92 (t, J = 7Hz, 12 H); 13C NMR (δH; 
200 MHz, CDCl3): 155.03, 138.80, 120.85, 98.90, 93.25, 38.14, 32.06, 30.23, 27.61, 
22.84, 14.27. 
 The product 36’ was further purified by recrystallization with dichloromethane 
yielding a white powder, (0.25 g). M. P. >280 ˚C; 1H NMR (δH; 200 MHz, CDCl3): 
7.05(d, J = 6.0Hz, 4H), 5.98 (d, J = 8.0Hz, 4H), 4.86 (t, J = 8.0 Hz, 4H), 4.37 (d, 6.0Hz, 
4H), 2.19 – 2.22 (m, 8H), 1.39 (br, 24H), 0.92 (t, J = 7Hz, 12 H). 
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6.2.1.5 Synthesis of C-pentyltetra-(2-acetamidopyridyl-5-ethynyl)cavitand, 37 
 
 
R = (CH2)4CH3               R = (CH2)4CH3 
                   36       26          37 
C-Pentryltetraiodocavitand 36 (0.20 g, 0.15 mmol) was placed in a round 
bottomed flask and warmed to 50 ºC with stirring for about 30 mins to remove moisture. 
2-acetamido-5-ethynylpyridine 26 (0.14 g, 0.88 mmol), bis(triphenylphosphine)palladium 
(II) dichloride (0.010 g, 0.014 mmol), triphenylphosphine (0.004 g, 0.016 mmol), and 
copper(I) iodide (0.002 g, 0.010 mmol) was added along with dry, freshly distilled THF 
(10 mL) and triethylamine (5 mL). Dinitrogen was bubbled through the mixture for 10 
minutes and refluxed at 70 ºC under dinitrogen. The reaction was monitored by TLC and 
upon completion (36 hrs) was cooled to room temperature. The solution was then diluted 
with ethyl acetate (100 mL), washed with (3 x 100 mL) and saturated aqueous sodium 
chloride solution (1 x 100 mL). The organic layer was separated and dried over 
anhydrous magnesium sulfate. The solvent was removed on a rotary evaporator and the 
residue was chromatographed on silica with hexane/ethyl acetate/methanol mixture as 
eluant.  The product was isolated as a white colored solid, which was recrystallized from 
ethyl acetate. (125 mg, 58 %). M. P. >285 ºC; 1H NMR (δH; 200 MHz, CDCl3): 9.14 (br, 
4 NH), 8.27 (s, 4H), 8.22 (s, 4H), 7.74 (d, J = 8.0 Hz, 4H), 7.12 (s, 4 H), 6.01 (d, J = 6.0 
Hz, 4H), 4.86 (t, J = 8Hz, 4H), 4.59 (d, 6.0 Hz, 4H), 2.25 (s, 12H), 2.18 – 2.21 (m, 8H), 
1.41 – 1.27 (m, 24H), 0.93 (m, 12 H); 13C NMR (δH; 200 MHz, CDCl3): 169.45, 155.44, 
151.11, 150.04, 141.24, 138.73, 120.71, 115.81, 113.96, 112.95, 94.26, 83.92, 36.72, 
32.02, 29.66, 27.61, 24.84, 22.84, 14.26. IR (KBr pellet): υ (cm
-1
) 3293, 2930, 2863, 
1697, 1573, 1517, 1368, 1292, 974. MALDI-TOF / TOF-MS m/z 1448 ([25 + Na]+) 
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6.2.1.6 Synthesis of C-pentyl-1,3-di-(2-acetamidopyridyl-5-ethynyl)-2,4-
dibromocavitand, 38 
 
 R = (CH2)4CH3                  R = (CH2)4CH3 
          36’       26           38 
C-Pentyl-1,3-dibromo-2,4-diiodocavitand 36’ (0.200 g, 0.163 mmol) was placed 
in a round bottomed flask and warmed to 50 ºC with stirring for 30 minutes to remove 
moisture. 2-Acetamido-5-ethynylpyridine 26 (0.075 g, 0.470 mmol), 
bis(triphenylphosphine)palladium (II) dichloride (0.005 g, 0.007 mmol), 
triphenylphosphine (0.002 mg, 0.008 mmol), and copper(I) iodide (0.001 mg, 0.005 
mmol) was added to it along with dry, freshly distilled THF (5 mL) and triethylamine (3 
mL). Dinitrogen was bubbled through the mixture for 10 minutes and refluxed at 70 ºC 
under dinitrogen. The reaction was monitored by TLC and upon completion (36 hrs) was 
cooled to room temperature. The solution was then diluted with ethyl acetate (100 mL), 
washed with (3 x 100 mL) and saturated aqueous sodium chloride solution (1 x 100 mL). 
The organic layer was separated and dried over anhydrous magnesium sulfate. The 
solvent was removed on a rotary evaporator and the residue was chromatographed on 
silica with hexane/ethyl acetate/methanol mixture as eluant.  The product was isolated as 
a white solid, which was recrystallized from ethyl acetate. (100 mg, 48 %). M. P. >285 
ºC; 1H NMR (δH; 200 MHz, CDCl3): 8.34 (s, 2 NH), 8.18 (d, 2H), 8.03 (s, 2H), 7.73 (d, J 
= 8.0 Hz, 2H), 7.08 (d, J = 4.0 Hz, 4 H), 6.00 (d, J = 8.0 Hz, 4H), 4.86 (t, J = 6.0 Hz, 4H), 
4.51 (d, 8.0 Hz, 4H), 2.23 (s, 14H),  1.40 (m, 24H), 0.93 (m, 12 H); 13C NMR (δH; 200 
MHz, CDCl3): 155.44, 152.21, 150.66, 141.05, 139.63, 138.56, 113.30, 37.29, 32.04, 
29.83, 27.60, 24.97, 22.84, 14.25. MALDI-TOF / TOF-MS m/z 1290 ([26 + Na]+). 
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6.2.1.7 Synthesis of C-pentyl-1,3-di(2-aminopyrazino-5-ethynyl)-2,4-diiodocavitand, 39 
 
 R = (CH2)4CH3                      R = (CH2)4CH3 
         36             39 
C-Pentryltetraiodocavitand 36 (2.0 g, 1.5 mmol) was placed in a round bottomed 
flask and warmed to 50 ºC with stirring for about 30 mins to remove moisture. 2-amino-
5-ethynylpyrazine (0.90 g, 7.56 mmol), bis(triphenylphosphine)palladium (II) dichloride 
(0.020 g, 0.028 mmol), triphenylphosphine (0.020 g, 0.080 mmol), and copper(I) iodide 
(0.008 g, 0.040 mmol) was added to it along with dry, freshly distilled THF (20 mL) and 
triethylamine (20 mL). Dinitrogen was bubbled through the mixture for 10 minutes and it 
was refluxed at 70 ºC under a dinitrogen atmosphere. The reaction was monitored by 
TLC and upon completion (36 hrs) was cooled to room temperature. The solution was 
then diluted with ethyl acetate (100 mL), washed with (3 x 100 mL) and saturated 
aqueous sodium chloride solution (1 x 100 mL). The organic layer was separated and 
dried over anhydrous magnesium sulfate. The solvent was removed on a rotary 
evaporator and the residue was chromatographed on silica with hexane/dichloromethane/ 
ethyl acetate mixture as eluant to remove the impurities.  The product was isolated as a 
white colored solid, which was recrystallized from ethyl acetate. M. P. >285 ºC; 1H NMR 
(δH; 200 MHz, CDCl3): 8.15 (s, 2H), 7.98 (s, 2H), 7.08 (br, 4H), 6.02 (d, J = 8.0 Hz, 4H), 
4.86 (t, J = 8Hz, 4H+2NH2), 4.48 (d, 6.0 Hz, 4H), 2.21 (s, J=6.0 Hz, 8H), 1.40 (m, 24H), 
0.93 (m, 12 H). 
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6.2.1.8 Synthesis of C-pentyltetra(3-pyridyl)cavitand, 40
44
 
 
R = (CH2)4CH3      R = (CH2)4CH3 
             35           8                      40 
A mixture of C-pentyltetrabromocavitand 35 (2.0 g, 1.8 mmol) and tetrakis-
triphenylphosphine palladium (II) (0.420 g, 0.362 mmol) were added to a round bottom 
flask under a stream of dinitrogen. Toluene (30 mL), ethanol (20 mL) and aqueous 
sodium bicarbonate (100 mg, 5 mL) were all purged with dinitrogen before being added 
to the round bottom flask along with 3-pyridylboronic acid 8 (2.80 g, 22.76 mmol). The 
reaction mixture was refluxed for 72 hours under a dinitrogen atmosphere. Upon 
completion of the reaction, the mixture was cooled to room temperature and diluted with 
water (100 mL). The aqueous phase was washed with dichloromethane (3 x 100 mL) and 
dried with magnesium sulfate. The solvent was removed using rotary evaporator and the 
residue obtained was purified by column chromatography using ethanol/ethyl acetate 
mixture as eluant over silica. The product was isolated as a white crystalline solid (1.50 g, 
76%). M.P. >280 ºC; 1H NMR (δH; 400 MHz, CDCl3): 8.408 (br, 4H), 8.244 (s, 4H), 
7.39(s, 8H), 7.183 (br, 4H), 5.243 (br, 4H), 4.881(s, 4H), 4.234 (s, 4H), 2.376 (m, 8H), 
1.481 (m, 24H), 0.962 (t, 12H). 
 
6.2.1.9 Synthesis of C-pentyltetra(4-pyridyl)cavitand, 41 
 
R = (CH2)4CH3       R = (CH2)4CH3 
               36                 41 
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C-Pentyltetraiodocavitand 36 (0.80 g, 0.61 mmol) was placed in a round bottom 
flask. It was heated to 50 ºC under a stream to dinitrogen for 30 mins with stirring. 
Toluene (20 mL), ethanol (10 mL) and cesium carbonate (150 mg, 0.46 mmol) were all 
purged with dinitrogen before being added to the round bottom flask in dinitrogen 
atmosphere. Tetrakis-triphenylphosphine palladium (II) (420 mg, 0.362 mmol) was added 
to the reaction mixture followed by 4-pyridylboronic acid (0.80 g, 6.52 mmol). The 
reaction mixture was refluxed at 80 ºC for 72 hours under dinitrogen. Upon completion of 
the reaction, the mixture was cooled to room temperature and diluted with water (100 
mL). The aqueous phase was washed with dichloromethane (3 x 100 mL) and dried with 
magnesium sulfate. The solvent was removed using rotary evaporator and the residue 
obtained was purified by column chromatography using ethanol/ethyl acetate/traces of 
Et3N mixture as eluant over silica. The product was isolated as a white powder (0.30 g, 
45%). M.P. >280 ºC; 1H NMR (δH; 200 MHz, CDCl3): 8.58 (d, J = 6.0 Hz, 8H), 7.37 (s, 
4H), 6.98 (d, J = 6.0 Hz, 8H), 5.29 (d, J = 6.0 Hz, 4H), 4.84 (t, J = 8.0 Hz, 4H), 4.23 (d, 
8.0 Hz, 4H), 2.34 (m, 8H), 1.46 (m, 24H), 0.96 (t, J = 7Hz, 12 H); 13C NMR (δH; 200 
MHz, CDCl3): 152.17, 149.46, 142.02, 138.00, 126.83, 124.91, 120.85, 100.39, 43.23, 
37.01, 31.99, 30.24, 27.58, 22.68, 14.14. MALDI-TOF / TOF-MS m/z 1124 ([30 + H]+). 
 
6.2.2 Co-crystallizations of cavitands  
6.2.2.1 Synthesis of tetra(2-acetamidopyridyl-5-ethynyl)cavitand co-crystals 
Co-crystallizations of tetra(2-acetamidopyridyl-5-ethynyl)cavitand was attempted 
with 20 different co-crystallizing agents to probe the molecular recognition abilities, 
which can later be interpreted into its potential to form hydrogen-bonded molecular 
capsules. However we were unable to grow suitable crystals for single-crystal X-ray 
crystallography for any of the co-crystals screened via IR spectroscopy. The co-crystals 
of 37  exhibited the characteristic O-H---N stretches around 1850 and 2550 cm-1, and free 
C=O stretch in 1700 cm-1 region, (Figure 6.6). 
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 FT-IR spectra of tetra(2-acetamidopyridyl-5-ethynyl)cavitand 
 
 
FT-IR spectra of co-crystal of tetra(2-acetamidopyridyl-5-ethynyl)cavitand and 3,4-
dichlorobenzoic acid 
 
Figure 6.6 FT-IR spectra of 37 and its co-crystal with 3,4-dichlorobenzoic acid. 
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Table 6.1 IR stretches in co-crystals of tetra(2-acetamidopyridyl-5-ethynyl)cavitand 37 
 
 Co-crystallizing agents IR stretches 
1 4-Cyanobenzoic acid 3246, 2549, 1866, 1703, 1540 
2 3-Hydroxybenzoic acid 3272, 2580, 1870, 1685, 1530 
3 4-Chlorobenzoic acid n/a 
4 4-Fluorobenzoic acid 3246, 2540, 1883, 1694, 1513 
5 4-Nitrobenzoic acid 3259, 2554, 1857, 1698, 1526 
6 3,4-Dichlorobenzoic acid 3250, 2501, 1870, 1694, 1522 
7 2,6-Difluorobenzoic acid 3246, 2540, 1874, 1702, 1510 
8 3,5-Dimethylbenzoic acid 3250, 2606, 1839, 1680, 1525 
9 2,4-Dinitrobenzoic acid 3395, 2496, 1945, 1698, 1531 
10 Pentafluorobenzoic acid 3250, 2527, 1914, 1698, 1526 
11 Suberic acid n/a 
12 Phthalic acid n/a 
13 Fumaric acid n/a 
14 Succinic acid n/a 
15 Sebacic acid n/a 
16 Cyanoxime n/a 
17 4-Fluorocyanoxime n/a 
18 4-Chlorocyanoxime n/a 
19 4-Bromocyanoxime n/a 
20 4-Carboxyphenylcavitand pentyl 3418, 2523, 1866, 1694, 1517 
 
 
6.2.2.2 Synthesis of C-pentyl-tetra(3-pyridyl)cavitand/1,4-diiodo-tetraflurobenzene 
(1:2), 40a 
C-Pentyl-tetra(3-pyridyl)cavitand 40 (0.020 g, 0.0178 mmol) was dissolved in 
5mL of acetonitrile. To this solution was added 1,4-diiodo-tetrafluorobenzene (0.029 g, 
0.0712 mmol) in 5 mL of ethanol. The resulting solution was warmed and allowed to 
stand for slow evaporation at room temperature. Colorless, block-shaped crystals were 
obtained after 4 days. M. P. >280°C; IR υ (cm-1) 2928 (C-N stretch), 1463 (C-I stretch), 
1251, 1084, 971, 944 (C-I bend), 584.  
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6.2.2.3 Synthesis of C-pentyl-tetra(4-pyridyl)cavitand/1,4-diiodo-tetraflurobenzene 
(1:2), 41a   
C-Pentyl-tetra(4-pyridyl)cavitand 41 (0.020 g, 0.0178 mmol) was dissolved in 
5mL of acetonitrile. To this solution was added 1,4-diiodo-tetrafluorobenzene (0.029 g, 
0.0712 mmol) in 5 mL of ethanol. The resulting solution was warmed and allowed to 
stand for slow evaporation at room temperature. Colorless, cubic crystals were obtained 
after 4 days. M. P. >300 °C; IR υ (cm-1) 2925 (C-N stretch), 1603, 1460 (C-I stretch), 
1216, 1086, 976, 942 (C-I bend), 584. 
6.2.2.4  Synthesis of C-pentyl-tetra(3-pyridyl)cavitand/halocalixarene
45
 (1:1), 40b   
  C-Pentyl-tetra(3-pyridyl)cavitand 40 (0.006 g, 0.0053 mmol) was 
dissolved in 5mL of ethanol. To this solution was added C-ethoxy-4-iodo-
tetrafluorobenzene-tert-butylcalixarene (0.010 g, 0.0052 mmol) in 5 mL of ethanol. The 
resulting solution was warmed and allowed to stand for slow evaporation at room 
temperature. Colorless, rectangular crystals were obtained after 4 days. . M. P. 185 - 187 
°C; IR υ (cm-1) 2928 (C-N stretch), 1727, 1480 (C-I stretch), 1241, 1106, 970, 948 (C-I 
bend), 583. 
6.3 Results and Discussion 
6.3.1 Precursors and their functionalization 
The synthesis of hydrogen- and halogen-bonded capsules started with the 
challenge of decorating the functionalizable upper rim with moieties having robust 
hydrogen or halogen bonding sites. The starting point was the condensation of resorcinol 
with hexanal to obtain the cyclic calix[4]resorcinarene. The upper rim was then 
brominated with N-bromosuccinimide and rigidity imparted to the structure by linking 
the hydroxyl arms using bromochloromethane to obtain a bromocavitand. Until this step 
the yield was good, and the product bromocavitand can be used for functionalization via 
cross-coupling reactions. However, for some coupling reactions a better leaving group is 
required, hence a further conversion into the iodocavitand was needed.  
The complications started from the conversion of C-pentyltetrabromocavitand 
into the iodocavitand. The process uses a moisture-sensitive reagent, n-butyllithium 
which requires a completely dry environment. The replacement of bromine atoms with 
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iodine may be hindered in the presence of moisture to yield protio-cavitands. Also, n-
butyllithium itself may be ruined by moisture.  The synthesis of C-
pentyltetraiodocavitand itself resulted in a mixture of cavitands with varying degrees of 
substitution. Along with the desired tetrasubstituted product, 1,3-disubstituted, 1,2-
disubstituted, trisubstituted and monosubstituted products were obtained. The purification 
via column chromatography was tedious and with low to moderate yields. Upon complete 
isolation and characterization, palladium-catalyzed Sonogashira and Suzuki Miyaura 
cross-coupling reactions were carried out, again with various substitution products. 
 
Table 6.2 Hydrogen-bond geometries for 37 and 38. 
__________________________________________________________________________________ 
Structure D-H...A d(D-H)/Å           d(H...A)/Å d(D...A)/Å <(DHA)/º 
______________________________________________________________________________________ 
  
37i N362-H362...O384#1  0.88  2.05  2.920(4)  170.6 
  N363-H363...O382#1  0.88  1.98  2.852(4)  173.1 
  N364-H364...O161#2  0.88  2.23  3.070(4)    159.2 
 
38ii  N322-H322...O121#2  0.88  2.03  2.903(4)  175.0 
 
(i) #1 -x+1,-y+1,-z    #2 -x+1,-y,-z  (ii)  #1 x,-y+3/2,z    #2 -x+1,-y+1,-z     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 187  
6.3.1.1 Crystal structure of C-pentyltetrabromocavitand, 35 
 
  
            35              35’ 
Figure 6.7 Thermal ellipsoid plots (50 % probabilities) and labeling schemes for 35 and 35’. 
Two crystal structures of tetrabromocavitands were obtained with ethyl acetate 
(35) and DMSO (35’) as guest molecules lying in the lower rim as well as near the upper 
rim of the cavitand (35). Previous crystal structures of 35 have dichloromethane and 
acetonitrile as guest molecules residing around the lower rim of the cavitand. 44  
 
      
        (a)      (b) 
Figure 6.8 C-pentyltetrabromocavitand, with (a) ethyl acetate as guest, 35; (b) DMSO as 
guest, 35’.  
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The crystal structures 35 and 35’ have certain similarities as well as 
dissimilarities. In line with the previous reported structures, these structures have their 
pentyl ‘feet’ residing inside the cavity of the other. In the structure of 35, two ‘feet’ of a 
cavitand are dipping into the upper rim of a neighboring cavitand (Figure 6.9a), whereas 
in structure 35’, only one of the pentyl feet of the cavitand resides in the cavity of a 
neighboring cavitand, (Figure 6.9b).  
 
  
   (a)      (b) 
Figure 6.9 Crystal packing in tetrabromocavitand molecule (a) 35 and (b) 35’. 
 
Another difference between these two crystal structures is the Br---Br interaction 
between the neighboring cavitand molecules. Both structures have two cavitand 
molecules in a inverted/alternate arrangement interacting via Br---Br interaction; 
however the crystal structure 35 consists of two symmetry related pairs of Br---Br 
interactions (3.592 Å) whereas for 35’ only single Br---Br interaction (3.405 Å) is 
observed, (Figure 6.10).  
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       (a)      (b) 
Figure 6.10 Linking of cavitands pairs via Br---Br interactions, (a) 35 (b) 35’. 
 
6.3.1.2 Crystal structure of C-pentyltetraiodocavitand, 36 
                 
Figure 6.11 Molecular structure and thermal ellipsoid plots (50 % probabilities) and 
labeling schemes for 36 
 
The crystal structure of iodocavitand, 36 revealed one acetonitrile molecule 
residing as guest between the ‘feet’ of the host with the nitrile end pointing upwards 
towards the cavity, (Figure 6.12a).  
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        (a)        (b) 
Figure 6.12 (a) An individual C-pentyltetraiodocavitand with acetonitrile guest, (b) 
Linking of two iodocavitands via an I---I interaction.   
 
A typical ‘foot-in-mouth’ arrangement is seen in the extended architecture of 36, 
with one pentyl ‘foot’ of an iodocavitand residing inside the upper rim of a neighboring 
iodocavitand molecule, (Figure 6.13). A single I---I interaction (3.636 Å) between the 
iodine atoms of two individual iodocavitand molecules was observed, (Figure 6.12b). 
 
 
Figure 6.13 ‘Foot-in-mouth’ arrangement between iodocavitand molecules in 36. 
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6.3.2 Quest for a  hydrogen-bond driven capsule  
 
Standard Sonogashira cross-coupling reactions were employed to impart 
hydrogen bonding capabilities to the cavitands. Tetraiodocavitands were used for the 
purpose and acetamidopyridine and aminopyrazine moieties were incorporated into the 
upper rim of the cavitand. 
6.3.2.1 Crystal structure of C-pentyltetra(2-acetamidopyriyl-5-ethynyl)cavitand, 37 
 
C-Pentyltetra-(2-acetamidopyridyl-5-ethynyl)cavitand, 37 was synthesized using 
Sonogashira cross-coupling conditions with 2-acetamido-5-ethynylpyridine under basic 
conditions. The main purpose of incorporating the ethynyl group is to give more depth to 
the cavitand hence enabling it to trap larger guest molecules. Again various degrees of 
substitution were observed with the major product being the desired tetrasubstituted 
cavitand. The product was purified using silica-gel column chromatography and 
recrystallized from a mixture of solvents (methanol/ethanol/ethyl acetate/toluene). 
 
                     
          (a)             (b) 
Figure 6.14 C-Pentyltetra(2-acetamidopyriyl-5-ethynyl)cavitand, 37 (a) thermal ellipsoid 
plots (50 % probabilities) and labeling schemes, (b) An individual cavitand. 
 
 The crystal structure determination of 37 revealed the presence of solvent 
molecules inside the cavity as well as near the upper rim of the cavitand. A toluene 
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molecule was found seated deep inside the cavity whereas two ethanol molecules and one 
methanol molecule was found lying near the upper rim of the cavitand. A single 
disordered ethyl acetate was found near the ‘feet’ of the cavitand. 
Upon extension of the architecture, it was found that the upper rims of two C-
pentyltetra(2-acetamidopyridyl-5-ethynyl)cavitands come together via hydrogen bonding 
interactions to give a capsular structure. The capsular framework is held together via a 
total of four N-H---O interactions (NH group of acetamido group of one cavitand with 
O=C group of complementary cavitand) between three “arms” of each cavitand. The 
ethanol and methanol molecules engage in multiple hydrogen bonds with each other and 
with the N-H group of the remaining “arm” of both cavitands in the capsule, (Figure 
6.15).  
    
Figure 6.15 Molecular structure and spacefilling diagram showing the capsular 
framework of 37. 
 
The hydrogen-bonded capsule included three ethanol molecules, two methanol 
molecules, and one toluene molecule inside its cavity.  The length of the capsule 
(distance between the lower ends of the aromatic ring in the “body” of the cavitand) is 22 
Å, whereas the maximum width is found to be 15 Å. Upon closer observation and 
 193  
rotating 90º wrt b, however it was found that the framework is not a perfect capsule, but 
rather a distorted one, (Figure 6.16). 
 
 
      (a) 
 
 
      (b) 
Figure 6.16 (a) Capsular framework of 37 (b) Distorted capsule upon 90º rotation w.r.t b. 
 
Similar synthesis using 2-amino-5-ethynylpyrazine was attempted (amino-
substituted was used due to hydrolysis of acetamido group of acetamidopyrazine in 
reaction medium), which however only yielded disubstituted products, (Section 6.2.1.7). 
Unfortunately for these cavitands, single crystals were not obtained for structure 
determination. 
 
 
 194  
6.3.2.2 Crystal structure of C-pentyl-1,3-di(2-acetamidopyridyl-5-ethynyl)-2,4-
dibromocavitand, 38 
 
C-Pentyl-1,3-di(2-acetamidopyridyl-5-ethynyl)-2,4-dibromocavitand, 38 was 
synthesized following standard Sonogashira coupling procedures from 1,3-dibromo-2,4-
diiodocavitand with moderate  yields (48%). The crystal structure determination of 38 
revealed the presence of disordered acetone molecules along the upper rim. 
  
   
Figure 6.17 C-Pentyl-1,3-di(2-acetamidopyriyl-5-ethynyl)-2,4-dibromocavitand, 38; 
(a) thermal ellipsoid plots (50 % probabilities) and labeling schemes, (b) An individual 
cavitand. 
 
Each cavitand molecule is connected to two inverted neighbors via two N-H---O 
(2.026 Å) hydrogen bonding between the NH group of the acetamido moiety in the “arm” 
and the oxygen atom in the methylene bridge on both sides to give extended 1D chain. 
The two individual chains are arranged such that the ‘feet’ of the cavitands in the upper 
chain lies in the cavity of the ones in the lower chain to give a ‘stacking of cones’ kind of 
arrangement, (Figure 6.18).  
 
 
 
 
 195  
 
Figure 6.18 Crystal packing of 38 revealing a linear 1D chain with ‘stacking of cones’ 
like architecture.  
 
6.3.3 Quest for halogen-bonded capsule 
Halogen-bond driven capsules require two cavitand molecules with halogen 
bonding potential to come together via heteromeric interactions. Unlike hydrogen-bond 
driven capsules, it is not possible to bring two cavitands together via homomeric 
interaction to form a capsule, hence a linker is needed to bind these frameworks. The 
heteromeric capsule however omits the need for a linker, but unfortunately our attempts 
at forming a heteromeric halogen bond driven capsule using 3-pyridyl or 4-pyridyl 
functionalized capsule with bromo- or iodo-cavitand failed to yield any suitable crystals.  
6.3.3.1 Crystal structure of C-pentyltetra(4-pyridyl)cavitand, 41 
Previous studies aimed at incorporating halogen bonding moieties on a cavitand 
resulted in the synthesis of C-pentyltetra(3-pyridyl)cavitand.44 With the outward pointing 
pyridyl-N in 3-pyridylcavitand it may be impossible to bring in another cavitand 
molecule together into a capsular framework without any structural modifications. 
However, if a 4-pyridylcavitand with the pyridyl-N pointing upwards, there is a 
possibility to bring in another cavitand molecule using a linker into a capsular 
framework. 
 196  
The synthesis of a 4-pyridylcavitand started with a standard Suzuki-Miyaura 
coupling reaction using tetrabromocavitand as the precursor. A reasonable yield of the 
product is not obtained, which prompted us to make few modifications along with the 
change of precursor to tetraiodocavitand to obtain moderate yields (45%).  
           
    R= (CH2)4CH3 
    (a)           (b) 
Figure 6.19 C-Pentyl(4-pyridyl)cavitand, 41; (a) thermal ellipsoid plots (50 % 
probabilities) and labeling schemes, (b) an individual cavitand. 
 
The crystal structure determination of 41 revealed the presence of two ethanol 
molecules as guests along the upper rim of the cavitand, (Figure 6.20a). The extension of 
the network revealed the crystal packing with cavitands arranged in two layers of 
cavitands, (Figure 6.20b). 
   
(a)      (b) 
Figure 6.20 (a) Individual cavitand 41, with ethanol as guest molecules, (b) Linear 
arrangement of cavitands in crystallographic screw axis(hydrogen atoms removed for 
clarity). 
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6.3.3.2 Crystal structure of C-pentyltetra-(3-pyridyl)cavitand/1,4-
diiodotetrafluorobenzene, 40a 
 
Figure 6.21 Thermal ellipsoid plots (50 % probabilities) and labeling schemes of co-crystal 
of C-pentyltetra(3-pyridyl)cavitand and 1,4-diiodotetrafluorobenzene. 
 
The co-crystallization of C-pentyltetra(3-pyridyl)cavitand was carried out with 
1,4-diiodotetrafluorobenzene as a linker in acetonitrile. The crystal structure showed a 
2:1 halogen-bonded co-crystal comprising 1,4-diiodotetrafluorobenzene linked with two 
tetra(3-pyridyl)cavitand via an N---I interaction, (2.809 Å). Two acetonitrile molecules 
are present, one inside the cavity with the methyl group pointing towards the cavity and 
the other along the ‘feet’ of the cavitand with the cyano group pointing towards the 
cavity, (Figure 6.22). It is however surprising that the remaining three pyridyl ‘arms’ 
remain inactive. 
 
Figure 6.22 Halogen bonding in 3-pyridylcavitand with N---I interaction with 1,4-diiodo-
tetrafluorobenzene 40a. 
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6.3.3.3 Crystal structure of C-pentyltetra-(4-pyridyl)cavitand/1,4-
diiodotetrafluorobenzene, 41a 
 
Figure 6.23 Thermal ellipsoid plots (50 % probabilities) and labeling schemes of co-crystal 
of C-pentyltetra(4-pyridyl)cavitand and 1,4-diiodotetrafluorobenzene 41a. 
 
The co-crystallization of C-pentyltetra(4-pyridyl)cavitand was carried out with 
1,4-diiodotetrafluorobenzene as a linker in acetonitrile. The crystal structure showed each 
of the pyridyl group in the “arms” halogen bonded to the diiodotetrafluorobenzene via N-
--I interactions (2.751 Å). Two acetonitrile molecules are present as guests, one inside the 
cavity with the methyl group pointing towards the cavity and the other along the ‘feet’ of 
the cavitand with the cyano group pointing towards the cavity, (Figure 6.23). Upon 
extension of the network, it was observed that each of the set of two adjacent 
diiodotetrafluorobenzenes bonded to the pyridylcavitand, in turn binds to two 
neighboring pyridyl cavitands, hence resulting in a zigzag 1D chain structure, (Figure 
6.24).  
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Figure 6.24 One-dimensional zigzag network of 41a bonded via N---I interaction. 
 
6.3.3.4 Crystal structure of C-pentyltetra-(3-pyridyl)cavitand/calixarene, 40b 
 
   
                R= (CH2)4CH3             
        (a)        (b) 
Figure 6.25 Structure of (a) C-pentyltetra-(3-pyridyl)cavitand, 40  (b) t-butyl-substituted 
halogen-derivatized calixarene. 
 
C-Pentyltetra-(3-pyridyl)cavitand was co-crystallized with a halogen 
functionalized substituted calixarene45 to obtain a halogen bonded capsule.  
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Figure 6.26 Thermal ellipsoid plots (50 % probabilities) and labeling schemes of co-crystal 
of C-pentyltetra(3-pyridyl)cavitand and halogen-derivatized calixarene in a capsular 
framework. 
 
The crystal structure of 40b shows one tetra(3-pyridyl)cavitand and one halo-
substituted calixarene molecule interacting via N---I halogen bonds to give a capsular 
framework. It contains one acetonitrile molecule lying along the t-butyl end of the 
calixarene with the methyl group pointing towards the interior of the cavity. Each of the 
four pyridyl-N from the cavitand is linked with iodines in the substituted calixarene with 
N---I bond distances of 2.780, 2.867, 2.875, and 2.876 Å.  The interior of the capsule is 
shaped like a ‘vase’ with the length of 16 Å and maximum width of 10 Å, the wider part 
being the cavity of the cavitand which tapers into the calixarene, (Figure 6.27). 
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Figure 6.27 Molecular structure and spacefill diagram showing the capsular framework 
of 40b. 
 
6.4 Conclusions 
 
Our studies show that resorcinarene-based cavitands can be utilized as building 
blocks to craft the assembly of discrete molecular capsules via both hydrogen bonds and 
halogen bonds. The capability of functionalization via palladium (0 and II) catalyzed 
Suzuki-Miyaura or Sonogashira cross-coupling reactions to furnish variety of cavitands 
with wide variations in structure and characteristics is very appealing. The 
bromo/iodocavitand can act as a point for heterodimeric capsule formation or can be 
further functionalized to generate cavitands with specific properties.    
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The addition of ethynyl groups adds to the depth of the cavitand and also 
increases the electron density in the walls bounding the interior of the cavity, hence 
enabling it to capture electron deficient and larger-sized guests. The incorporation of 
substituted pyridines, pyrazine as well as pyrimidine moieties allowed us to manipulate 
the binding capabilities as well as to increase the probability of forming symmetric as 
well as asymmetric dimeric capsules via hydrogen bonding and even halogen bonding 
with or without the help of a suitable linker. 
Decorating the upper rim of the cavitand with appropriate functionalities also 
gives an opportunity to explore the probability of trapping two different guests in the 
interior of two complementary cavitands (electron-deficient and electron-rich cavitands), 
and bringing them in close contact in a heterodimeric capsule.  
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Table A.1 Crystal data and structure refinement for 4 
 
 
Identification code  ar0912m 
Empirical formula  C8 H9 Br N2 O 
Formula weight  229.08 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  Pbca 
Unit cell dimensions a = 9.3809(8) Å α= 90°. 
 b = 8.3436(7) Å β= 90°. 
 c = 22.7825(18) Å γ = 90°. 
Volume 1783.2(3) Å3 
Z 8 
Density (calculated) 1.707 g/cm3 
Absorption coefficient 4.562 mm-1 
F(000) 912 
Crystal size 0.22 x 0.18 x 0.12 mm3 
Theta range for data collection 2.81 to 31.62°. 
Index ranges -13<=h<=13, -12<=k<=12, -33<=l<=33 
Reflections collected 36371 
Independent reflections 2983 [R(int) = 0.0871] 
Completeness to theta = 31.62° 99.4 %  
Absorption correction None 
Max. and min. transmission 0.6105 and 0.4335 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2983 / 0 / 113 
Goodness-of-fit on F2 1.073 
Final R indices [I>2sigma(I)] R1 = 0.0436, wR2 = 0.0994 
R indices (all data) R1 = 0.0803, wR2 = 0.1167 
Largest diff. peak and hole 0.798 and -0.594 e.Å-3 
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Table A.2 Crystal data and structure refinement for 6 
 
 
Identification code  ar0708m 
Empirical formula  C7 H7 Br N2 O 
Formula weight  215.06 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 3.8683(3) Å α= 81.734(3)°. 
 b = 8.6800(7) Å β= 88.723(3)°. 
 c = 22.5717(18) Å γ = 85.962(3)°. 
Volume 748.09(10) Å3 
Z 4 
Density (calculated) 1.909 g/cm3 
Absorption coefficient 5.431 mm-1 
F(000) 424 
Crystal size 0.25 x 0.10 x 0.10 mm3 
Theta range for data collection 0.91 to 31.19°. 
Index ranges -5<=h<=5, -12<=k<=12, -26<=l<=32 
Reflections collected 13566 
Independent reflections 4521 [R(int) = 0.0283] 
Completeness to theta = 31.19° 92.6 %  
Absorption correction None 
Max. and min. transmission 0.6127 and 0.3438 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4521 / 0 / 207 
Goodness-of-fit on F2 0.982 
Final R indices [I>2sigma(I)] R1 = 0.0304, wR2 = 0.0668 
R indices (all data) R1 = 0.0489, wR2 = 0.0739 
Largest diff. peak and hole 0.678 and -0.553 e.Å-3 
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Table A.3 Crystal data and structure refinement for 1a 
 
 
Identification code  ar0908m 
Empirical formula  C13 H11 N3 O2 
Formula weight  241.25 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1) 
Unit cell dimensions a = 8.3508(5) Å α= 90°. 
 b = 6.9219(4) Å β= 102.214(4)°. 
 c = 10.4152(6) Å γ = 90°. 
Volume 588.41(6) Å3 
Z 2 
Density (calculated) 1.362 g/cm3 
Absorption coefficient 0.095 mm-1 
F(000) 252 
Crystal size 0.24 x 0.18 x 0.12 mm3 
Theta range for data collection 3.51 to 32.58°. 
Index ranges -12<=h<=12, -8<=k<=10, -15<=l<=14 
Reflections collected 7738 
Independent reflections 2293 [R(int) = 0.0237] 
Completeness to theta = 32.58° 99.7 %  
Absorption correction None 
Max. and min. transmission 0.9887 and 0.9775 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2293 / 1 / 172 
Goodness-of-fit on F2 1.051 
Final R indices [I>2sigma(I)] R1 = 0.0380, wR2 = 0.1018 
R indices (all data) R1 = 0.0439, wR2 = 0.1064 
Absolute structure parameter 0.4(11) 
Largest diff. peak and hole 0.333 and -0.180 e.Å-3 
 210  
Table A.4 Crystal data and structure refinement for 1c 
 
 
Identification code  ar0815m 
Empirical formula  C12 H11 Cl N2 O2 
Formula weight  250.68 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  Pn 
Unit cell dimensions a = 6.6153(14) Å α= 90°. 
 b = 7.9832(17) Å β= 99.763(5)°. 
 c = 11.143(3) Å γ = 90°. 
Volume 579.9(2) Å3 
Z 2 
Density (calculated) 1.436 g/cm3 
Absorption coefficient 0.320 mm-1 
F(000) 260 
Crystal size 0.20 x 0.12 x 0.08 mm3 
Theta range for data collection 3.15 to 31.50°. 
Index ranges -9<=h<=9, -11<=k<=11, -15<=l<=16 
Reflections collected 6842 
Independent reflections 3349 [R(int) = 0.0191] 
Completeness to theta = 25.00° 99.7 %  
Absorption correction None 
Max. and min. transmission 0.9749 and 0.9388 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3349 / 2 / 163 
Goodness-of-fit on F2 1.087 
Final R indices [I>2sigma(I)] R1 = 0.0297, wR2 = 0.0771 
R indices (all data) R1 = 0.0322, wR2 = 0.0790 
Absolute structure parameter 0.02(4) 
Largest diff. peak and hole 0.292 and -0.188 e.Å-3 
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Table A.5 Crystal data and structure refinement for 1g 
 
 
Identification code  ar0902m 
Empirical formula  C12 H10 F2 N2 O2 
Formula weight  252.22 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  Pbca 
Unit cell dimensions a = 9.0887(5) Å α= 90°. 
 b = 11.5417(7) Å β= 90°. 
 c = 20.9156(13) Å γ = 90°. 
Volume 2194.0(2) Å3 
Z 8 
Density (calculated) 1.527 g/cm3 
Absorption coefficient 0.128 mm-1 
F(000) 1040 
Crystal size 0.25 x 0.25 x 0.15 mm3 
Theta range for data collection 3.01 to 31.50°. 
Index ranges -6<=h<=13, -16<=k<=16, -29<=l<=30 
Reflections collected 35383 
Independent reflections 3553 [R(int) = 0.0401] 
Completeness to theta = 31.50° 97.1 %  
Absorption correction None 
Max. and min. transmission 0.9810 and 0.9687 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3553 / 0 / 172 
Goodness-of-fit on F2 1.065 
Final R indices [I>2sigma(I)] R1 = 0.0393, wR2 = 0.1079 
R indices (all data) R1 = 0.0494, wR2 = 0.1139 
Largest diff. peak and hole 0.379 and -0.213 e.Å-3 
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Table A.6 Crystal data and structure refinement for 1j 
 
 
Identification code  ar0905m 
Empirical formula  C12 H7 F5 N2 O2 
Formula weight  306.20 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 12.1134(12) Å α= 90°. 
 b = 9.0910(9) Å β= 114.822(4)°. 
 c = 11.9721(13) Å γ = 90°. 
Volume 1196.6(2) Å3 
Z 4 
Density (calculated) 1.700 g/cm3 
Absorption coefficient 0.168 mm-1 
F(000) 616 
Crystal size 0.20 x 0.16 x 0.12 mm3 
Theta range for data collection 2.91 to 32.58°. 
Index ranges -18<=h<=18, -13<=k<=12, -18<=l<=15 
Reflections collected 15805 
Independent reflections 4348 [R(int) = 0.0258] 
Completeness to theta = 32.58° 99.9 %  
Absorption correction None 
Max. and min. transmission 0.9801 and 0.9671 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4348 / 0 / 199 
Goodness-of-fit on F2 1.027 
Final R indices [I>2sigma(I)] R1 = 0.0407, wR2 = 0.1168 
R indices (all data) R1 = 0.0498, wR2 = 0.1234 
Largest diff. peak and hole 0.493 and -0.236 e.Å-3 
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Table A.7 Crystal data and structure refinement for 1k 
 
 
Identification code  ar0904m 
Empirical formula  C18 H26 N4 O4 
Formula weight  362.43 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 8.8279(6) Å α= 90°. 
 b = 5.6026(4) Å β= 94.946(3)°. 
 c = 18.5118(11) Å γ = 90°. 
Volume 912.17(10) Å3 
Z 2 
Density (calculated) 1.320 g/cm3 
Absorption coefficient 0.095 mm-1 
F(000) 388 
Crystal size 0.25 x 0.20 x 0.15 mm3 
Theta range for data collection 2.21 to 32.58°. 
Index ranges -11<=h<=13, -8<=k<=7, -28<=l<=20 
Reflections collected 11583 
Independent reflections 3225 [R(int) = 0.0206] 
Completeness to theta = 32.58° 97.1 %  
Absorption correction None 
Max. and min. transmission 0.9859 and 0.9767 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3225 / 0 / 127 
Goodness-of-fit on F2 1.109 
Final R indices [I>2sigma(I)] R1 = 0.0386, wR2 = 0.1088 
R indices (all data) R1 = 0.0436, wR2 = 0.1164 
Largest diff. peak and hole 0.433 and -0.266 e.Å-3 
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Table A.8 Crystal data and structure refinement for 1n 
 
 
Identification code  ar0909m 
Empirical formula  C9 H12 N2 O4 
Formula weight  212.21 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 10.0946(9) Å α= 90°. 
 b = 5.1454(5) Å β= 104.255(3)°. 
 c = 18.9656(17) Å γ = 90°. 
Volume 954.76(15) Å3 
Z 4 
Density (calculated) 1.476 g/cm3 
Absorption coefficient 0.117 mm-1 
F(000) 448 
Crystal size 0.35 x 0.25 x 0.15 mm3 
Theta range for data collection 2.08 to 32.57°. 
Index ranges -10<=h<=15, -6<=k<=7, -28<=l<=28 
Reflections collected 10173 
Independent reflections 3337 [R(int) = 0.0197] 
Completeness to theta = 30.00° 99.0 %  
Absorption correction None 
Max. and min. transmission 0.9826 and 0.9601 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3337 / 0 / 148 
Goodness-of-fit on F2 1.025 
Final R indices [I>2sigma(I)] R1 = 0.0387, wR2 = 0.1092 
R indices (all data) R1 = 0.0436, wR2 = 0.1149 
Largest diff. peak and hole 0.489 and -0.269 e.Å-3 
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Table A.9 Crystal data and structure refinement for 1o 
 
 
Identification code  ar0816m 
Empirical formula  C20 H30 N4 O4 
Formula weight  390.48 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 8.2382(6) Å α= 90°. 
 b = 7.3603(5) Å β= 102.979(3)°. 
 c = 17.7902(11) Å γ = 90°. 
Volume 1051.16(12) Å3 
Z 2 
Density (calculated) 1.234 g/cm3 
Absorption coefficient 0.087 mm-1 
F(000) 420 
Crystal size 0.25 x 0.25 x 0.20 mm3 
Theta range for data collection 2.35 to 31.51°. 
Index ranges -9<=h<=12, -9<=k<=10, -26<=l<=26 
Reflections collected 12489 
Independent reflections 3494 [R(int) = 0.0206] 
Completeness to theta = 31.51° 99.9 %  
Absorption correction None 
Max. and min. transmission 0.9828 and 0.9786 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3494 / 0 / 136 
Goodness-of-fit on F2 1.091 
Final R indices [I>2sigma(I)] R1 = 0.0400, wR2 = 0.1100 
R indices (all data) R1 = 0.0474, wR2 = 0.1159 
Largest diff. peak and hole 0.430 and -0.307 e.Å-3 
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Table A.10 Crystal data and structure refinement for 2a 
 
 
Identification code  ar0709m 
Empirical formula  C13 H10 Br N3 O2 
Formula weight  320.15 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  Pca2(1) 
Unit cell dimensions a = 12.3903(8) Å α= 90°. 
 b = 5.6871(3) Å β= 90°. 
 c = 18.0290(11) Å γ = 90°. 
Volume 1270.41(13) Å3 
Z 4 
Density (calculated) 1.674 g/cm3 
Absorption coefficient 3.237 mm-1 
F(000) 640 
Crystal size 0.25 x 0.20 x 0.10 mm3 
Theta range for data collection 3.29 to 33.17°. 
Index ranges -18<=h<=19, -8<=k<=5, -27<=l<=27 
Reflections collected 22901 
Independent reflections 4830 [R(int) = 0.0752] 
Completeness to theta = 33.17° 99.8 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7379 and 0.4984 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4830 / 1 / 181 
Goodness-of-fit on F2 0.991 
Final R indices [I>2sigma(I)] R1 = 0.0331, wR2 = 0.0735 
R indices (all data) R1 = 0.0409, wR2 = 0.0756 
Absolute structure parameter -0.006(7) 
Largest diff. peak and hole 1.329 and -0.641 e.Å-3 
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Table A.11 Crystal data and structure refinement for 2e 
 
 
Identification code  ar0719m 
Empirical formula  C12 H10 Br N3 O4 
Formula weight  340.14 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 7.9727(5) Å α= 90°. 
 b = 6.2956(4) Å β= 90.580(4)°. 
 c = 24.6286(15) Å γ = 90°. 
Volume 1236.12(13) Å3 
Z 4 
Density (calculated) 1.828 g/cm3 
Absorption coefficient 3.344 mm-1 
F(000) 680 
Crystal size 0.20 x 0.20 x 0.15 mm3 
Theta range for data collection 1.65 to 32.58°. 
Index ranges -12<=h<=10, -9<=k<=9, -37<=l<=37 
Reflections collected 18835 
Independent reflections 4299 [R(int) = 0.0328] 
Completeness to theta = 32.58° 95.3 %  
Absorption correction None 
Max. and min. transmission 0.6339 and 0.5544 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4299 / 0 / 190 
Goodness-of-fit on F2 1.198 
Final R indices [I>2sigma(I)] R1 = 0.0478, wR2 = 0.1243 
R indices (all data) R1 = 0.0562, wR2 = 0.1281 
Largest diff. peak and hole 1.785 and -1.655 e.Å-3 
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 Table A.12 Crystal data and structure refinement for 3n 
 
 
Identification code  ih0519 
Empirical formula  C18 H22 N4 O6 
Formula weight  390.40 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 9.1172(8) Å α= 90°. 
 b = 9.2969(8) Å β= 92.694(2)°. 
 c = 10.6430(9) Å γ = 90°. 
Volume 901.12(13) Å3 
Z 2 
Density (calculated) 1.439 g/cm3 
Absorption coefficient 0.110 mm-1 
F(000) 412 
Crystal size 0.33 x 0.27 x 0.24 mm3 
Theta range for data collection 2.88 to 30.04°. 
Index ranges -12<=h<=12, -11<=k<=13, -14<=l<=14 
Reflections collected 9947 
Independent reflections 2600 [R(int) = 0.0298] 
Completeness to theta = 30.04° 98.9 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2600 / 0 / 134 
Goodness-of-fit on F2 1.134 
Final R indices [I>2sigma(I)] R1 = 0.0447, wR2 = 0.1217 
R indices (all data) R1 = 0.0475, wR2 = 0.1249 
Extinction coefficient 0.010(3) 
Largest diff. peak and hole 0.498 and -0.374 e.Å-3 
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Table A.13 Crystal data and structure refinement for 4f 
 
 
Identification code  ar0801m 
Empirical formula  C15 H13 Br Cl2 N2 O3 
Formula weight  420.08 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 3.9019(2) Å α= 73.128(3)°. 
 b = 12.5454(8) Å β= 86.428(3)°. 
 c = 16.9260(10) Å γ = 85.881(3)°. 
Volume 790.08(8) Å3 
Z 2 
Density (calculated) 1.766 g/cm3 
Absorption coefficient 2.955 mm-1 
F(000) 420 
Crystal size 0.25 x 0.10 x 0.05 mm3 
Theta range for data collection 2.60 to 30.51°. 
Index ranges -5<=h<=5, -17<=k<=17, -24<=l<=24 
Reflections collected 16452 
Independent reflections 4701 [R(int) = 0.0293] 
Completeness to theta = 30.51° 97.3 %  
Absorption correction None 
Max. and min. transmission 0.8663 and 0.5254 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4701 / 0 / 214 
Goodness-of-fit on F2 1.037 
Final R indices [I>2sigma(I)] R1 = 0.0250, wR2 = 0.0652 
R indices (all data) R1 = 0.0295, wR2 = 0.0674 
Largest diff. peak and hole 0.710 and -0.774 e.Å-3 
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Table A.14 Crystal data and structure refinement for 4k (SR2-c) 
 
 
Identification code  ar0729m 
Empirical formula  C24 H32 Br2 N4 O6 
Formula weight  632.36 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P1 
Unit cell dimensions a = 5.3172(2) Å α= 101.970(2)°. 
 b = 8.6548(3) Å β= 93.037(2)°. 
 c = 14.9927(6) Å γ = 100.816(2)°. 
Volume 659.92(4) Å3 
Z 1 
Density (calculated) 1.591 g/cm3 
Absorption coefficient 3.117 mm-1 
F(000) 322 
Crystal size 0.20 x 0.16 x 0.12 mm3 
Theta range for data collection 3.28 to 27.13°. 
Index ranges -6<=h<=6, -11<=k<=11, -19<=l<=19 
Reflections collected 12733 
Independent reflections 2892 [R(int) = 0.0298] 
Completeness to theta = 27.13° 99.4 %  
Absorption correction None 
Max. and min. transmission 0.7061 and 0.5703 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2892 / 0 / 170 
Goodness-of-fit on F2 1.001 
Final R indices [I>2sigma(I)] R1 = 0.0230, wR2 = 0.0543 
R indices (all data) R1 = 0.0283, wR2 = 0.0567 
Largest diff. peak and hole 0.285 and -0.263 e.Å-3 
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Table A.15 Crystal data and structure refinement for 4m 
 
 
Identification code  ar0713m 
Empirical formula  C20 H22 Br2 N4 O6 
Formula weight  574.24 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 4.8333(3) Å α= 90°. 
 b = 9.5923(5) Å β= 90.961(2)°. 
 c = 23.7901(12) Å γ = 90°. 
Volume 1102.81(11) Å3 
Z 2 
Density (calculated) 1.729 g/cm3 
Absorption coefficient 3.721 mm-1 
F(000) 576 
Crystal size 0.20 x 0.08 x 0.08 mm3 
Theta range for data collection 1.71 to 31.28°. 
Index ranges -6<=h<=6, -13<=k<=13, -34<=l<=26 
Reflections collected 19971 
Independent reflections 3473 [R(int) = 0.0443] 
Completeness to theta = 31.28° 96.8 %  
Absorption correction None 
Max. and min. transmission 0.7551 and 0.5232 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3473 / 0 / 152 
Goodness-of-fit on F2 1.037 
Final R indices [I>2sigma(I)] R1 = 0.0296, wR2 = 0.0628 
R indices (all data) R1 = 0.0423, wR2 = 0.0669 
Largest diff. peak and hole 0.514 and -0.395 e.Å-3 
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Table A.16 Crystal data and structure refinement for 4n (SR2-a) 
 
 
Identification code  ar0806m 
Empirical formula  C20 H24 Br2 N4 O6 
Formula weight  576.25 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 13.8624(15) Å α= 95.707(8)°. 
 b = 13.9754(16) Å β= 90.355(7)°. 
 c = 24.726(3) Å γ = 101.437(7)°. 
Volume 4670.1(9) Å3 
Z 8 
Density (calculated) 1.639 g/cm3 
Absorption coefficient 3.515 mm-1 
F(000) 2320 
Crystal size 0.25 x 0.18 x 0.12 mm3 
Theta range for data collection 0.83 to 29.57°. 
Index ranges -19<=h<=19, -19<=k<=18, -34<=l<=33 
Reflections collected 72939 
Independent reflections 26200 [R(int) = 0.1786] 
Completeness to theta = 29.57° 99.9 %  
Absorption correction None 
Max. and min. transmission 0.6778 and 0.4736 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 26200 / 0 / 457 
Goodness-of-fit on F2 1.164 
Final R indices [I>2sigma(I)] R1 = 0.1567, wR2 = 0.3532 
R indices (all data) R1 = 0.3711, wR2 = 0.4480 
Largest diff. peak and hole 4.708 and -2.630 e.Å-3 
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Table A.17 Crystal data and structure refinement for 4o (SR2-d) 
 
 
Identification code  ar0921m 
Empirical formula  C26 H36 Br2 N4 O6 
Formula weight  660.41 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.1849(4) Å α= 71.293(2)°. 
 b = 11.4665(8) Å β= 81.204(2)°. 
 c = 12.4870(9) Å γ = 88.593(2)°. 
Volume 694.66(9) Å3 
Z 1 
Density (calculated) 1.579 g/cm3 
Absorption coefficient 2.965 mm-1 
F(000) 338 
Crystal size 0.40 x 0.20 x 0.10 mm3 
Theta range for data collection 1.88 to 31.51°. 
Index ranges -7<=h<=7, -10<=k<=16, -15<=l<=18 
Reflections collected 12522 
Independent reflections 4500 [R(int) = 0.0287] 
Completeness to theta = 31.51° 97.2 %  
Absorption correction None 
Max. and min. transmission 0.7559 and 0.3834 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4500 / 0 / 178 
Goodness-of-fit on F2 0.985 
Final R indices [I>2sigma(I)] R1 = 0.0313, wR2 = 0.0708 
R indices (all data) R1 = 0.0426, wR2 = 0.0758 
Largest diff. peak and hole 0.464 and -0.467 e.Å-3 
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Table A.18 Crystal data and structure refinement for 5i 
 
 
Identification code  ar0817m 
Empirical formula  C12 H8 Br2 N4 O6 
Formula weight  464.04 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 7.3849(5) Å α= 90°. 
 b = 31.340(2) Å β= 90.344(3)°. 
 c = 13.3082(9) Å γ = 90°. 
Volume 3080.1(4) Å3 
Z 8 
Density (calculated) 2.001 g/cm3 
Absorption coefficient 5.303 mm-1 
F(000) 1808 
Crystal size 0.22 x 0.14 x 0.08 mm3 
Theta range for data collection 1.30 to 31.51°. 
Index ranges -10<=h<=10, -44<=k<=44, -19<=l<=18 
Reflections collected 35388 
Independent reflections 10050 [R(int) = 0.0333] 
Completeness to theta = 31.51° 97.9 %  
Absorption correction None 
Max. and min. transmission 0.6763 and 0.3883 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 10050 / 0 / 451 
Goodness-of-fit on F2 1.049 
Final R indices [I>2sigma(I)] R1 = 0.0364, wR2 = 0.0866 
R indices (all data) R1 = 0.0556, wR2 = 0.0928 
Largest diff. peak and hole 1.475 and -0.582 e.Å-3 
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Table A.19 Crystal data and structure refinement for 5m 
 
 
Identification code  ar0820m 
Empirical formula  C14 H12 Br4 N4 O4 
Formula weight  619.92 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 14.0298(10) Å α= 90°. 
 b = 3.8527(3) Å β= 102.337(3)°. 
 c = 17.5918(13) Å γ = 90°. 
Volume 928.92(12) Å3 
Z 2 
Density (calculated) 2.216 g/cm3 
Absorption coefficient 8.693 mm-1 
F(000) 592 
Crystal size 0.16 x 0.14 x 0.08 mm3 
Theta range for data collection 2.97 to 33.72°. 
Index ranges -21<=h<=21, -6<=k<=6, -27<=l<=21 
Reflections collected 19668 
Independent reflections 3635 [R(int) = 0.0324] 
Completeness to theta = 33.72° 98.6 %  
Absorption correction None 
Max. and min. transmission 0.5431 and 0.3368 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3635 / 0 / 127 
Goodness-of-fit on F2 1.017 
Final R indices [I>2sigma(I)] R1 = 0.0211, wR2 = 0.0501 
R indices (all data) R1 = 0.0268, wR2 = 0.0521 
Largest diff. peak and hole 0.688 and -0.480 e.Å-3 
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Table A.20 Crystal data and structure refinement for 6n (SR1-a) 
 
 
Identification code  ar0728m 
Empirical formula  C18 H20 Br2 N4 O6 
Formula weight  548.20 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 4.9878(3) Å α= 113.250(5)°. 
 b = 9.9931(7) Å β= 92.103(5)°. 
 c = 11.4625(8) Å γ = 93.352(5)°. 
Volume 522.92(6) Å3 
Z 1 
Density (calculated) 1.741 g/cm3 
Absorption coefficient 3.919 mm-1 
F(000) 274 
Crystal size 0.33 x 0.16 x 0.10 mm3 
Theta range for data collection 3.49 to 27.12°. 
Index ranges -6<=h<=6, -12<=k<=12, -14<=l<=14 
Reflections collected 8216 
Independent reflections 2184 [R(int) = 0.0599] 
Completeness to theta = 25.00° 94.4 %  
Absorption correction None 
Max. and min. transmission 0.6906 and 0.3561 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2184 / 0 / 143 
Goodness-of-fit on F2 0.978 
Final R indices [I>2sigma(I)] R1 = 0.0414, wR2 = 0.0840 
R indices (all data) R1 = 0.0784, wR2 = 0.0973 
Largest diff. peak and hole 0.772 and -0.548 e.Å-3 
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Table A.21 Crystal data and structure refinement for 10 
 
 
Identification code  ar0704m 
Empirical formula  C9 H8 N4 
Formula weight  172.19 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1) 
Unit cell dimensions a = 5.2455(3) Å α= 90°. 
 b = 25.6547(15) Å β= 98.522(3)°. 
 c = 6.4584(4) Å γ = 90°. 
Volume 859.52(9) Å3 
Z 4 
Density (calculated) 1.331 Mg/m3 
Absorption coefficient 0.087 mm-1 
F(000) 360 
Crystal size 0.30 x 0.25 x 0.15 mm3 
Theta range for data collection 1.59 to 35.62°. 
Index ranges -8<=h<=8, -41<=k<=41, -9<=l<=10 
Reflections collected 16192 
Independent reflections 4034 [R(int) = 0.0279] 
Completeness to theta = 35.62° 99.6 %  
Absorption correction None 
Max. and min. transmission 0.9871 and 0.9744 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4034 / 1 / 247 
Goodness-of-fit on F2 1.046 
Final R indices [I>2sigma(I)] R1 = 0.0436, wR2 = 0.1142 
R indices (all data) R1 = 0.0513, wR2 = 0.1186 
Absolute structure parameter -0.7(16) 
Largest diff. peak and hole 0.448 and -0.235 e.Å-3 
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Table A.22 Crystal data and structure refinement for 10c 
 
 
Identification code  ar1005m 
Empirical formula  C16 H13 Cl N4 O2 
Formula weight  328.75 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 19.1029(12) Å α= 90°. 
 b = 7.5386(4) Å β= 98.284(3)°. 
 c = 10.6738(7) Å γ = 90°. 
Volume 1521.09(16) Å3 
Z 4 
Density (calculated) 1.436 g/cm3 
Absorption coefficient 0.267 mm-1 
F(000) 680 
Crystal size 0.36 x 0.32 x 0.08 mm3 
Theta range for data collection 1.08 to 31.51°. 
Index ranges -28<=h<=15, -5<=k<=11, -13<=l<=15 
Reflections collected 15674 
Independent reflections 4844 [R(int) = 0.0286] 
Completeness to theta = 30.00° 97.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9790 and 0.9102 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4844 / 0 / 217 
Goodness-of-fit on F2 1.054 
Final R indices [I>2sigma(I)] R1 = 0.0481, wR2 = 0.1334 
R indices (all data) R1 = 0.0676, wR2 = 0.1471 
Largest diff. peak and hole 0.482 and -0.384 e.Å-3 
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Table A.23 Crystal data and structure refinement for 10j 
 
Identification code  ar1014m 
Empirical formula  C16 H9 F5 N4 O2 
Formula weight  384.27 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 6.0919(5) Å α= 77.386(2)°. 
 b = 7.5337(6) Å β= 80.438(2)°. 
 c = 17.0979(13) Å γ = 81.482(2)°. 
Volume 750.00(10) Å3 
Z 2 
Density (calculated) 1.702 g/cm3 
Absorption coefficient 0.157 mm-1 
F(000) 388 
Crystal size 0.32 x 0.20 x 0.08 mm3 
Theta range for data collection 2.79 to 32.57°. 
Index ranges -9<=h<=7, -11<=k<=9, -24<=l<=25 
Reflections collected 19595 
Independent reflections 5166 [R(int) = 0.0242] 
Completeness to theta = 30.00° 98.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9875 and 0.9513 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5166 / 0 / 253 
Goodness-of-fit on F2 1.072 
Final R indices [I>2sigma(I)] R1 = 0.0422, wR2 = 0.1218 
R indices (all data) R1 = 0.0526, wR2 = 0.1313 
Largest diff. peak and hole 0.484 and -0.313 e.Å-3 
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Table A.24 Crystal data and structure refinement for 10k 
 
 
Identification code  ar1020m 
Empirical formula  C26 H30 N8 O4 
Formula weight  518.58 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.4540(14) Å α= 90.854(4)°. 
 b = 7.0445(17) Å β= 92.146(4)°. 
 c = 17.042(4) Å γ = 105.123(4)°. 
Volume 631.4(3) Å3 
Z 1 
Density (calculated) 1.364 g/cm3 
Absorption coefficient 0.096 mm-1 
F(000) 274 
Crystal size 0.28 x 0.26 x 0.10 mm3 
Theta range for data collection 2.39 to 29.02°. 
Index ranges -7<=h<=7, -9<=k<=9, -22<=l<=23 
Reflections collected 5818 
Independent reflections 3031 [R(int) = 0.0785] 
Completeness to theta = 27.50° 97.4 %  
Absorption correction None 
Max. and min. transmission 0.9905 and 0.9737 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3031 / 0 / 181 
Goodness-of-fit on F2 1.053 
Final R indices [I>2sigma(I)] R1 = 0.0518, wR2 = 0.1358 
R indices (all data) R1 = 0.0598, wR2 = 0.1424 
Largest diff. peak and hole 0.310 and -0.306 e.Å-3 
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Table A.25 Crystal data and structure refinement for 10n (SR3-a) 
 
 
Identification code  ar1015m 
Empirical formula  C22 H22 N8 O4 
Formula weight  462.48 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 7.2159(8) Å α= 90°. 
 b = 13.0960(14) Å β= 98.989(4)°. 
 c = 22.341(3) Å γ = 90°. 
Volume 2085.3(4) Å3 
Z 4 
Density (calculated) 1.473 g/cm3 
Absorption coefficient 0.106 mm-1 
F(000) 968 
Crystal size 0.30 x 0.22 x 0.12 mm3 
Theta range for data collection 3.11 to 30.03°. 
Index ranges -10<=h<=10, -18<=k<=13, -31<=l<=31 
Reflections collected 18085 
Independent reflections 5954 [R(int) = 0.0736] 
Completeness to theta = 30.03° 97.4 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9874 and 0.9688 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5954 / 0 / 325 
Goodness-of-fit on F2 1.129 
Final R indices [I>2sigma(I)] R1 = 0.0814, wR2 = 0.1863 
R indices (all data) R1 = 0.1344, wR2 = 0.2168 
Largest diff. peak and hole 0.597 and -0.455 e.Å-3 
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Table A.26 Crystal data and structure refinement for 10o (SR3-d) 
 
 
Identification code  ar1001m 
Empirical formula  C28 H34 N8 O4 
Formula weight  546.63 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.4295(3) Å α= 84.697(3)°. 
 b = 7.0626(4) Å β= 89.661(4)°. 
 c = 18.6385(11) Å γ = 74.553(4)°. 
Volume 685.82(7) Å3 
Z 1 
Density (calculated) 1.324 g/cm3 
Absorption coefficient 0.092 mm-1 
F(000) 290 
Crystal size 0.28 x 0.24 x 0.12 mm3 
Theta range for data collection 2.20 to 32.57°. 
Index ranges -8<=h<=8, -10<=k<=10, -28<=l<=28 
Reflections collected 17030 
Independent reflections 4957 [R(int) = 0.0583] 
Completeness to theta = 32.57° 99.2 %  
Absorption correction None 
Max. and min. transmission 0.9891 and 0.9747 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4957 / 0 / 190 
Goodness-of-fit on F2 1.073 
Final R indices [I>2sigma(I)] R1 = 0.0522, wR2 = 0.1403 
R indices (all data) R1 = 0.0718, wR2 = 0.1554 
Largest diff. peak and hole 0.431 and -0.285 e.Å-3 
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Table A.27 Crystal data and structure refinement for 10r 
 
 
Identification code  ar1009m 
Empirical formula  C17 H13 Cl N6 O 
Formula weight  352.78 
Temperature  296(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 18.4973(11) Å α= 90°. 
 b = 7.5005(4) Å β= 105.707(4)°. 
 c = 12.5176(7) Å γ = 90°. 
Volume 1671.83(16) Å3 
Z 4 
Density (calculated) 1.402 g/cm3 
Absorption coefficient 0.247 mm-1 
F(000) 728 
Crystal size 0.28 x 0.24 x 0.14 mm3 
Theta range for data collection 2.29 to 31.00°. 
Index ranges -26<=h<=26, -10<=k<=10, -18<=l<=17 
Reflections collected 19450 
Independent reflections 5301 [R(int) = 0.0647] 
Completeness to theta = 31.00° 99.6 %  
Absorption correction None 
Max. and min. transmission 0.9663 and 0.9341 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5301 / 0 / 235 
Goodness-of-fit on F2 1.060 
Final R indices [I>2sigma(I)] R1 = 0.0570, wR2 = 0.1668 
R indices (all data) R1 = 0.0818, wR2 = 0.1835 
Largest diff. peak and hole 0.280 and -0.343 e.Å-3 
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Table A.28 Crystal data and structure refinement for 12 
 
 
Identification code  ar1006m 
Empirical formula  C10 H10 N4 
Formula weight  186.22 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 11.9569(9) Å α= 90°. 
 b = 7.3412(5) Å β= 96.834(4)°. 
 c = 10.2804(7) Å γ = 90°. 
Volume 895.98(11) Å3 
Z 4 
Density (calculated) 1.381 g/cm3 
Absorption coefficient 0.089 mm-1 
F(000) 392 
Crystal size 0.22 x 0.16 x 0.08 mm3 
Theta range for data collection 3.26 to 32.57°. 
Index ranges -17<=h<=14, -10<=k<=9, -15<=l<=15 
Reflections collected 9469 
Independent reflections 3027 [R(int) = 0.0346] 
Completeness to theta = 30.00° 98.7 %  
Absorption correction None 
Max. and min. transmission 0.9929 and 0.9807 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3027 / 0 / 134 
Goodness-of-fit on F2 1.038 
Final R indices [I>2sigma(I)] R1 = 0.0514, wR2 = 0.1411 
R indices (all data) R1 = 0.0765, wR2 = 0.1578 
Largest diff. peak and hole 0.452 and -0.272 e.Å-3 
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Table A.29 Crystal data and structure refinement for 12n 
 
 
Identification code  ar1004m 
Empirical formula  C24 H26 N8 O4 
Formula weight  490.53 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 14.8427(10) Å α= 90°. 
 b = 7.3677(5) Å β= 101.321(4)°. 
 c = 10.6264(8) Å γ = 90°. 
Volume 1139.46(14) Å3 
Z 2 
Density (calculated) 1.430 g/cm3 
Absorption coefficient 0.102 mm-1 
F(000) 516 
Crystal size 0.28 x 0.14 x 0.10 mm3 
Theta range for data collection 2.80 to 32.57°. 
Index ranges -22<=h<=19, -6<=k<=11, -15<=l<=15 
Reflections collected 13858 
Independent reflections 4011 [R(int) = 0.0303] 
Completeness to theta = 32.57° 96.8 %  
Absorption correction None 
Max. and min. transmission 0.9899 and 0.9721 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4011 / 0 / 173 
Goodness-of-fit on F2 1.060 
Final R indices [I>2sigma(I)] R1 = 0.0544, wR2 = 0.1514 
R indices (all data) R1 = 0.0825, wR2 = 0.1732 
Largest diff. peak and hole 0.467 and -0.311 e.Å-3 
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 Table A.30 Crystal data and structure refinement for 15 
 
 
Identification code  ar1018m 
Empirical formula  C9 H8 N4 
Formula weight  172.19 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 8.7786(8) Å α= 90°. 
 b = 9.7939(8) Å β= 105.850(7)°. 
 c = 9.4421(10) Å γ = 90°. 
Volume 780.94(13) Å3 
Z 4 
Density (calculated) 1.465 g/cm3 
Absorption coefficient 0.096 mm-1 
F(000) 360 
Crystal size 0.26 x 0.18 x 0.12 mm3 
Theta range for data collection 2.81 to 30.60°. 
Index ranges -12<=h<=12, -14<=k<=13, -12<=l<=13 
Reflections collected 8233 
Independent reflections 2384 [R(int) = 0.0582] 
Completeness to theta = 30.60° 99.4 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9886 and 0.9755 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2384 / 0 / 124 
Goodness-of-fit on F2 1.053 
Final R indices [I>2sigma(I)] R1 = 0.0563, wR2 = 0.1464 
R indices (all data) R1 = 0.0842, wR2 = 0.1648 
Largest diff. peak and hole 0.536 and -0.220 e.Å-3 
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Table A.31 Crystal data and structure refinement for 15e 
 
 
Identification code  ar1012m 
Empirical formula  C16 H13 N5 O4 
Formula weight  339.31 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 7.2069(12) Å α= 97.387(9)°. 
 b = 7.3475(12) Å β= 93.282(9)°. 
 c = 15.599(3) Å γ = 116.353(7)°. 
Volume 727.9(2) Å3 
Z 2 
Density (calculated) 1.548 g/cm3 
Absorption coefficient 0.115 mm-1 
F(000) 352 
Crystal size 0.36 x 0.16 x 0.08 mm3 
Theta range for data collection 3.14 to 30.87°. 
Index ranges -10<=h<=10, -10<=k<=10, 0<=l<=22 
Reflections collected 9417 
Independent reflections 9417 [R(int) = 0.0000] 
Completeness to theta = 30.87° 96.5 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9908 and 0.9596 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 9417 / 0 / 227 
Goodness-of-fit on F2 1.798 
Final R indices [I>2sigma(I)] R1 = 0.1692, wR2 = 0.3773 
R indices (all data) R1 = 0.2580, wR2 = 0.4092 
Largest diff. peak and hole 0.987 and -0.570 e.Å-3 
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Table A.32 Crystal data and structure refinement for 16 
 
Identification code  ar0710m 
Empirical formula  C12 H11 N3 O 
Formula weight  213.24 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 7.2839(7) Å α= 93.643(7)°. 
 b = 10.4921(11) Å β= 101.724(6)°. 
 c = 13.8219(13) Å γ = 97.267(7)°. 
Volume 1021.63(17) Å3 
Z 4 
Density (calculated) 1.386 g/cm3 
Absorption coefficient 0.092 mm-1 
F(000) 448 
Crystal size 0.30 x 0.10 x 0.05 mm3 
Theta range for data collection 1.97 to 29.61°. 
Index ranges -9<=h<=10, -14<=k<=14, -19<=l<=19 
Reflections collected 25236 
Independent reflections 25236 [R(int) = 0.0000] 
Completeness to theta = 29.61° 95.2 %  
Absorption correction None 
Max. and min. transmission 0.9954 and 0.9728 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 25236 / 0 / 292 
Goodness-of-fit on F2 0.790 
Final R indices [I>2sigma(I)] R1 = 0.0618, wR2 = 0.1323 
R indices (all data) R1 = 0.1865, wR2 = 0.1699 
Largest diff. peak and hole 0.527 and -0.410 e.Å-3 
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Table A.33 Crystal data and structure refinement for 16p  
 
 
 
Identification code  ar0702m 
Empirical formula  C20 H17 N5 O2 
Formula weight  359.39 
Temperature  133(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 4.8980(3) Å α= 103.791(2)°. 
 b = 11.0334(6) Å β= 97.134(3)°. 
 c = 17.2045(10) Å γ = 100.278(2)°. 
Volume 874.84(9) Å3 
Z 2 
Density (calculated) 1.364 g/cm3 
Absorption coefficient 0.092 mm-1 
F(000) 376 
Crystal size 0.25 x 0.20 x 0.20 mm3 
Theta range for data collection 1.95 to 30.47°. 
Index ranges -6<=h<=6, -15<=k<=15, -24<=l<=24 
Reflections collected 34094 
Independent reflections 5216 [R(int) = 0.0353] 
Completeness to theta = 30.47° 98.6 %  
Absorption correction None 
Max. and min. transmission 0.9818 and 0.9773 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5216 / 0 / 250 
Goodness-of-fit on F2 1.082 
Final R indices [I>2sigma(I)] R1 = 0.0403, wR2 = 0.1102 
R indices (all data) R1 = 0.0525, wR2 = 0.1172 
Largest diff. peak and hole 0.297 and -0.187 e.Å-3 
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Table A.34 Crystal data and structure refinement for 21 
 
 
Identification code  ar0604m 
Empirical formula  C14 H11 N3 O 
Formula weight  237.26 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 10.711(3) Å α= 116.949(17)°. 
 b = 11.567(3) Å β= 109.883(18)°. 
 c = 11.613(3) Å γ = 90.970(16)°. 
Volume 1180.8(5) Å3 
Z 4 
Density (calculated) 1.335 g/cm3 
Absorption coefficient 0.088 mm-1 
F(000) 496 
Crystal size 0.30 x 0.25 x 0.15 mm3 
Theta range for data collection 2.02 to 27.63°. 
Index ranges -13<=h<=12, -15<=k<=14, -15<=l<=14 
Reflections collected 8761 
Independent reflections 5176 [R(int) = 0.1487] 
Completeness to theta = 27.63° 94.5 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5176 / 0 / 333 
Goodness-of-fit on F2 1.032 
Final R indices [I>2sigma(I)] R1 = 0.0733, wR2 = 0.1876 
R indices (all data) R1 = 0.1200, wR2 = 0.2294 
Largest diff. peak and hole 0.338 and -0.353 e.Å-3 
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Table A.35 Crystal data and structure refinement for 24 
 
 
Identification code  ar0803m 
Empirical formula  C14 H13 N4 O1.50 
Formula weight  261.28 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 11.4425(4) Å α= 96.6520(10)°. 
 b = 11.5867(3) Å β= 111.7030(10)°. 
 c = 12.3007(4) Å γ = 117.1760(10)°. 
Volume 1265.45(7) Å3 
Z 4 
Density (calculated) 1.371 g/cm3 
Absorption coefficient 0.094 mm-1 
F(000) 548 
Crystal size 0.20 x 0.10 x 0.05 mm3 
Theta range for data collection 1.90 to 33.14°. 
Index ranges -17<=h<=16, -17<=k<=17, -18<=l<=18 
Reflections collected 25333 
Independent reflections 9499 [R(int) = 0.0252] 
Completeness to theta = 33.14° 98.4 %  
Absorption correction None 
Max. and min. transmission 0.9953 and 0.9815 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 9499 / 0 / 378 
Goodness-of-fit on F2 1.039 
Final R indices [I>2sigma(I)] R1 = 0.0501, wR2 = 0.1393 
R indices (all data) R1 = 0.0657, wR2 = 0.1513 
Largest diff. peak and hole 0.520 and -0.257 e.Å-3 
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Table A.36 Crystal data and structure refinement for 24h 
 
 
Identification code  ar0808m 
Empirical formula  C32 H32 N4 O5 
Formula weight  552.62 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 7.2753(2) Å α= 90°. 
 b = 51.4772(16) Å β= 113.373(2)°. 
 c = 8.4137(3) Å γ = 90°. 
Volume 2892.46(16) Å3 
Z 4 
Density (calculated) 1.269 g/cm3 
Absorption coefficient 0.087 mm-1 
F(000) 1168 
Crystal size 0.25 x 0.15 x 0.04 mm3 
Theta range for data collection 2.67 to 31.51°. 
Index ranges -10<=h<=10, -74<=k<=72, -12<=l<=11 
Reflections collected 31609 
Independent reflections 9354 [R(int) = 0.0531] 
Completeness to theta = 31.51° 96.9 %  
Absorption correction None 
Max. and min. transmission 0.9965 and 0.9786 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 9354 / 0 / 390 
Goodness-of-fit on F2 1.033 
Final R indices [I>2sigma(I)] R1 = 0.0591, wR2 = 0.1398 
R indices (all data) R1 = 0.1092, wR2 = 0.1620 
Largest diff. peak and hole 0.485 and -0.325 e.Å-3 
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Table A.37 Crystal data and structure refinement for 24l 
 
 
Identification code  ar0809m 
Empirical formula  C36 H30 N8 O8.40 
Formula weight  709.08 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 8.5333(6) Å α= 102.318(3)°. 
 b = 12.6109(9) Å β= 103.824(4)°. 
 c = 17.3881(12) Å γ = 101.808(4)°. 
Volume 1709.5(2) Å3 
Z 2 
Density (calculated) 1.378 g/cm3 
Absorption coefficient 0.101 mm-1 
F(000) 738 
Crystal size 0.30 x 0.25 x 0.12 mm3 
Theta range for data collection 1.25 to 31.50°. 
Index ranges -12<=h<=12, -18<=k<=18, -25<=l<=25 
Reflections collected 21749 
Independent reflections 10076 [R(int) = 0.0257] 
Completeness to theta = 25.00° 89.2 %  
Absorption correction None 
Max. and min. transmission 0.9880 and 0.9704 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 10076 / 0 / 481 
Goodness-of-fit on F2 1.414 
Final R indices [I>2sigma(I)] R1 = 0.0749, wR2 = 0.2147 
R indices (all data) R1 = 0.1139, wR2 = 0.2356 
Largest diff. peak and hole 0.711 and -0.533 e.Å-3 
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Table A.38 Crystal data and structure refinement for 27 
 
 
Identification code  ar0701m 
Empirical formula  C28 H28 N10 O3 S 
Formula weight  584.66 
Temperature  133(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2/c 
Unit cell dimensions a = 13.553(2) Å α= 90°. 
 b = 12.1888(18) Å β= 111.307(6)°. 
 c = 18.161(3) Å γ = 90°. 
Volume 2795.1(7) Å3 
Z 4 
Density (calculated) 1.389 g/cm3 
Absorption coefficient 0.167 mm-1 
F(000) 1224 
Crystal size 0.30 x 0.20 x 0.15 mm3 
Theta range for data collection 2.32 to 36.32°. 
Index ranges -22<=h<=22, -20<=k<=19, -30<=l<=28 
Reflections collected 38879 
Independent reflections 6724 [R(int) = 0.0364] 
Completeness to theta = 36.32° 99.1 %  
Absorption correction None 
Max. and min. transmission 0.9754 and 0.9517 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6724 / 0 / 214 
Goodness-of-fit on F2 1.045 
Final R indices [I>2sigma(I)] R1 = 0.0498, wR2 = 0.1404 
R indices (all data) R1 = 0.0705, wR2 = 0.1543 
Largest diff. peak and hole 0.565 and -0.382 e.Å-3 
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Table A.39 Crystal data and structure refinement for 27i 
 
 
Identification code  ar0703m 
Empirical formula  C20 H15 N7 O7 
Formula weight  465.39 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 4.9179(4) Å α= 90°. 
 b = 42.483(3) Å β= 103.945(4)°. 
 c = 10.0242(8) Å γ = 90°. 
Volume 2032.6(3) Å3 
Z 4 
Density (calculated) 1.521 g/cm3 
Absorption coefficient 0.119 mm-1 
F(000) 960 
Crystal size 0.25 x 0.10 x 0.08 mm3 
Theta range for data collection 1.92 to 29.57°. 
Index ranges -6<=h<=4, -58<=k<=57, -13<=l<=13 
Reflections collected 29121 
Independent reflections 5619 [R(int) = 0.0529] 
Completeness to theta = 29.57° 99.0 %  
Absorption correction None 
Max. and min. transmission 0.9906 and 0.9709 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5619 / 0 / 320 
Goodness-of-fit on F2 1.020 
Final R indices [I>2sigma(I)] R1 = 0.0597, wR2 = 0.1298 
R indices (all data) R1 = 0.1267, wR2 = 0.1548 
Largest diff. peak and hole 0.314 and -0.327 e.Å-3 
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Table A.40 Crystal data and structure refinement for 35 
 
 
 
Identification code  ar0724m 
Empirical formula  C60 H76 Br4 O12 
Formula weight  1308.85 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 11.9718(13) Å α= 102.441(6)°. 
 b = 14.4406(16) Å β= 104.039(6)°. 
 c = 19.602(2) Å γ = 104.479(6)°. 
Volume 3042.5(6) Å3 
Z 2 
Density (calculated) 1.429 g/cm3 
Absorption coefficient 2.703 mm-1 
F(000) 1344 
Crystal size 0.25 x 0.15 x 0.15 mm3 
Theta range for data collection 1.52 to 30.51°. 
Index ranges -16<=h<=17, -20<=k<=20, -26<=l<=27 
Reflections collected 93764 
Independent reflections 18547 [R(int) = 0.0679] 
Completeness to theta = 30.51° 99.9 %  
Absorption correction None 
Max. and min. transmission 0.6872 and 0.5513 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 18547 / 44 / 699 
Goodness-of-fit on F2 1.042 
Final R indices [I>2sigma(I)] R1 = 0.0478, wR2 = 0.1283 
R indices (all data) R1 = 0.0836, wR2 = 0.1455 
Largest diff. peak and hole 0.959 and -0.601 e.Å-3 
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Table A.41 Crystal data and structure refinement for 35’ 
 
 
Identification code  ar0923m 
Empirical formula  C54 H66 Br4 O9 S 
Formula weight  1210.77 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 18.3282(10) Å α= 90°. 
 b = 16.0987(8) Å β= 110.518(2)°. 
 c = 18.5304(10) Å γ = 90°. 
Volume 5120.7(5) Å3 
Z 4 
Density (calculated) 1.571 g/cm3 
Absorption coefficient 3.241 mm-1 
F(000) 2472 
Crystal size 0.36 x 0.28 x 0.18 mm3 
Theta range for data collection 1.73 to 32.03°. 
Index ranges -27<=h<=27, -24<=k<=15, -17<=l<=27 
Reflections collected 72820 
Independent reflections 16776 [R(int) = 0.0317] 
Completeness to theta = 27.50° 98.5 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.5931 and 0.3883 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 16776 / 0 / 613 
Goodness-of-fit on F2 1.058 
Final R indices [I>2sigma(I)] R1 = 0.0405, wR2 = 0.0966 
R indices (all data) R1 = 0.0697, wR2 = 0.1106 
Largest diff. peak and hole 1.298 and -1.355 e.Å-3 
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Table A.42 Crystal data and structure refinement for 36 
 
 
 Identification code  ar0914m 
Empirical formula  C54 H63 I4 N O8 
Formula weight  1361.65 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 19.0866(13) Å α= 90°. 
 b = 16.7107(11) Å β= 117.933(3)°. 
 c = 18.6754(12) Å γ = 90°. 
Volume 5262.6(6) Å3 
Z 4 
Density (calculated) 1.719 g/cm3 
Absorption coefficient 2.422 mm-1 
F(000) 2680 
Crystal size 0.57 x 0.28 x 0.17 mm3 
Theta range for data collection 2.46 to 30.65°. 
Index ranges -27<=h<=22, 0<=k<=23, 0<=l<=25 
Reflections collected 14131 
Independent reflections 14131 [R(int) = 0.0000] 
Completeness to theta = 25.00° 99.0 %  
Absorption correction None 
Max. and min. transmission 0.6836 and 0.3390 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 14131 / 0 / 604 
Goodness-of-fit on F2 1.070 
Final R indices [I>2sigma(I)] R1 = 0.0430, wR2 = 0.1153 
R indices (all data) R1 = 0.0614, wR2 = 0.1229 
Largest diff. peak and hole 1.940 and -1.329 e.Å-3 
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Table A.43 Crystal data and structure refinement for 37 
 
 
Identification code  ar0712m 
Empirical formula  C100.60 H113.30 N8 O16.80 
Formula weight  1703.29 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 14.7722(7) Å α= 109.733(3)°. 
 b = 15.9370(8) Å β= 96.094(3)°. 
 c = 22.1716(11) Å γ = 93.890(3)°. 
Volume 4855.4(4) Å3 
Z 2 
Density (calculated) 1.165 Mg/m3 
Absorption coefficient 0.080 mm-1 
F(000) 1815 
Crystal size 0.30 x 0.20 x 0.10 mm3 
Theta range for data collection 0.99 to 28.40°. 
Index ranges -19<=h<=19, -21<=k<=21, -28<=l<=29 
Reflections collected 99701 
Independent reflections 23980 [R(int) = 0.0575] 
Completeness to theta = 28.40° 98.4 %  
Absorption correction None 
Max. and min. transmission 0.9921 and 0.9765 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 23980 / 45 / 1136 
Goodness-of-fit on F2 1.806 
Final R indices [I>2sigma(I)] R1 = 0.1055, wR2 = 0.2969 
R indices (all data) R1 = 0.1804, wR2 = 0.3241 
Largest diff. peak and hole 1.223 and -0.708 e.Å-3 
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Table A.44 Crystal data and structure refinement for 38 
 
 
Identification code  ar0721m 
Empirical formula  C79 H93 Br2 N4 O12 
Formula weight  1450.39 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/m 
Unit cell dimensions a = 13.3457(7) Å α= 90°. 
 b = 19.5826(9) Å β= 99.793(2)°. 
 c = 14.0550(8) Å γ = 90°. 
Volume 3619.7(3) Å3 
Z 2 
Density (calculated) 1.331 g/cm3 
Absorption coefficient 1.184 mm-1 
F(000) 1522 
Crystal size 0.28 x 0.24 x 0.10 mm3 
Theta range for data collection 1.47 to 29.13°. 
Index ranges -18<=h<=18, -26<=k<=26, -14<=l<=19 
Reflections collected 45929 
Independent reflections 9980 [R(int) = 0.0389] 
Completeness to theta = 29.13° 99.7 %  
Absorption correction None 
Max. and min. transmission 0.8907 and 0.7327 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 9980 / 44 / 481 
Goodness-of-fit on F2 1.251 
Final R indices [I>2sigma(I)] R1 = 0.0823, wR2 = 0.2499 
R indices (all data) R1 = 0.1321, wR2 = 0.2791 
Largest diff. peak and hole 1.441 and -1.063 e.Å-3 
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Table A.45 Crystal data and structure refinement for 40a 
 
 
Identification code  ar0822m 
Empirical formula  C162 H171.20 F4 I2 N13.60 O16.40 
Formula weight  2900.93 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 12.2272(7) Å α= 95.883(3)°. 
 b = 13.5156(7) Å β= 103.793(2)°. 
 c = 23.4101(12) Å γ = 100.699(3)°. 
Volume 3647.9(3) Å3 
Z 1 
Density (calculated) 1.321 g/cm3 
Absorption coefficient 0.505 mm-1 
F(000) 1512 
Crystal size 0.30 x 0.25 x 0.15 mm3 
Theta range for data collection 0.91 to 32.58°. 
Index ranges -18<=h<=17, -19<=k<=20, -32<=l<=34 
Reflections collected 79170 
Independent reflections 24629 [R(int) = 0.0316] 
Completeness to theta = 25.00° 99.4 %  
Absorption correction None 
Max. and min. transmission 0.9280 and 0.8632 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 24629 / 12 / 917 
Goodness-of-fit on F2 1.018 
Final R indices [I>2sigma(I)] R1 = 0.0382, wR2 = 0.0959 
R indices (all data) R1 = 0.0513, wR2 = 0.1031 
Largest diff. peak and hole 1.010 and -0.670 e.Å-3 
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Table A.46 Crystal data and structure refinement for 40b 
 
 
Identification code  ar0901m 
Empirical formula  C150 H147 F16 I4 N5 O20.50 
Formula weight  3159.33 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 18.758(3) Å α= 100.106(10)°. 
 b = 19.828(3) Å β= 98.682(10)°. 
 c = 22.558(3) Å γ = 110.342(9)°. 
Volume 7538.1(19) Å3 
Z 2 
Density (calculated) 1.392 g/cm3 
Absorption coefficient 0.911 mm-1 
F(000) 3204 
Crystal size 0.45 x 0.40 x 0.25 mm3 
Theta range for data collection 1.13 to 26.31°. 
Index ranges -22<=h<=22, -24<=k<=23, 0<=l<=27 
Reflections collected 32547 
Independent reflections 32547 [R(int) = 0.0000] 
Completeness to theta = 26.31° 82.8 %  
Absorption correction TWINABS 
Max. and min. transmission 0.8043 and 0.6847 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 32547 / 895 / 703 
Goodness-of-fit on F2 2.282 
Final R indices [I>2sigma(I)] R1 = 0.2143, wR2 = 0.4462 
R indices (all data) R1 = 0.3441, wR2 = 0.4890 
Largest diff. peak and hole 2.421 and -2.276 e.Å-3 
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Table A.47 Crystal data and structure refinement for 41 
 
 
Identification code  ar0824m 
Empirical formula  C76 H86 N4 O10 
Formula weight  1215.49 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 24.918(2) Å α= 90°. 
 b = 14.3312(15) Å β= 107.680(6)°. 
 c = 19.1136(19) Å γ = 90°. 
Volume 6503.2(11) Å3 
Z 4 
Density (calculated) 1.241 g/cm3 
Absorption coefficient 0.082 mm-1 
F(000) 2600 
Crystal size 0.24 x 0.20 x 0.05 mm3 
Theta range for data collection 2.14 to 28.34°. 
Index ranges -30<=h<=33, -17<=k<=8, -24<=l<=25 
Reflections collected 31545 
Independent reflections 14736 [R(int) = 0.1805] 
Completeness to theta = 22.50° 96.0 %  
Absorption correction None 
Max. and min. transmission 0.9959 and 0.9806 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 14736 / 3171 / 860 
Goodness-of-fit on F2 0.945 
Final R indices [I>2sigma(I)] R1 = 0.1099, wR2 = 0.2571 
R indices (all data) R1 = 0.3632, wR2 = 0.3766 
Largest diff. peak and hole 0.925 and -0.545 e.Å-3 
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Table A.48 Crystal data and structure refinement for 41a 
 
 
Identification code  ar0826m 
Empirical formula  C88 H82 F8 I4 N6 O8 
Formula weight  2011.20 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 12.3175(5) Å α= 88.893(2)°. 
 b = 13.2596(6) Å β= 88.152(2)°. 
 c = 25.4769(11) Å γ = 79.980(2)°. 
Volume 4095.0(3) Å3 
Z 2 
Density (calculated) 1.631 g/cm3 
Absorption coefficient 1.601 mm-1 
F(000) 2000 
Crystal size 0.24 x 0.18 x 0.10 mm3 
Theta range for data collection 0.80 to 30.51°. 
Index ranges -16<=h<=16, -18<=k<=15, -36<=l<=33 
Reflections collected 59351 
Independent reflections 22662 [R(int) = 0.0417] 
Completeness to theta = 27.50° 99.5 %  
Absorption correction None 
Max. and min. transmission 0.8563 and 0.7000 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 22662 / 36 / 1057 
Goodness-of-fit on F2 1.033 
Final R indices [I>2sigma(I)] R1 = 0.0513, wR2 = 0.1244 
R indices (all data) R1 = 0.0806, wR2 = 0.1412 
Largest diff. peak and hole 2.524 and -1.537 e.Å-3 
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Table A.49 Crystal data and structure refinement for SR1-e 
 
 
Identification code  ar0916m 
Empirical formula  C26 H36 Br2 N4 O6 
Formula weight  660.41 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.1413(5) Å α= 98.672(6)°. 
 b = 9.8969(10) Å β= 90.297(6)°. 
 c = 14.1428(15) Å γ = 90.815(6)°. 
Volume 711.31(13) Å3 
Z 1 
Density (calculated) 1.542 g/cm3 
Absorption coefficient 2.895 mm-1 
F(000) 338 
Crystal size 0.32 x 0.24 x 0.12 mm3 
Theta range for data collection 2.35 to 32.69°. 
Index ranges -7<=h<=7, -13<=k<=15, -21<=l<=19 
Reflections collected 12441 
Independent reflections 4862 [R(int) = 0.0458] 
Completeness to theta = 27.50° 97.4 %  
Absorption correction None 
Max. and min. transmission 0.7226 and 0.4576 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4862 / 0 / 179 
Goodness-of-fit on F2 1.058 
Final R indices [I>2sigma(I)] R1 = 0.0596, wR2 = 0.1450 
R indices (all data) R1 = 0.0908, wR2 = 0.1619 
Largest diff. peak and hole 2.527 and -1.450 e.Å-3 
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Table A.50 Crystal data and structure refinement for SR2-b 
 
 
Identification code  ar0915m 
Empirical formula  C22 H28 Br2 N4 O6 
Formula weight  604.30 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 4.7253(9) Å α= 79.367(5)°. 
 b = 10.624(2) Å β= 84.778(5)°. 
 c = 12.692(2) Å γ = 82.062(5)°. 
Volume 618.8(2) Å3 
Z 1 
Density (calculated) 1.622 g/cm3 
Absorption coefficient 3.320 mm-1 
F(000) 306 
Crystal size 0.32 x 0.24 x 0.14 mm3 
Theta range for data collection 1.97 to 31.50°. 
Index ranges -6<=h<=6, -15<=k<=15, -17<=l<=17 
Reflections collected 8959 
Independent reflections 3773 [R(int) = 0.0352] 
Completeness to theta = 25.00° 95.5 %  
Absorption correction None 
Max. and min. transmission 0.6536 and 0.4164 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3773 / 0 / 160 
Goodness-of-fit on F2 1.046 
Final R indices [I>2sigma(I)] R1 = 0.0358, wR2 = 0.0925 
R indices (all data) R1 = 0.0422, wR2 = 0.0973 
Largest diff. peak and hole 0.857 and -0.573 e.Å-3 
 257  
Table A.51 Crystal data and structure refinement for SR2-e 
 
 
Identification code  ar1003m 
Empirical formula  C28 H40 Br2 N4 O6 
Formula weight  688.46 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.2550(4) Å α= 82.638(3)°. 
 b = 9.2658(7) Å β= 80.927(2)°. 
 c = 15.8434(12) Å γ = 84.634(2)°. 
Volume 753.39(10) Å3 
Z 1 
Density (calculated) 1.517 g/cm3 
Absorption coefficient 2.737 mm-1 
F(000) 354 
Crystal size 0.30 x 0.20 x 0.08 mm3 
Theta range for data collection 2.45 to 33.14°. 
Index ranges -8<=h<=6, -12<=k<=13, -24<=l<=23 
Reflections collected 13430 
Independent reflections 5020 [R(int) = 0.0275] 
Completeness to theta = 30.00° 97.9 %  
Absorption correction None 
Max. and min. transmission 0.8108 and 0.4940 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5020 / 0 / 187 
Goodness-of-fit on F2 1.082 
Final R indices [I>2sigma(I)] R1 = 0.0359, wR2 = 0.0803 
R indices (all data) R1 = 0.0507, wR2 = 0.0852 
Largest diff. peak and hole 0.767 and -0.651 e.Å-3 
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 Table A.52 Crystal data and structure refinement for SR3-b 
 
 
Identification code  ar1010m 
Empirical formula  C24 H26 N8 O4 
Formula weight  490.53 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 15.3250(15) Å α= 90°. 
 b = 7.5844(7) Å β= 101.884(4)°. 
 c = 10.3773(10) Å γ = 90°. 
Volume 1180.3(2) Å3 
Z 2 
Density (calculated) 1.380 g/cm3 
Absorption coefficient 0.098 mm-1 
F(000) 516 
Crystal size 0.34 x 0.22 x 0.12 mm3 
Theta range for data collection 1.36 to 30.50°. 
Index ranges -20<=h<=21, -10<=k<=6, -14<=l<=13 
Reflections collected 9563 
Independent reflections 3530 [R(int) = 0.0357] 
Completeness to theta = 30.50° 97.8 %  
Absorption correction None 
Max. and min. transmission 0.9883 and 0.9674 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3530 / 0 / 172 
Goodness-of-fit on F2 1.060 
Final R indices [I>2sigma(I)] R1 = 0.0541, wR2 = 0.1421 
R indices (all data) R1 = 0.0772, wR2 = 0.1652 
Largest diff. peak and hole 0.404 and -0.341 e.Å-3 
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 Table A.53 Crystal data and structure refinement for SR3-e 
 
 
Identification code  ar1008m 
Empirical formula  C30 H38 N8 O4 
Formula weight  574.68 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.4083(4) Å α= 80.343(2)°. 
 b = 7.0348(5) Å β= 83.201(3)°. 
 c = 20.0745(15) Å γ = 74.450(2)°. 
Volume 723.21(9) Å3 
Z 1 
Density (calculated) 1.320 g/cm3 
Absorption coefficient 0.091 mm-1 
F(000) 306 
Crystal size 0.38 x 0.20 x 0.08 mm3 
Theta range for data collection 3.04 to 31.00°. 
Index ranges -7<=h<=7, -6<=k<=10, -29<=l<=29 
Reflections collected 11245 
Independent reflections 4394 [R(int) = 0.0273] 
Completeness to theta = 30.00° 96.9 %  
Absorption correction None 
Max. and min. transmission 0.9928 and 0.9664 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4394 / 0 / 199 
Goodness-of-fit on F2 1.109 
Final R indices [I>2sigma(I)] R1 = 0.0501, wR2 = 0.1457 
R indices (all data) R1 = 0.0659, wR2 = 0.1611 
Largest diff. peak and hole 0.451 and -0.261 e.Å-3 
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Table A.54 Crystal data and structure refinement for SR4-c 
 
 
Identification code  ar0925m 
Empirical formula  C29 H37 Cl F N O6 
Formula weight  550.05 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 8.5818(4) Å α= 86.103(2)°. 
 b = 8.8742(5) Å β= 83.495(2)°. 
 c = 18.3524(10) Å γ = 73.728(2)°. 
Volume 1332.07(12) Å3 
Z 2 
Density (calculated) 1.371 g/cm3 
Absorption coefficient 0.195 mm-1 
F(000) 584 
Crystal size 0.36 x 0.28 x 0.16 mm3 
Theta range for data collection 2.48 to 30.61°. 
Index ranges -12<=h<=12, -12<=k<=12, 0<=l<=26 
Reflections collected 15845 
Independent reflections 15845 [R(int) = 0.0000] 
Completeness to theta = 30.61° 98.4 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9694 and 0.9330 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 15845 / 0 / 353 
Goodness-of-fit on F2 1.035 
Final R indices [I>2sigma(I)] R1 = 0.0481, wR2 = 0.1305 
R indices (all data) R1 = 0.0737, wR2 = 0.1514 
Largest diff. peak and hole 0.557 and -0.345 e.Å-3 
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Appendix B - 1H, 13C NMR, and Mass Data 
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Figure B.1 2-acetamidopyridine, 3, 1H 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR 
200 MHz 
CDCl3 
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Figure B.2 2-propiamido-5-bromopyridine, 4, 1H & 13C 
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13C NMR 
200 MHz 
CDCl3 
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Figure B.3 2-acetamido-5-bromopyridine, 6, 1H 
 
 
 
 
Figure B.4 2-acetamido-3,5-dibromopyridine, 7, 1H 
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Figure B.5 3-pyridylbenzoic acid, 8, 1H 
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Figure B.6 2-amino-5-bromopyrimidine, 9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR 
200 MHz 
CDCl3 
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Figure B.7 2-amino-5-(3-pyridyl)pyrimidine, 10, 1H & 13C 
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13C NMR 
200 MHz 
CDCl3 
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Figure B.8 2-amino-4-methyl-5-bromopyrimidine, 11, 1H 
 
 
 
Figure B.9 2-amino-4-methyl-5-(3-pyridyl)pyrimidine, 12, 1H 
 
1H NMR 
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1H NMR 
400 MHz 
CDCl3 
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Figure B.10 2-amino-5-bromopyrazine, 13, 1H 
 
 
 
 
 
 
Figure B.11 2-amino-3,5-dibromopyrazine, 14, 1H 
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Figure B.12 2-amino-5-(3-pyridyl)pyrazine, 15, 1H 
 
 
 
 
Figure B.13 2-acetamido-5-(3-pyridyl)pyridine, 16, 1H 
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Figure B.14 2-acetamido-5-bromopyrimidine, 17, 1H  
 
 
Figure B.15 2-acetamido-5-(3-pyridyl)pyrimidine, 18 
 
1H NMR 
400 MHz 
DMSO-d6 
1H NMR 
400 MHz 
CDCl3 
 272  
 
 
 
 
Figure B.16 2-acetamido-5-(3-pyridyl)pyrimidine, 18, 1H & 13C 
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Figure B.17 TMS-protected 3-trimethylsilanylethynylpyridine, 19, 1H  
 
 
 
 
 
Figure B.18 3-ethynylpyridine, 20, 1H  
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Figure B.19 2-acetamido-5-(3-pyridyl)ethynylpyridine, 21, 1H 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR 
400 MHz 
DMSO-d6 
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Figure B.20 2-amino-5-trimethylsilanylethynylpyridine, 22, 1H  
 
 
 
 
Figure B.21 2-amino-5-ethynylpyridine, 23, 1H   
1H NMR 
200 MHz 
CDCl3 
1H NMR 
200 MHz 
CDCl3 
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Figure B.22 2-acetamido-5-(3-(2-aminopyridyl))ethynylpyridine, 24, 1H  
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Figure B.23 2-acetamido-5-trimethylsilanylethynylpyridine, 25, 1H 
 
 
Figure B.24 2-acetamido-5-ethynylpyridine, 26, 1H   
1H NMR 
200 MHz 
CDCl3 
1H NMR 
200 MHz 
CDCl3 
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Figure B.25 2-amino-5-(3-(2-acetamidopyridyl))ethynylpyrazine, 27, 1H & 13C 
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Figure B.26 2-acetamido-5-bromopyrazine, 28, 1H 
 
 
 
 
 
 
 
 
 
 
 
 
  
1H NMR 
200 MHz 
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Figure B.27 2-acetamido-5-(3-(2-acetamidopyridyl))ethynylpyrazine, 29, 1H & 13C 
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Figure B.28 2-amino-5-trimethylsilanylethynylpyrimidine, 30, 1H  
 
 
 
Figure B.29 2-amino-5-trimethylsilanylethynylpyrazine, 31, 1H  
1H NMR 
400 MHz 
CDCl3 
1H NMR 
200 MHz 
CDCl3 
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Figure B.30 2-amino-5-(3-(2-aminopyrazino))ethynylpyrimidine, 32, 1H & 13C  
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Figure B.31 2-amino-5-ethynylprazine, 1H  
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Figure B.32 C-Pentylbromocalix[4]resorcinarene, 34, 1H  
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Figure B.33 C-Pentyltetrabromocavitand, 35, 1H 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR 
200 MHz 
CDCl3 
 286  
 
 
 
Figure B.34 C-PentyltetraprotioCavitand, 1H 
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Figure B.35 C-Pentyltetraiodocavitand, 36, 1H & 13C 
1H NMR 
200 MHz 
CDCl3 
13C NMR 
200 MHz 
CDCl3 
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Figure B.36 C-Pentyl-1,3-dibromo-2,4-diiodo-cavitand, 36’, 1H 
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Figure B.37 C-Pentyl-1,2-dibromo/diIodo-2,4-diprotiocavitand, 1H 
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Figure B.38 C-Pentyl-triiodo-monoprotiocavitand, 1H 
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Figure B.39 C-Pentyl-monobromo/iodo-triprotiocavitand, 1H 
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Figure B.40 C-Pentyl-tetra-(2-acetamidopyridyl-5-ethynyl)cavitand, 37, 1H & 13C 
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Figure B.41 C-Pentyl-1,3-di-(2-acetamidopyridyl-5-ethynyl)-2,4-bibromocavitand, 38, 
1H & 13C 
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Figure B.42 C-Pentyl-mono-(2-aminopyrazino-5-ethynyl)-tribromocavitand, 1H 
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Figure B.43 C-Pentyl-mono-(2-aminopyrazino-5-ethynyl)-triiodocavitand, 1H 
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Figure B.44 C-Pentyl-1,2-di(2-aminopyrazino-5-ethynyl)-3,4-diiodocavitand, 1H 
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Figure B.45 C-Pentyl-1,3-di(2-aminopyrazino-5-ethynyl)-2,4-diiodocavitand, 39, 1H 
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Figure B.46 C-Pentyltetra(3-pyridyl)cavitand, 40, 1H 
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Figure 6.47 C-Pentyltetra(4-pyridyl)cavitand, 41, 1H & 13C 
 
1H NMR 
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13C NMR 
200 MHz 
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Figure B.48 Mass Spectra of C-Pentyltetraiodocavitand, 36 
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Figure B.49 Mass Spectra of C-Pentyltetra(4-pyridyl)cavitand, 41 
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